Patent Application
20230052528
Taspase1 (threonine aspartase) is a protease is overexpressed in numerous liquid and solid malignancies. Indeed, loss of Taspase1 strongly inhibits development of HER2-driven breast tumors and EGFR-driven, drug-resistant and non drug-resistant lung cancer. Identifying inhibitors of Taspase1 has proven to be a challenge. Disclosed herein, inter alia, are solutions to these and other problems known in the art.
In an aspect is provided a compound having the formula:
R1 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1BN(O)m1, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O) NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L2 is substituted or unsubstituted alkylene.
R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R2 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R3 is independently —CN,
R16 is independently hydrogen, halogen, —CX163, —CHX162, —CH2X16, —CN, —SOn16R16A, —SOv16NR16AR16B, —NHNR16AR16B, —ONR16AR16B, —NHC(O)NHNR16AR16B, —NHC(O)NR16AR16B, —N(O)m16, —NR16AR16B, —C(O)R16A, —C(O)—OR16A, —C(O)NR16AR16B, —OR16A, —NR16ASO2R16B, —NR16AC(O)R16B, —NR16AC(O)OR16B, —NR16AOR16B, —OCX163, —OCHX162, —OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R17 is independently hydrogen, halogen, —CX173, —CHX172, —CH2X17, —CN, —SOn17R17A, —SOv17NR17AR17B, —NHNR17AR17B, —ONR17AR17B, —NHC(O)NHNR17AR17B, —NHC(O)NR17AR17B, —N(O)m17, —NR17AR17B, —C(O)R17A, —C(O)—OR17A, —C(O)NR17AR17B, —OR17A, —NR17ASO2R17B, —NR17AC(O)R17B, —NR17AC(O)OR17B, —NR17AOR17B, —OCX173, —OCHX172, —OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R18 is independently hydrogen,
halogen, —CX183, —CHX182, —CH2X18, —CN, —SOn18R18A, —SOv18NR18AR18B, —NHNR18AR18B, —ONR18AR18B, —NHC(O)NHNR18AR18B,
—NHC(O)NR18AR18B, —N(O)m18, —NR18AR18B, —C(O)R18A, —C(O)—OR18A, —C(O)N18AR18B, —OR18A, —NR18ASO2R18B, —NR18AC(O)R18B, —NR18AC(O)OR18B, —NR18AOR18B, —OCX183, —OCHX182, —OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R19 is independently hydrogen, halogen, —CX193, —CHX192, —CH2X19, —CN, —SOn19R19A, —SOv19NR19AR19B, —NHNR19AR19B, —ONR19AR19B, —NHC(O)NHNR19AR19B, —NHC(O)NR19AR19B, —N(O)m19, —NR19AR19B, —C(O)R19A, —C(O)—OR19A, —C(O)NR19AR19B, —OR19A, —NR19ASO2R19B, —NR19AC(O)R19B, —NR19AC(O)OR19B, —NR19AOR19B, —OCX193, —OCHX192, —OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R16A, R16B, R17A, R17B, R18A, R18B, R19A, and R19B are independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
X, X1, X2, X16, X17, X18, and X19 are independently —F, —Cl, —Br, or —I.
n1, n2, n16, n17, n18, and n19 are independently an integer from 0 to 4.
m1, m2, m16, m17, m18, m19, v1, v2, v16, v17, v18, and v19 are independently 1 or 2.
z1 is an integer from 0 to 5.
z2 is an integer from 0 to 8.
In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.
In an aspect is provided a method of inhibiting Taspase1 protein activity, the method including contacting the Taspase1 protein with a compound as described herein.
In an aspect is provided a method of treating cancer, the method including administering to a subject in need thereof an effective amount of a compound as described herein.
The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH2O— is equivalent to —OCH2—.
The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals. The alkyl may include a designated number of carbons (e.g., C1-C10 means one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1 and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (—O—). An alkyl moiety may be an alkenyl moiety. An alkyl moiety may be an alkynyl moiety. An alkyl moiety may be fully saturated. An alkenyl may include more than one double bond and/or one or more triple bonds in addition to the one or more double bonds. An alkynyl may include more than one triple bond and/or one or more double bonds in addition to the one or more triple bonds. In embodiments, the alkyl is fully saturated. In embodiments, the alkyl is monounsaturated. In embodiments, the alkyl is polyunsaturated.
The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, —CH2CH2CH2CH2—. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term “alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. In embodiments, the alkylene is fully saturated. In embodiments, the alkylene is monounsaturated. In embodiments, the alkylene is polyunsaturated. An alkenylene includes one or more double bonds. An alkynylene includes one or more triple bonds.
The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., O, N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —CH2—S—CH2, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, —CH═CH—N(CH3)—CH3, —O—CH3, —O—CH2—CH3, and —CN. Up to two or three heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3 and —CH2—O—Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). The term “heteroalkenyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond. A heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds. The term “heteroalkynyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one triple bond. A heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds. In embodiments, the heteroalkyl is fully saturated. In embodiments, the heteroalkyl is monounsaturated. In embodiments, the heteroalkyl is polyunsaturated.
Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH2—CH2—S—CH2—CH2— and —CH2—S—CH2—CH2—NH—CH2—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —C(O)2R′— represents both —C(O)2R′— and —R′C(O)2—. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as —C(O)R′, —C(O)NR′, —NR′R″, —OR′, —SR′, and/or —SO2R′. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R″ or the like, it will be understood that the terms heteroalkyl and —NR′R″ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R″ or the like. The term “heteroalkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkene. The term “heteroalkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkyne. In embodiments, the heteroalkylene is fully saturated. In embodiments, the heteroalkylene is monounsaturated. In embodiments, the heteroalkylene is polyunsaturated. A heteroalkenylene includes one or more double bonds. A heteroalkynylene includes one or more triple bonds.
The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. In embodiments, the cycloalkyl is fully saturated. In embodiments, the cycloalkyl is monounsaturated. In embodiments, the cycloalkyl is polyunsaturated. In embodiments, the heterocycloalkyl is fully saturated. In embodiments, the heterocycloalkyl is monounsaturated. In embodiments, the heterocycloalkyl is polyunsaturated.
In embodiments, the term “cycloalkyl” means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system. In embodiments, monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In embodiments, cycloalkyl groups are fully saturated. In embodiments, a bicyclic or multicyclic cycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkyl ring of the multiple rings. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems are bridged monocyclic rings or fused bicyclic rings. In embodiments, bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (i.e., a bridging group of the form (CH2)w, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. In embodiments, fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. In embodiments, the bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. In embodiments, cycloalkyl groups are optionally substituted with one or two groups which are independently oxo or thia. In embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted by one or two groups which are independently oxo or thia. In embodiments, multicyclic cycloalkyl ring systems are a monocyclic cycloalkyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl. In embodiments, the multicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the base ring. In embodiments, multicyclic cycloalkyl ring systems are a monocyclic cycloalkyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl. Examples of multicyclic cycloalkyl groups include, but are not limited to tetradecahydrophenanthrenyl, perhydrophenothiazin-1-yl, and perhydrophenoxazin-1-yl.
In embodiments, a cycloalkyl is a cycloalkenyl. The term “cycloalkenyl” is used in accordance with its plain ordinary meaning. In embodiments, a cycloalkenyl is a monocyclic, bicyclic, or a multicyclic cycloalkenyl ring system. In embodiments, a bicyclic or multicyclic cycloalkenyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkenyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkenyl ring of the multiple rings. In embodiments, monocyclic cycloalkenyl ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups are unsaturated (i.e., containing at least one annular carbon double bond), but not aromatic. Examples of monocyclic cycloalkenyl ring systems include cyclopentenyl and cyclohexenyl. In embodiments, bicyclic cycloalkenyl rings are bridged monocyclic rings or a fused bicyclic rings. In embodiments, bridged monocyclic rings contain a monocyclic cycloalkenyl ring where two non adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (i.e., a bridging group of the form (CH2)w, where w is 1, 2, or 3). Representative examples of bicyclic cycloalkenyls include, but are not limited to, norbornenyl and bicyclo[2.2.2]oct 2 enyl. In embodiments, fused bicyclic cycloalkenyl ring systems contain a monocyclic cycloalkenyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. In embodiments, the bridged or fused bicyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkenyl ring. In embodiments, cycloalkenyl groups are optionally substituted with one or two groups which are independently oxo or thia. In embodiments, multicyclic cycloalkenyl rings contain a monocyclic cycloalkenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two ring systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl. In embodiments, the multicyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained within the base ring. In embodiments, multicyclic cycloalkenyl rings contain a monocyclic cycloalkenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two ring systems independently selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl.
In embodiments, the term “heterocycloalkyl” means a monocyclic, bicyclic, or a multicyclic heterocycloalkyl ring system. In embodiments, heterocycloalkyl groups are fully saturated. In embodiments, a bicyclic or multicyclic heterocycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a heterocycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heterocycloalkyl ring of the multiple rings. In embodiments, a heterocycloalkyl is a heterocyclyl. The term “heterocyclyl” as used herein, means a monocyclic, bicyclic, or multicyclic heterocycle. The heterocyclyl monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S where the ring is saturated or unsaturated, but not aromatic. The 3 or 4 membered ring contains 1 heteroatom selected from the group consisting of O, N and S. The 5 membered ring can contain zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The 6 or 7 membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The heterocyclyl monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heterocyclyl monocyclic heterocycle. Representative examples of heterocyclyl monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. The heterocyclyl bicyclic heterocycle is a monocyclic heterocycle fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocycle, or a monocyclic heteroaryl. The heterocyclyl bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle portion of the bicyclic ring system. Representative examples of bicyclic heterocyclyls include, but are not limited to, 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, indolin-1-yl, indolin-2-yl, indolin-3-yl, 2,3-dihydrobenzothien-2-yl, decahydroquinolinyl, decahydroisoquinolinyl, octahydro-1H-indolyl, and octahydrobenzofuranyl. In embodiments, heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain embodiments, the bicyclic heterocyclyl is a 5 or 6 membered monocyclic heterocyclyl ring fused to a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the bicyclic heterocyclyl is optionally substituted by one or two groups which are independently oxo or thia. Multicyclic heterocyclyl ring systems are a monocyclic heterocyclyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of a phenyl, a bicyclic aryl, a monocyclic or bicyclic heteroaryl, a monocyclic or bicyclic cycloalkyl, a monocyclic or bicyclic cycloalkenyl, and a monocyclic or bicyclic heterocyclyl. The multicyclic heterocyclyl is attached to the parent molecular moiety through any carbon atom or nitrogen atom contained within the base ring. In embodiments, multicyclic heterocyclyl ring systems are a monocyclic heterocyclyl ring (base ring) fused to either (i) one ring system selected from the group consisting of a bicyclic aryl, a bicyclic heteroaryl, a bicyclic cycloalkyl, a bicyclic cycloalkenyl, and a bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of a phenyl, a monocyclic heteroaryl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, and a monocyclic heterocyclyl. Examples of multicyclic heterocyclyl groups include, but are not limited to 10H-phenothiazin-10-yl, 9,10-dihydroacridin-9-yl, 9,10-dihydroacridin-10-yl, 10H-phenoxazin-10-yl, 10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl, 1,2,3,4-tetrahydropyrido[4,3-g]isoquinolin-2-yl, 12H-benzo[b]phenoxazin-12-yl, and dodecahydro-1H-carbazol-9-yl.
The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C1-C4)alkyl” includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
The term “acyl” means, unless otherwise stated, —C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. In embodiments, a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within an aryl ring of the multiple rings. The term “heteroaryl” refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). In embodiments, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heteroaromatic ring of the multiple rings). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl, benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4 pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be —O— bonded to a ring heteroatom nitrogen.
A fused ring heterocycloalkyl-aryl is an aryl fused to a heterocycloalkyl. A fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl. A fused ring heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl. A fused ring heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl. Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl-cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be unsubstituted or substituted with one or more of the substituents described herein.
Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
The symbol “” denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.
The term “oxo,” as used herein, means an oxygen that is double bonded to a carbon atom.
The term “alkylsulfonyl,” as used herein, means a moiety having the formula —S(O2)—R′, where R′ is a substituted or unsubstituted alkyl group as defined above. R′ may have a specified number of carbons (e.g., “C1-C4 alkylsulfonyl”).
The term “alkylarylene” as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:
An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g. at carbons 2, 3, 4, or 6) with halogen, oxo, —N3, —CF3, —CCl3, —CBr3, —Cl3, —CN, —CHO, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO2CH3—SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, substituted or unsubstituted C1-C5 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl). In embodiments, the alkylarylene is unsubstituted.
Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “cycloalkyl,” “heterocycloalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —NR′NR″R′″, —ONR′R″, —NR′C(O)NR″NR′″R″″—CN, —NO2, —NR′SO2R″—NR′C(O)R″, —NR′C(O)—OR″, —NR′OR″, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R, R′, R″, R′″, and R″″ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ group when more than one of these groups is present. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, —NR′R″ includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″—NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —NR′NR″R′″, —ONR′R″, —NR′C(O)NR″NR′″R″″, —CN, —NO2, —R′, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl, —NR′SO2R″, —NR′C(O)R″, —NR′C(O)—OR″, —NR′OR″, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″, R′″, and R″″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ groups when more than one of these groups is present.
Substituents for rings (e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.
Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′)q—U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r—B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)2—, —S(O)2NR′—, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′)s—X′— (C″R″R′″)d—, where s and d are independently integers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituents R, R′, R″, and R′″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
A “substituent group,” as used herein, means a group selected from the following moieties:
A “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
A “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C6 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C20 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section, figures, or tables below.
In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and/or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkyl ene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene, respectively).
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one size-limited substituent group, wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one lower substituent group, wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group is different.
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group is different.
Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate. The present disclosure is meant to include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
The term “tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.
Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13C- or 14C-enriched carbon are within the scope of this disclosure.
The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.
As used herein, the term “bioconjugate” and “bioconjugate linker” refers to the resulting association between atoms or molecules of “bioconjugate reactive groups” or “bioconjugate reactive moieties”. The association can be direct or indirect. For example, a conjugate between a first bioconjugate reactive group (e.g., —NH2, —C(O)OH, —N-hydroxysuccinimide, or -maleimide) and a second bioconjugate reactive group (e.g., sulfhydryl, sulfur-containing amino acid, amine, amine sidechain containing amino acid, or carboxylate) provided herein can be direct, e.g., by covalent bond or linker (e.g. a first linker of second linker), or indirect, e.g., by non-covalent bond (e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like). In embodiments, bioconjugates or bioconjugate linkers are formed using bioconjugate chemistry (i.e. the association of two bioconjugate reactive groups) including, but are not limited to nucleophilic substitutions (e.g., reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition). These and other useful reactions are discussed in, for example, March, ADVANCED ORGANIC CHEMISTRY, 3rd Ed., John Wiley & Sons, New York, 1985; Hermanson, BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and Feeney et al., MODIFICATION OF PROTEINS; Advances in Chemistry Series, Vol. 198, American Chemical Society, Washington, D.C., 1982. In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., haloacetyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., pyridyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., —N hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. an amine). In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., -sulfo-N-hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. an amine).
Useful bioconjugate reactive moieties used for bioconjugate chemistries herein include, for example:
The bioconjugate reactive groups can be chosen such that they do not participate in, or interfere with, the chemical stability of the conjugate described herein. Alternatively, a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group. In embodiments, the bioconjugate comprises a molecular entity derived from the reaction of an unsaturated bond, such as a maleimide, and a sulfhydryl group.
“Analog,” or “analogue” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
The terms “a” or “an,” as used in herein means one or more. In addition, the phrase “substituted with a[n],” as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is “substituted with an unsubstituted C1-C20 alkyl, or unsubstituted 2 to 20 membered heteroalkyl,” the group may contain one or more unsubstituted C1-C20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
Moreover, where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R13 substituents are present, each R13 substituent may be distinguished as R13.1, R13.2, R13.3, R13.4, etc., wherein each of R13.1, R13.2, R13.3, R13.4 etc. is defined within the scope of the definition of R13 and optionally differently.
Radioactive substances (e.g., radioisotopes) that may be used as imaging and/or labeling agents in accordance with the embodiments of the disclosure include, but are not limited to, 18F, 32P, 33P, 45Ti, 47Sc, 52Fe, 59Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 77As, 86Y, 90Y. 89Sr, 89Zr, 94Tc, 94Tc, 99mTc, 99Mo, 105Pd, 105Rh, 111Ag, 111In, 123I, 124I, 125I, 131I, 142Pr, 143Pr, 149Pm, 153Sm, 154-1581Gd, 161Tb, 166Dy, 166Ho, 169Er, 175Lu, 177Lu, 186Re, 188Re, 189Re, 194Ir, 198Au, 199Au, 211At, 211Pb, 212Bi, 212Pb, 213Bi, 223Ra and 225Ac. Paramagnetic ions that may be used as additional imaging agents in accordance with the embodiments of the disclosure include, but are not limited to, ions of transition and lanthanide metals (e.g. metals having atomic numbers of 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.
Descriptions of compounds of the present disclosure are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
A person of ordinary skill in the art will understand when a variable (e.g., moiety or linker) of a compound or of a compound genus (e.g., a genus described herein) is described by a name or formula of a standalone compound with all valencies filled, the unfilled valence(s) of the variable will be dictated by the context in which the variable is used. For example, when a variable of a compound as described herein is connected (e.g., bonded) to the remainder of the compound through a single bond, that variable is understood to represent a monovalent form (i.e., capable of forming a single bond due to an unfilled valence) of a standalone compound (e.g., if the variable is named “methane” in an embodiment but the variable is known to be attached by a single bond to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is actually a monovalent form of methane, i.e., methyl or —CH3). Likewise, for a linker variable (e.g., L1, L2, or L3 as described herein), a person of ordinary skill in the art will understand that the variable is the divalent form of a standalone compound (e.g., if the variable is assigned to “PEG” or “polyethylene glycol” in an embodiment but the variable is connected by two separate bonds to the remainder of the compound, a person of ordinary skill in the art would understand that the variable is a divalent (i.e., capable of forming two bonds through two unfilled valences) form of PEG instead of the standalone compound PEG).
The term “exogenous” refers to a molecule or substance (e.g., a compound, nucleic acid or protein) that originates from outside a given cell or organism. For example, an “exogenous promoter” as referred to herein is a promoter that does not originate from the plant it is expressed by. Conversely, the term “endogenous” or “endogenous promoter” refers to a molecule or substance that is native to, or originates within, a given cell or organism.
The term “lipid moiety” is used in accordance with its ordinary meaning in chemistry and refers to a hydrophobic molecule which is typically characterized by an aliphatic hydrocarbon chain. In embodiments, the lipid moiety includes a carbon chain of 3 to 100 carbons. In embodiments, the lipid moiety includes a carbon chain of 5 to 50 carbons. In embodiments, the lipid moiety includes a carbon chain of 5 to 25 carbons. In embodiments, the lipid moiety includes a carbon chain of 8 to 525 carbons. Lipid moieties may include saturated or unsaturated carbon chains, and may be optionally substituted. In embodiments, the lipid moiety is optionally substituted with a charged moiety at the terminal end. In embodiments, the lipid moiety is an alkyl or heteroalkyl optionally substituted with a carboxylic acid moiety at the terminal end.
A charged moiety refers to a functional group possessing an abundance of electron density (i.e. electronegative) or is deficient in electron density (i.e. electropositive). Non-limiting examples of a charged moiety includes carboxylic acid, alcohol, phosphate, aldehyde, and sulfonamide. In embodiments, a charged moiety is capable of forming hydrogen bonds.
The terms “bind” and “bound” as used herein is used in accordance with its plain and ordinary meaning and refers to the association between atoms or molecules. The association can be covalent (e.g., covalent bond or covalent linker (e.g., a first linker or second linker)) or non-covalent (e.g., non-covalent bond (e.g., electrostatic interactions (e.g., ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like)).
The term “capable of binding” as used herein refers to a moiety (e.g. a compound as described herein) that is able to measurably bind to a target (e.g., a NF-κB, a Toll-like receptor protein). Ki is the binding constant that describes the energy of association for the non-covalent portion of the molecule. Kinact is the rate at which the covalent bond is formed between the small molecule and the protein. In embodiments, where a moiety is capable of binding a target, the moiety is capable of binding with a Ki of less than about 150 μM, 125 μM, 110 μM, 100 μM, 75 μM, 50 μM, 20 μM, 10 μM, 5 μM, 1 μM, 500 nM, 250 nM, 100 nM, 75 nM, 50 nM, 25 nM, 15 nM, 10 nM, 5 nM, 1 nM, or about 0.1 nM. In embodiments, the Kinact is less than about, 1 s−1, 0.5 s−1, 0.1 s−1, 0.05 s−1, 0.01 s−1, 0.005 s−1, or about 0.001 s−1.
As used herein, the term “salt” refers to acid or base salts of the compounds used in the methods of the present invention. Illustrative examples of acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
Thus, the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids. The present disclosure includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, propionates, tartrates (e.g., (+)-tartrates, (−)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.
The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.
In addition to salt forms, the present disclosure provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Prodrugs of the compounds described herein may be converted in vivo after administration. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.
Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
“Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the disclosure. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure.
The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
As used herein, the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/−10% of the specified value. In embodiments, about includes the specified value.
A “synergistic amount” as used herein refers to the sum of a first amount (e.g., an amount of a Taspase1 inhibitor) and a second amount (e.g., a therapeutic agent) that results in a synergistic effect (i.e. an effect greater than an additive effect). Therefore, the terms “synergy”, “synergism”, “synergistic”, “combined synergistic amount”, and “synergistic therapeutic effect” which are used herein interchangeably, refer to a measured effect of the Taspase1 inhibitor in combination with a second agent (e.g., an anticancer agent) where the measured effect is greater than the sum of the individual effects of the Taspase1 inhibitor provided herein and the second agent (e.g., anticancer agent) administered alone as a single agent.
In embodiments, a synergistic amount may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% of the amount of the Taspase1 inhibitor provided herein when used separately from the therapeutic agent. In embodiments, a synergistic amount may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% of the amount of the therapeutic agent when used separately from the Taspase1 inhibitor provided herein.
The term “EC50” or “half maximal effective concentration” as used herein refers to the concentration of a molecule (e.g., antibody, chimeric antigen receptor or bispecific antibody) capable of inducing a response which is halfway between the baseline response and the maximum response after a specified exposure time. In embodiments, the EC50 is the concentration of a molecule (e.g., antibody, chimeric antigen receptor or bispecific antibody) that produces 50% of the maximal possible effect of that molecule.
The term “IC50” or “half maximal inhibitory concentration” as used herein refers to the concentration of an inhibitory molecule (e.g., small molecule, antibody, chimeric antigen receptor or bispecific antibody) that is required to inhibit a given biologal process or biological component by 50%.
The term “small molecule” is used in accordance with its well understood meaning and refers to a low molecular weight organic compound that may regulate a biological process. In embodiments, the small molecule is a compound that weighs less than 1000 daltons. In embodiments, the small molecule is a compound that weighs less than 900 daltons. In embodiments, the small molecule weighs less than 800 daltons. In embodiments, the small molecule weighs less than 700 daltons. In embodiments, the small molecule weighs less than 600 daltons. In embodiments, the small molecule weighs less than 500 daltons. In embodiments, the small molecule weighs less than 450 daltons. In embodiments, the small molecule weighs less than 400 daltons.
An “Taspase1 inhibitor” refers to a compound (e.g. a compound described herein) that reduces the activity of Taspase1 when compared to a control, such as absence of the compound or a compound with known inactivity.
“Contacting” is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.
The term “contacting” may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway.
As defined herein, the term “activation”, “activate”, “activating”, “activator” and the like in reference to a protein-inhibitor interaction means positively affecting (e.g. increasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the activator. In embodiments activation means positively affecting (e.g. increasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the activator. The terms may reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease. Thus, activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein associated with a disease (e.g., a protein which is decreased in a disease relative to a non-diseased control). Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein
The terms “agonist,” “activator,” “upregulator,” etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
As defined herein, the term “inhibition”, “inhibit”, “inhibiting” and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation). A “Taspase1 inhibitor” is a compound that negatively affects (e.g. decreases) the activity or function of Taspase1 relative to the activity or function of Taspase1 in the absence of the inhibitor.
The terms “inhibitor,” “repressor” or “antagonist” or “downregulator” interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
The terms “Taspase1” and “Taspase 1” and “TASP1” and “Tasp1” and “Threonine aspartase 1” refer to a protein (including homologs, isoforms, and functional fragments thereof) which cleaves substrates following aspartate residues. The term includes any recombinant or naturally-occurring form of Taspase1 variants thereof that maintain Taspase1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wild-type Taspase1). In embodiments, the Taspase1 protein encoded by the TASP1 gene has the amino acid sequence set forth in or corresponding to Entrez 55617, UniProt Q9H6P5, RefSeq (protein) NP 001310531, RefSeq (protein) NP 001310532, RefSeq (protein) NP 001310533, or RefSeq (protein) NP 060184. In embodiments, the TASP1 gene has the nucleic acid sequence set forth in RefSeq (mRNA) NM 017714, RefSeq (mRNA) NM 001323602, RefSeq (mRNA) NM 001323603, or RefSeq (mRNA) NM 001323604. In embodiments, the amino acid sequence or nucleic acid sequence is the sequence known at the time of filing of the present application. In embodiments, the Taspase1 protein sequence corresponds to NP 001310531.1. In embodiments, the Taspase1 protein sequence corresponds to NP 001310532.1. In embodiments, the Taspase1 protein sequence corresponds to NP 001310533.1. In embodiments, the Taspase1 protein sequence corresponds to NP 060184. In embodiments, the Taspase1 protein sequence corresponds to NP 060184.2. In embodiments, the Taspase1 is a human Taspase1, such as a human cancer causing Taspase1.
The terms “TASP1 gene” as used herein refer to the any of the recombinant or naturally-occurring forms of the TASP1 gene or variants or homologs thereof that code for a Taspase1 polypeptide capable of maintaining the activity of the Taspase1 polypeptide (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to Taspase1 polypeptide). In embodiments, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity across the whole sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 continuous nucleic acid portion) compared to a naturally occurring TASP1 gene.
The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
The term “modulator” refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule relative to the absence of the modulator. In some embodiments, a Taspase1 associated disease modulator is a compound that reduces the severity of one or more symptoms of a disease associated with Taspase1 (e.g. cancer). A Taspase1 modulator is a compound that increases or decreases the activity or function or level of activity or level of function of Taspase1.
The term “modulate” is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
The term “associated” or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g. a protein associated disease, a cancer associated with Taspase1 activity, Taspase1 associated cancer, Taspase1 associated disease (e.g., cancer, inflammatory disease, autoimmune disease, or infectious disease)) means that the disease (e.g. cancer, inflammatory disease, autoimmune disease, or infectious disease) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. For example, a cancer associated with Taspase1 activity or function may be a cancer that results (entirely or partially) from aberrant Taspase1 function (e.g. enzyme activity, protein-protein interaction, signaling pathway) or a cancer wherein a particular symptom of the disease is caused (entirely or partially) by aberrant Taspase1 activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease. For example, a cancer associated with Taspase1 activity or function or a Taspase1 associated disease (e.g., cancer, inflammatory disease, autoimmune disease, or infectious disease), may be treated with a Taspase1 modulator or Taspase1 inhibitor, in the instance where increased Taspase1 activity or function (e.g. signaling pathway activity) causes the disease (e.g., cancer, inflammatory disease, autoimmune disease, or infectious disease).
The term “aberrant” as used herein refers to different from normal. When used to describe enzymatic activity or protein function, aberrant refers to activity or function that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.
The term “signaling pathway” as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propagated to other signaling pathway components. For example, binding of a Taspase1 with a compound as described herein may reduce the level of a product of the Taspase1 catalyzed reaction or the level of a downstream derivative of the product or binding may reduce the interactions between the Taspase1 enzyme or an Taspase1 reaction product and downstream effectors or signaling pathway components (e.g., epigenetic regulatory proteins MLL and the transcription factor (TF) IIA family of nuclear proteins), resulting in changes in cell growth, proliferation, or survival.
In this disclosure, “comprises,” “comprising,” “containing” and “having” and the like can have the meaning ascribed to them in U.S. patent law and can mean “includes,” “including,” and the like. “Consisting essentially of” or “consists essentially” likewise has the meaning ascribed in U.S. patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
The terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be a cancer. The disease may be an autoimmune disease. The disease may be an inflammatory disease. The disease may be an infectious disease. In some further instances, “cancer” refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphomas (e.g., Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including AML, ALL, and CML), or multiple myeloma.
As used herein, the term “inflammatory disease” refers to a disease or condition characterized by aberrant inflammation (e.g. an increased level of inflammation compared to a control such as a healthy person not suffering from a disease). Examples of inflammatory diseases include autoimmune diseases, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, Vitiligo, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, ischemia reperfusion injury, stroke, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, scleroderma, and atopic dermatitis.
As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemias, lymphomas, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, Medulloblastoma, melanoma, cervical cancer, gastric cancer, ovarian cancer, lung cancer, cancer of the head, Hodgkin's Disease, and Non-Hodgkin's Lymphomas. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, ovary, pancreas, rectum, stomach, and uterus. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung carcinoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
The term “leukemia” refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.
As used herein, the term “lymphoma” refers to a group of cancers affecting hematopoietic and lymphoid tissues. It begins in lymphocytes, the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow. Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin's disease. Hodgkin's disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed-Sternberg malignant B lymphocytes. Non-Hodgkin's lymphomas (NHL) can be classified based on the rate at which cancer grows and the type of cells involved. There are aggressive (high grade) and indolent (low grade) types of NHL. Based on the type of cells involved, there are B-cell and T-cell NHLs. Exemplary B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma, Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B-lymphoblastic lymphoma. Exemplary T-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
The term “sarcoma” generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.
The term “melanoma” is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
The term “carcinoma” refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum.
As used herein, the terms “metastasis,” “metastatic,” and “metastatic cancer” can be used interchangeably and refer to the spread of a proliferative disease or disorder, e.g., cancer, from one organ or another non-adjacent organ or body part. “Metastatic cancer” is also called “Stage IV cancer.” Cancer occurs at an originating site, e.g., breast, which site is referred to as a primary tumor, e.g., primary breast cancer. Some cancer cells in the primary tumor or originating site acquire the ability to penetrate and infiltrate surrounding normal tissue in the local area and/or the ability to penetrate the walls of the lymphatic system or vascular system circulating through the system to other sites and tissues in the body. A second clinically detectable tumor formed from cancer cells of a primary tumor is referred to as a metastatic or secondary tumor. When cancer cells metastasize, the metastatic tumor and its cells are presumed to be similar to those of the original tumor. Thus, if lung cancer metastasizes to the breast, the secondary tumor at the site of the breast consists of abnormal lung cells and not abnormal breast cells. The secondary tumor in the breast is referred to a metastatic lung cancer. Thus, the phrase metastatic cancer refers to a disease in which a subject has or had a primary tumor and has one or more secondary tumors. The phrases non-metastatic cancer or subjects with cancer that is not metastatic refers to diseases in which subjects have a primary tumor but not one or more secondary tumors. For example, metastatic lung cancer refers to a disease in a subject with or with a history of a primary lung tumor and with one or more secondary tumors at a second location or multiple locations, e.g., in the breast.
As used herein, the term “autoimmune disease” refers to a disease or condition in which a subject's immune system has an aberrant immune response against a substance that does not normally elicit an immune response in a healthy subject. Examples of autoimmune diseases that may be treated with a compound, pharmaceutical composition, or method described herein include Acute Disseminated Encephalomyelitis (ADEM), Acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome (APS), Autoimmune angioedema, Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease, Autoimmune urticaria, Axonal or neuronal neuropathies, Balo disease, Behcet's disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac disease, Chagas disease, Chronic fatigue syndrome, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST disease, Essential mixed cryoglobulinemia, Demyelinating neuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Experimental allergic encephalomyelitis, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis (GPA) (formerly called Wegener's Granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis, Interstitial cystitis, Juvenile arthritis, Juvenile diabetes (Type 1 diabetes), Juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus (SLE), Lyme disease, chronic, Meniere's disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neuromyelitis optica (Devic's), Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome, Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Reiter's syndrome, Relapsing polychondritis, Restless legs syndrome, Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome, Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia, Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Type 1 diabetes, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo, or Wegener's granulomatosis (i.e., Granulomatosis with Polyangiitis (GPA).
As used herein, the term “inflammatory disease” refers to a disease or condition characterized by aberrant inflammation (e.g. an increased level of inflammation compared to a control such as a healthy person not suffering from a disease). Examples of inflammatory diseases include traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, Vitiligo, asthma, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, and atopic dermatitis.
As used herein, the term “neurodegenerative disorder” refers to a disease or condition in which the function of a subject's nervous system becomes impaired. Examples of neurodegenerative diseases that may be treated with a compound, pharmaceutical composition, or method described herein include Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, chronic fatigue syndrome, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, kuru, Lewy body dementia, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple sclerosis, Multiple System Atrophy, myalgic encephalomyelitis, Narcolepsy, Neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoffs disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Schizophrenia, Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, progressive supranuclear palsy, or Tabes dorsalis.
The terms “treating”, or “treatment” refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. The term “treating” and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing.
“Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, “treatment” as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms (e.g., ocular pain, seeing halos around lights, red eye, very high intraocular pressure), fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things.
“Treating” and “treatment” as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of an active agent. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient. In embodiments, the treating or treatment is not prophylactic treatment (e.g., the patient has a disease, the patient suffers from a disease).
The term “prevent” refers to a decrease in the occurrence of Taspase1 disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.
“Patient” or “subject in need thereof” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.
A “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
The term “therapeutically effective amount,” as used herein, refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present disclosure, should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
As used herein, the term “administering” means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. In embodiments, the administering does not include administration of any active agent other than the recited active agent.
“Co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds provided herein can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present disclosure can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
A “cell” as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaroytic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
“Control” or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).
Cancer model organism, as used herein, is an organism exhibiting a phenotype indicative of cancer, or the activity of cancer-causing elements, within the organism. The term cancer is defined above. A wide variety of organisms may serve as cancer model organisms, and include for example, cancer cells and mammalian organisms such as rodents (e.g. mouse or rat) and primates (such as humans). Cancer cell lines are widely understood by those skilled in the art as cells exhibiting phenotypes or genotypes similar to in vivo cancers. Cancer cell lines as used herein includes cell lines from animals (e.g. mice) and from humans.
An “anticancer agent” as used herein refers to a molecule (e.g. compound, peptide, protein, or nucleic acid) used to treat cancer through destruction or inhibition of cancer cells or tissues. Anticancer agents may be selective for certain cancers or certain tissues. In embodiments, anticancer agents herein may include epigenetic inhibitors and multi-kinase inhibitors.
“Anti-cancer agent” and “anticancer agent” are used in accordance with their plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK 1, MEK2, or MEK 1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g. cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2′-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec®), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B 1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin I1 (including recombinant interleukin II, or rIL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g. Taxol™ (i.e. paclitaxel), Taxotere™, compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g. Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e. LU-103793 and NSC-D-669356), Epothilones (e.g. Epothilone A, Epothilone B, Epothilone C (i.e. desoxyepothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e. BMS-310705), 21-hydroxyepothilone D (i.e. Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663), Soblidotin (i.e. TZT-1027), Vincristine sulfate, Cryptophycin 52 (i.e. LY-355703), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), Oncocidin A1 (i.e. BTO-956 and DIME), Fijianolide B, Laulimalide, Narcosine (also known as NSC-5366), Nascapine, Hemiasterlin, Vanadocene acetylacetonate, Monsatrol, lnanocine (i.e. NSC-698666), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (−)-Phenylahistin (i.e. NSCL-96F037), Myoseverin B, Resverastatin phosphate sodium, steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to 111In 90Y or 131I, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinibBIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like.
An “epigenetic inhibitor” as used herein, refers to an inhibitor of an epigenetic process, such as DNA methylation (a DNA methylation Inhibitor) or modification of histones (a Histone Modification Inhibitor). An epigenetic inhibitor may be a histone-deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, a histone methyltransferase (HMT) inhibitor, a histone demethylase (HDM) inhibitor, or a histone acetyltransferase (HAT). Examples of HDAC inhibitors include Vorinostat, romidepsin, CI-994, Belinostat, Panobinostat, Givinostat, Entinostat, Mocetinostat, SRT501, CUDC-101, JNJ-26481585, or PCI24781. Examples of DNMT inhibitors include azacitidine and decitabine. Examples of HMT inhibitors include EPZ-5676. Examples of HDM inhibitors include pargyline and tranylcypromine. Examples of HAT inhibitors include CCT077791 and garcinol.
A “multi-kinase inhibitor” is a small molecule inhibitor of at least one protein kinase, including tyrosine protein kinases and serine/threonine kinases. A multi-kinase inhibitor may include a single kinase inhibitor. Multi-kinase inhibitors may block phosphorylation. Multi-kinases inhibitors may act as covalent modifiers of protein kinases. Multi-kinase inhibitors may bind to the kinase active site or to a secondary or tertiary site inhibiting protein kinase activity. A multi-kinase inhibitor may be an anti-cancer multi-kinase inhibitor. Exemplary anti-cancer multi-kinase inhibitors include dasatinib, sunitinib, erlotinib, bevacizumab, vatalanib, vemurafenib, vandetanib, cabozantinib, poatinib, axitinib, ruxolitinib, regorafenib, crizotinib, bosutinib, cetuximab, gefitinib, imatinib, lapatinib, lenvatinib, mubritinib, nilotinib, panitumumab, pazopanib, trastuzumab, or sorafenib.
The term “irreversible covalent bond” is used in accordance with its plain ordinary meaning in the art and refers to the resulting association between atoms or molecules of (e.g., electrophilic chemical moiety and nucleophilic moiety) wherein the probability of dissociation is low. In embodiments, the irreversible covalent bond does not easily dissociate under normal biological conditions. In embodiments, the irreversible covalent bond is formed through a chemical reaction between two species (e.g., electrophilic chemical moiety and nucleophilic moiety).
The term “electrophilic moiety” is used in accordance with its plain ordinary chemical meaning and refers to a chemical group (e.g., monovalent chemical group) that is electrophilic. In embodiments, the electrophilic chemical moiety is referred to herein as a “warhead” or “E.” In embodiments, E is:
wherein R16, R17, R18, R19, and X17 are as described herein, including in embodiments. In embodiments, an electrophilic moiety is a covalent cysteine modifier moiety.
The term “covalent cysteine modifier moiety” as used herein refers to a monovalent electrophilic moiety that is able to measurably bind to a cysteine amino acid. In embodiments, the covalent cysteine modifier moiety binds via an irreversible covalent bond. In embodiments, the covalent cysteine modifier moiety is capable of binding with a Kd of less than about 10 μM, 5 μM, 1 μM, 500 nM, 250 nM, 100 nM, 75 nM, 50 nM, 25 nM, 15 nM, 10 nM, 5 nM, 1 nM, or about 0.1 nM. In embodiments, the covalent cysteine modifier moiety binds via a covalent bond.
The term “nucleophilic moiety” is used in accordance with its plain ordinary chemical meaning and refers to a chemical group (e.g., monovalent chemical group) that is nucleophilic.
An amino acid residue in a protein “corresponds” to a given residue when it occupies the same essential structural position within the protein as the given residue. Instead of a primary sequence alignment, a three-dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the human protein and the overall structures compared. In this case, an amino acid that occupies the same essential position as a specified amino acid in the structural model is said to correspond to the specified residue. For example, a selected residue in a selected protein corresponds to C293 of a Taspase1 protein (e.g., human Taspase1 protein) when the selected residue occupies the same essential spatial or other structural relationship as C293 in the Taspase1 protein (e.g., human Taspase1 protein). In some embodiments, where a selected protein is aligned for maximum homology with the Taspase1 protein (e.g., human Taspase1 protein), the position in the aligned selected protein aligning with C293 is said to correspond to C293 of the Taspase1 protein (e.g., human Taspase1 protein). Instead of a primary sequence alignment, a three-dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the Taspase1 protein (e.g., human Taspase1 protein) and the overall structures compared. In this case, an amino acid that occupies the same essential position as C293 of a Taspase1 protein (e.g., human Taspase1 protein) in the structural model is said to correspond to the C293 residue. Another example is wherein a selected residue in a selected protein corresponds to C293 in a Taspase1 protein (e.g., human Taspase1 protein) when the selected residue (e.g., cysteine residue) occupies essential the same sequence, spatial, or other structural position within the protein as C293 in the Taspase1 protein (e.g., human Taspase 1 protein).
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may in embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5′-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.
The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.
In an aspect is provided a compound having the formula:
R1 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1B, —N(O)m1, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O) NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L2 is substituted or unsubstituted alkylene.
R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R2 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R3 is independently —CN,
In an alternative aspect, R3 is an electrophilic moiety. In embodiments, R3 is a covalent cysteine modifier moiety.
R16 is independently hydrogen, halogen, —CX163, —CHX162, —CH2X16, —CN, —SOn16R16A, —SOv16NR16AR16B, —NHNR16AR16B, —ONR16AR16B, —NHC(O)NHNR16AR16B, —NHC(O)NR16AR16B, —N(O)m16, —NR16AR16B, —C(O)R16A, —C(O)—OR16A, —C(O)NR16AR16B, —OR16A, —NR16ASO2R16B, —NR16AC(O)R16B, —NR16AC(O)OR16B, —NR16AOR16B, —OCX163, —OCHX162, —OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R17 is independently hydrogen,
halogen, —CX173, —CHX172, —CH2X17, —CN, —SOn17R17A, —SOv17NR17AR17B, —NHNR17AR17B, —ONR17AR17B, —NHC(O)NHNR17AR17B, —NHC(O)NR17AR17B, —N(O)m17, —NR17AR17B, —C(O)R17A, —C(O)—OR17A, —C(O)NR17AR17B, —OR17A, —NR17ASO2R17B, —NR17AC(O)R17B, —NR17AC(O)OR17B, —NR17AOR17B, —OCX173, —OCHX172, —OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R18 is independently hydrogen,
halogen, —CX183, —CHX182, —CH2X18, —CN, —SOn18R18A, —SOv18 NR18AR18B, —NHNR18AR18B, —ONR18AR18B, —NHC(O)NHNR18AR18B, —NHC(O)NR18AR18B, —N(O)m18, —NR18AR8B, —C(O)R18A, —C(O)—OR18A, —C(O)NR18AR18B, —OR18A, —NR18ASO2R18B, —NR18AC(O)R18B, —NR18AC(O)OR18B, —NR18AOR18B, —OCX183, —OCHX182, —OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R19 is independently hydrogen,
halogen, —CX193, —CHX192, —CH2X19, —CN, —SOn19R19A, —SOv19NR19AR19B, —NHNR9AR19B, —ONR19AR19B, —NHC(O)NHNR19AR19B, —NHC(O)NR19AR19B, —N(O)m19, —NR9AR19B, —C(O)R19A, —C(O)—OR19A, —C(O)NR19AR19B, —OR19A, —NR19ASO2R19B, —NR19AC(O)R19B, —NR19AC(O)OR19B, —NR19AOR19B, —OCX193, —OCHX192, —OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R16A, R16B, R17A, R17B, R18A, R18B, R19A, and R19B are independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
X, X1, X2, X16, X17, X18, and X19 are independently —F, —Cl, —Br, or —I.
n1, n2, n16, n17, n18, and n19 are independently an integer from 0 to 4.
m1, m2, m16, m17, m18, m19, v1, v2, v16, v17, v18, and v19 are independently 1 or 2.
z1 is an integer from 0 to 5.
z2 is an integer from 0 to 8.
In embodiments, the compound has the formula:
R1.1 is independently hydrogen or any value of R1 as described herein.
R1.2 is independently hydrogen or any value of R2 as described herein.
R1.3 is independently hydrogen or any value of R3 as described herein.
R2.1 is independently hydrogen or any value of R2 as described herein.
In embodiments, R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SR1D, —SCX13, —SCH2X1, —SCHX12, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, R2.1 is independently hydrogen, oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
In embodiments, the compound has the formula:
R1.1, R1.2, R3, and L2 are as described herein
L2 is unsubstituted C1-C6 alkylene.
In embodiments, R1.1, R1.2, and R1.3 are independently hydrogen,
halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl 3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, R1.1, R1.2, and R1.3 are independently hydrogen,
halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —OH, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1 1 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —OH, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1.2 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —OH, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1.3 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —OH, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl.
In embodiments, R2.1 is independently hydrogen, oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, R20-substituted or unsubstituted C1-C6 alkyl (e.g., C1-C6 alkyl, C1-C4 alkyl, or C1-C2 alkyl), R20-substituted or unsubstituted 2 to 6 membered heteroalkyl (e.g., 2 to 6 membered heteroalkyl, 2 to 4 membered heteroalkyl, or 2 to 3 membered heteroalkyl), R20-substituted or unsubstituted C3-C6 cycloalkyl (e.g., C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted 3 to 6 membered heterocycloalkyl (e.g., 3 to 6 membered heterocycloalkyl, 3 to 5 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted C6-C12 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted 5 to 12 membered heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2.1 is independently hydrogen, R20-substituted or unsubstituted C1-C6 alkyl (e.g., C1-C6 alkyl, C1-C4 alkyl, or C1-C2 alkyl), R20-substituted or unsubstituted 2 to 6 membered heteroalkyl (e.g., 2 to 6 membered heteroalkyl, 2 to 4 membered heteroalkyl, or 2 to 3 membered heteroalkyl), R20-substituted or unsubstituted C3-C6 cycloalkyl (e.g., C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted 3 to 6 membered heterocycloalkyl (e.g., 3 to 6 membered heterocycloalkyl, 3 to 5 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted C6-C12 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted 5 to 12 membered heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R20 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, R21-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R21-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R21-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R21-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R21-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R21-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R20 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI 2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R21 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2.1 is independently hydrogen, unsubstituted C1-C6 alkyl (e.g., C1-C6 alkyl, C1-C4 alkyl, or C1-C2 alkyl), unsubstituted 2 to 6 membered heteroalkyl (e.g., 2 to 6 membered heteroalkyl, 2 to 4 membered heteroalkyl, or 2 to 3 membered heteroalkyl), unsubstituted C3-C6 cycloalkyl (e.g., C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted 3 to 6 membered heterocycloalkyl (e.g., 3 to 6 membered heterocycloalkyl, 3 to 5 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted C6-C12 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted 5 to 12 membered heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2.1 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
In embodiments, R2.1 is independently —CH2O—CH2CCH, —CH2O—CH2CN, —CH2O—CH2-heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
In embodiments, R2.1 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl.
In embodiments, R2.1 is independently hydrogen, R20-substituted or unsubstituted C1-C6 alkyl, or R20-substituted or unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R20 is independently —OH, R21-substituted or unsubstituted 5 to 6 membered heterocycloalkyl or R21-substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R21 is independently oxo.
In embodiments, R2.1 is independently
In embodiments, R2.1 is independently
wherein R20 is unsubstituted C1-C6 alkyl. In embodiments, R2.1 is independently
wherein R20 is unsubstituted C1-C2 alkyl. In embodiments, R2.1 is independently
wherein R20 is unsubstituted C2 alkenyl. In embodiments, R2.1 is independently
wherein R20 is unsubstituted C2 alkynyl. In embodiments, R2.1 is independently
wherein R20 is R21-substituted or unsubstituted 5 to 6 membered heterocycloalkyl. In embodiments, R2.1 is independently
wherein R20 is unsubstituted 5 to 6 membered heterocycloalkyl. In embodiments, R2.1 is independently
wherein R20 is R21-substituted 5 to 6 membered heterocycloalkyl and R21 is oxo. In embodiments, R2.1 is independently
wherein R20 is unsubstituted 5 to 6 membered heteroaryl. In embodiments, R2.1 is independently
wherein R20 is unsubstituted pyrazolyl. In embodiments, R2.1 is independently
wherein R20 is unsubstituted triazolyl. In embodiments, R21 is independently:
In embodiments, R2.1 is independently:
In embodiments, R2.1 is independently:
In embodiments, R2.1 is independently:
In embodiments, R21 is independently:
In embodiments, R3 is independently —CN,
In embodiments, R3 is independently
In embodiments, R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl. In embodiments, R16 is independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl. In embodiments, R17 is independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl. In embodiments, R18 is independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl.
In embodiments, R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted C6 aryl.
In embodiments, R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl.
In embodiments, R1A, R1B, R1C, and R1D are independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
In embodiments, R1A, R1B, and R1D are independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.
In embodiments, X is independently —F, —Cl, —Br, or —I.
In embodiments, L2 is unsubstituted n-propylene or unsubstituted n-butylene.
In embodiments, R1.1 is independently hydrogen, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —O CH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, alkenyl, alkynyl, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, unsubstituted isobutoxy, or unsubstituted pyrazolyl; R12 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, or unsubstituted C1-C4 alkyl; and R1.3 is independently hydrogen, halogen, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, or unsubstituted isobutoxy.
In embodiments, R1.1 is independently hydrogen, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —O CH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, alkenyl, alkynyl, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, unsubstituted isobutoxy, or unsubstituted pyrazolyl.
In embodiments, R1.2 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, or unsubstituted C1-C4 alkyl.
In embodiments, R1.3 is independently hydrogen,
halogen, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, or unsubstituted isobutoxy.
In embodiments, R1.1 is independently
hydrogen, —OCF3, —CN, —SCH3, —SCF3, —SOCH3, —SO2CH3, —NHCH3, —SF5, unsubstituted C2-C4 alkenyl, unsubstituted C2-C4 alkynyl, unsubstituted isopropoxy, or unsubstituted pyrazolyl; R12 is independently hydrogen, —F, —Br, or —CF3; and R1.3 is independently hydrogen, —F, or —OCF3.
In embodiments, R1.1 is independently
hydrogen, —OCF3, —CN, —SCH3, —SCF3, —SOCH3, —SO2CH3, —NHCH3, —SF5, unsubstituted C2-C4 alkenyl, unsubstituted C2-C4 alkynyl, unsubstituted isopropoxy, or unsubstituted pyrazolyl.
In embodiments, R1.2 is independently hydrogen, —F, —Br, or —CF3.
In embodiments, R1.3 is independently hydrogen, —F or —OCF3.
In embodiments, R3 is independently —CN.
In embodiments, R3 is independently
In embodiments, R3 is independently
In embodiments, R3 is independently
In embodiments, R3 is independently
In embodiments, R16 is hydrogen; R17 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl; and R18 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl.
In embodiments, R16 is hydrogen; R17 is independently hydrogen or unsubstituted C1-C4 alkyl; and R18 is independently hydrogen or unsubstituted C1-C4 alkyl.
In embodiments, R16 is hydrogen; R17 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl; and R18 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl.
In embodiments, R16 is hydrogen; R17 is independently hydrogen or unsubstituted methyl; and R18 is independently hydrogen or unsubstituted methyl.
In embodiments, R16, R17 and R18 are hydrogen.
In embodiments, R16 is hydrogen. In embodiments, R16 is unsubstituted C1-C4 alkyl. In embodiments, R16 is unsubstituted methyl. In embodiments, R16 is unsubstituted ethyl. In embodiments, R16 is unsubstituted n-propyl. In embodiments, R16 is unsubstituted iso-propyl. In embodiments, R16 is unsubstituted n-butyl. In embodiments, R16 is unsubstituted t-butyl. In embodiments, R17 is hydrogen. In embodiments, R17 is unsubstituted C1-C4 alkyl. In embodiments, R17 is unsubstituted methyl. In embodiments, R17 is unsubstituted ethyl. In embodiments, R17 is unsubstituted n-propyl. In embodiments, R17 is unsubstituted iso-propyl. In embodiments, R17 is unsubstituted n-butyl. In embodiments, R17 is unsubstituted t-butyl. In embodiments, R18 is hydrogen. In embodiments, R18 is unsubstituted C1-C4 alkyl. In embodiments, R18 is unsubstituted methyl. In embodiments, R18 is unsubstituted ethyl. In embodiments, R18 is unsubstituted n-propyl. In embodiments, R18 is unsubstituted iso-propyl. In embodiments, R18 is unsubstituted n-butyl. In embodiments, R18 is unsubstituted t-butyl.
In embodiments, R16 is hydrogen. In embodiments, R16 is C1-C4 alkyl. In embodiments, R16 is methyl. In embodiments, R16 is substituted or unsubstituted aryl. In embodiments, R16 is substituted phenyl. In embodiments, R16 is halo substituted phenyl. In embodiments, R16 is fluoro substituted phenyl. In embodiments, R16 is unsubstituted phenyl. In embodiments, R16 is
In embodiments, R16, R17, and R18 are independently hydrogen, —CN, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted 2 to 12 membered heteroalkyl; or substituted or unsubstituted C6-C10 aryl. In embodiments, R16, R17, and R18 are independently hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted 2 to 12 membered heteroalkyl; or substituted or unsubstituted C6-C10 aryl. In embodiments, R16, R17, and R18 are hydrogen.
In embodiments, R16 is independently hydrogen, —CN, unsubstituted C1-C12 alkyl (e.g., C1-C10, alkyl, C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted 2 to 12 membered heteroalkyl (e.g., 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), or unsubstituted C6-C10 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl).
In embodiments, R16 is independently hydrogen, —CN, R26-substituted or unsubstituted C1-C12 alkyl (e.g., C1-C10, alkyl, C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R26-substituted or unsubstituted 2 to 12 membered heteroalkyl (e.g., 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), or R26-substituted or unsubstituted C6-C10 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl).
R26 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, R36-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R36-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R36-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R36-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R36-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R36-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R26 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R36 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI 2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R17 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl. In embodiments, R17 is hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R17 is hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl. In embodiments, R17 is hydrogen or unsubstituted methyl. In embodiments, R17 is hydrogen. In embodiments, R17 is unsubstituted methyl.
In embodiments, R17 is independently hydrogen, —CN, unsubstituted C1-C12 alkyl (e.g., C1-C10, alkyl, C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted 2 to 12 membered heteroalkyl (e.g., 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), or unsubstituted C6-C10 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl).
In embodiments, R17 is independently hydrogen, —CN, R27-substituted or unsubstituted C1 C12 alkyl (e.g., C1-C10, alkyl, C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R27-substituted or unsubstituted 2 to 12 membered heteroalkyl (e.g., 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), or R27-substituted or unsubstituted C6-C10 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl).
R27 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, R37-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R37-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R37-substituted or unsubstituted cycloalkyl (e.g., C3-C5 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R37-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R37-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R37-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R27 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R37 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI 2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R18 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl. In embodiments, R18 is independently hydrogen or unsubstituted C1-C4 alkyl. In embodiments, R18 is independently hydrogen or unsubstituted C3-C6 cycloalkyl. In embodiments, R18 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl. In embodiments, R18 is independently hydrogen or unsubstituted methyl. In embodiments, R18 is hydrogen. In embodiments, R18 is unsubstituted methyl. In embodiments, R18 is unsubstituted cyclopropyl. In embodiments, R18 is —CN.
In embodiments, R18 is independently hydrogen, —CN, unsubstituted C1-C12 alkyl (e.g., C1-C10, alkyl, C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted 2 to 12 membered heteroalkyl (e.g., 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), or unsubstituted C6-C10 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl).
In embodiments, R18 is independently hydrogen, —CN, R28-substituted or unsubstituted C1-C12 alkyl (e.g., C1-C10, alkyl, C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R28-substituted or unsubstituted 2 to 12 membered heteroalkyl (e.g., 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), or R28-substituted or unsubstituted C6-C10 aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl).
R28 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, R38-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R38-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R38-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R38-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R38-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R38-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R28 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI 2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R38 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI 2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R16 is independently hydrogen or R26-substituted or unsubstituted C1-C4 alkyl.
In embodiments, R17 is independently hydrogen, R27-substituted or unsubstituted C1-C4 alkyl, or R27-substituted or unsubstituted C3-C6 cycloalkyl. In embodiments, R17 is independently hydrogen or R27-substituted or unsubstituted C1-C4 alkyl.
In embodiments, R18 is independently hydrogen, R28-substituted or unsubstituted C1-C4 alkyl, or R28-substituted or unsubstituted C3-C6 cycloalkyl. In embodiments, R18 is independently hydrogen or R28-substituted or unsubstituted C1-C4 alkyl.
In embodiments, R26 is independently —F, —Cl, —Br, or —I. In embodiments, R26 is independently-F. In embodiments, R26 is independently —Cl. In embodiments, R26 is independently-Br. In embodiments, R26 is independently —I.
In embodiments, the compound has the formula:
wherein R1.1, R1.2, R2, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
R1.1, wherein R1.1, R1.2, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.3, R2, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.3, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.3, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.3, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R2 and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1 and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.2, R2, and R3 are as described herein. In embodiments, the compound has the formula:
wherein, R1.2, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.2, R2.1, and R3 are as described herein. In embodiments, the compound has the formula:
wherein R1.2 and R3 are as described herein. In embodiments, the compound has the formula:
R1.1, R1.2, R1.3, R2, z2, and R3 are as described herein. R1.4 and R1.5 may each independently be hydrogen or any value of R1 as described herein.
In embodiments, the compound has the formula:
R1.1, R1.2, R1.3, R2, z2, and R3 are as described herein. R1.4 and R1.5 may each independently be hydrogen or any value of R1 as described herein.
In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2, R16, R17, R18, and z2 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2.1, R1.6, R17, and R18 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2, R16, R17, R18, and z2 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2.1, R16, R17, and R18 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2, R16, R17, R18, and z2 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2.1, R16, R17, and R18 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2, R16, and z2 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2.1, and R16 are as described herein.
In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, and R2.1 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, and R2.1 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R2.1, and R26, are as described herein. The symbol z26 is an integer from 0 to 5. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, and R2.1 are as described herein. R26.1, R26.2, R26.3, R26.4, and R26.5 may each independently be hydrogen or any value of R26 as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, and R2.1 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, and R2.1 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2 and R1.3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, and R1.3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R26, and z26 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, R26.1, R26.2, R26.3, R26.4, and R26.5 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, and R1.3 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, and R13 are as described herein.
In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, L2, R16, R17, and R18 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, L2, R16, R17, and R18 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, L2, R16, R17, and R18 are as described herein. In embodiments, the compound has the formula:
wherein R1.1, R1.2, R1.3, L2, and R16 are as described herein.
In embodiments, R26.1 is hydrogen. In embodiments, R26.2 is hydrogen. In embodiments, R26.3 is hydrogen. In embodiments, R26.4 is hydrogen. In embodiments, R26.5 is hydrogen.
In embodiments, R26.1 is-F, —Cl, —Br, or —I. In embodiments, R26.1 is-F. In embodiments, R26.1 is —Cl. In embodiments, R26.1 is-Br. In embodiments, R26.1 is —I. In embodiments, R26.2 is —F, —Cl, —Br, or —I. In embodiments, R26.2 is-F. In embodiments, R26.2 is —Cl. In embodiments, R26.2 is-Br. In embodiments, R26.2 is —I. In embodiments, R26.3 is —F, —Cl, —Br, or —I. In embodiments, R26.3 is-F. In embodiments, R26.3 is —Cl. In embodiments, R26.3 is-Br. In embodiments, R26.3 is —I. In embodiments, R26.4 is —F, —Cl, —Br, or —I. In embodiments, R26.4 is-F. In embodiments, R26.4 is —Cl. In embodiments, R26.4 is-Br. In embodiments, R26.4 is —I. In embodiments, R26.5 is —F, —Cl, —Br, or —I. In embodiments, R26.5 is-F. In embodiments, R26.5 is —Cl. In embodiments, R26.5 is-Br. In embodiments, R26.5 is —I.
In embodiments, R1 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R1 is independently oxo, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SR1D, —SOR1D, —SO2R1D, —SO3R1D, —SO4R1D, —SONR1AR1B, —SO2NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1B, —N(O), —N(O)2, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O)NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1A C(O)OR1C, —NR1AOR1C, —SF5, —N3, R10-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R10-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R10-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R10-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R10-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R10-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R1 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, R10-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R10-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R10-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R10-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R10-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R10-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R1 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R10 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, R11-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R11-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R11-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R11-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R11-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R11-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
R11 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R10 is independently oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, —SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, two adjacent R1 substituents are joined to form a substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, two adjacent R1 substituents are joined to form a R10-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R10-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R10-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R10-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, two adjacent R1 substituents are joined to form a unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R1A, R1B, R1C, and R1D are independently
hydrogen, —CX3, —CN, —COOH, —CONH2, —CHX2, —CH2X, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R1A, R1B, R1C, and R1D are independently hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C5 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R1A, R1B, R1C, and R1D are independently
hydrogen, —CX3, —CN, —COOH, —CONH2, —CHX2, —CH2X, R10-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R10-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R10-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R10-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R10-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R10-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R1A, R1B, R1C, and R1D are independently hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —C H2I, —CN, —COOH, —CONH2, R10-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R10-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R10-substituted or unsubstituted cycloalkyl (e.g., C3-C5 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R10-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R10-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R10-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R1A, R1B, R1C, and R1D are independently hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form an R10-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl) or R10-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl) or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R1 is independently —OCH3. In embodiments, R1 is independently —OCH2CH3. In embodiments, R1 is independently —OCH2CH2CH3. In embodiments, R1 is independently unsubstituted C1-C4 alkoxy. In embodiments, R1 is independently —OCF3. In embodiments, R1 is independently —OCF2CF3. In embodiments, R1 is independently unsubstituted C1-C4 haloalkoxy. In embodiments, R1 is independently-Br. In embodiments, R1 is independently —Cl. In embodiments, R1 is independently-F. In embodiments, R1 is independently halogen. In embodiments, R1 is independently —CH3. In embodiments, R1 is independently —CH2CH3. In embodiments, R1 is independently unsubstituted C1-C4 alkyl. In embodiments, R1 is independently —CF3. In embodiments, R1 is independently —CF2CF3. In embodiments, R1 is independently-CX13. In embodiments, R1 is independently unsubstituted C1-C4 haloalkyl. In embodiments, R1 is independently —OCH3 or —F. In embodiments, R1 is independently unsubstituted C1-C4 alkoxy or halogen. In embodiments, R1 is —CN. In embodiments, R1 is independently-SH. In embodiments, R1 is independently —SCH3. In embodiments, R1 is independently —SCF3. In embodiments, R1 is independently —SOCH3. In embodiments, R1 is independently —SO2CH3. In embodiments, R1 is independently —SOCF3. In embodiments, R1 is independently —SO2CF3. In embodiments, R1 is independently —SOn1R1D. In embodiments, R1D is independently hydrogen. In embodiments, R1D is independently unsubstituted C1-C4 alkyl. In embodiments, R1D is independently unsubstituted C1-C4 haloalkyl. In embodiment, n1 is 0. In embodiment, n1 is 1. In embodiment, n1 is 2. In embodiments, R1 is independently —SF5. In embodiments, R1 is independently unsubstituted 2 to 6 membered heteroalkyl. In embodiments, R1 is independently unsubstituted 5 to 6 membered heteroaryl. In embodiments, R1 is independently pyrazolyl. In embodiments, R1 is independently pyrrolyl. In embodiments, R1 is independently pyridazinyl. In embodiments, R1 is independently triazinyl. In embodiments, R1 is independently pyrimidinyl. In embodiments, R1 is independently imidazolyl. In embodiments, R1 is independently pyrazinyl. In embodiments, R1 is independently purinyl. In embodiments, R1 is independently oxazolyl. In embodiments, R1 is independently isoxazolyl. In embodiments, R1 is independently thiazolyl. In embodiments, R1 is independently isothiazolyl. In embodiments, R1 is independently furyl. In embodiments, R1 is independently thienyl. In embodiments, R1 is independently pyridyl. In embodiments, R1 is independently pyrimidyl. In embodiments, R1 is independently —C(O)NH2. In embodiments, R1 is independently —C(O)NR1AR1B. In embodiments, R1A is independently hydrogen. In embodiments, R1A is independently unsubstituted C1-C4 alkyl. In embodiments, R1A is independently-CH3. In embodiments, R1A is independently —CH2CH3. In embodiments, R1B is independently hydrogen. In embodiments, R1B is independently unsubstituted C1-C4 alkyl.
In embodiments, R1B is independently —CH3. In embodiments, R1B is independently —CH2CH3. In embodiments, R1C is independently hydrogen. In embodiments, R1C is independently unsubstituted C1-C4 alkyl. In embodiments, R1C is independently —CH3. In embodiments, R1C is independently —CH2CH3. In embodiments, R1D is independently hydrogen. In embodiments, R1D is independently unsubstituted C1-C4 alkyl. In embodiments, R1D is independently —CH3. In embodiments, R1D is independently —CH2CH3.
In embodiments, R1 is independently halogen. In embodiments, R1 is independently —CCl3. In embodiments, R1 is independently —CBr3. In embodiments, R1 is independently —CF3. In embodiments, R1 is independently —Cl3. In embodiments, R1 is independently —CHCl2. In embodiments, R1 is independently —CHBr2. In embodiments, R1 is independently —CHF2. In embodiments, R1 is independently —CHI2. In embodiments, R1 is independently —CH2Cl. In embodiments, R1 is independently —CH2Br. In embodiments, R1 is independently —CH2F. In embodiments, R1 is independently —CH2I. In embodiments, R1 is independently —CN. In embodiments, R1 is independently-OH. In embodiments, R1 is independently —NH2. —NHCH3. In embodiments, R1 is independently-COOH. In embodiments, R1 is independently —CONH2. In embodiments, R1 is independently —NO2. In embodiments, R1 is independently-SH. In embodiments, R1 is independently —SO3H. In embodiments, R1 is independently —SO4H. In embodiments, R1 is independently —SO2NH2. In embodiments, R1 is independently —SCH3. In embodiments, R1 is independently —SCF3. In embodiments, R1 is independently —SCHF2. In embodiments, R1 is independently —SCH2F. In embodiments, R1 is independently —SCCl3. In embodiments, R1 is independently —SCHCl2. In embodiments, R1 is independently —SCH2Cl. In embodiments, R1 is independently —SCBr3. In embodiments, R1 is independently —SCHBr2. In embodiments, R1 is independently —SCH2Br. In embodiments, R1 is independently —SCl3. In embodiments, R1 is independently —SCHI2. In embodiments, R1 is independently —SCH2I. In embodiments, R1 is independently —SOCH3. In embodiments, R1 is independently —SO2CH3. In embodiments, R1 is independently —SF5. In embodiments, R1 is independently —NHNH2. In embodiments, R1 is independently —ONH2. In embodiments, R1 is independently —NHC(O)NHNH2. In embodiments, R1 is independently —NHC(O)NH2. In embodiments, R1 is independently —NHSO2H. In embodiments, R1 is independently —NHC(O)H. In embodiments, R1 is independently —NHC(O)OH. In embodiments, R1 is independently-NHOH. In embodiments, R1 is independently —OCCl3. In embodiments, R1 is independently —OCF3. In embodiments, R1 is independently —OCBr3. In embodiments, R1 is independently —OCl3. In embodiments, R1 is independently —OCHCl2. In embodiments, R1 is independently —OCHBr2. In embodiments, R1 is independently —OCHI2. In embodiments, R1 is independently —OCHF2. In embodiments, R1 is independently —OCH2Cl. In embodiments, R1 is independently —OCH2Br. In embodiments, R1 is independently —OCH2I. In embodiments, R1 is independently —OCH2F. In embodiments, R1 is independently —N3.
In embodiments, R1 is independently halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, —CN, —SR1D, —SO2R1D—SO2NR1AR1B, —NHC(O)NR1AR1B, —N(O)2, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O)NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, R1 is independently unsubstituted C4-C6 alkyl, unsubstituted C5-C6 cycloalkyl, unsubstituted 5 to 6 membered heterocycloalkyl, or substituted or unsubstituted phenyl.
In embodiments, R1.1 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, or substituted or unsubstituted C1-C8 alkyl. In embodiments, R1.1 is independently hydrogen. In embodiments, R1.1 is independently —CF3. In embodiments, R1.1 is halogen or —OCF3. In embodiments, R1.1 is independently-Br. In embodiments, R1.1 is independently —Cl. In embodiments, R1.1 is independently-F. In embodiments, R1.1 is —OCF3. In embodiments, R1.1 is independently —OCF2CF3. In embodiments, R1.1 is independently unsubstituted C1-C4 haloalkoxy. In embodiments, R1.1 is independently —OCH3. In embodiments, R1.1 is independently —OCH2CH3. In embodiments, R1.1 is independently —OCH2CH2CH3. In embodiments, R1.1 is independently unsubstituted C1-C4 alkoxy. In embodiments, R1.1 is —CN. In embodiments, R1 is independently-SH. In embodiments, R1.1 is independently —SCH3. In embodiments, R1.1 is independently —SCF3. In embodiments, R1.1 is independently —SOCH3. In embodiments, R1.1 is independently —SO2CH3. In embodiments, R1.1 is independently —SOCF3. In embodiments, R1.1 is independently —SO2CF3. In embodiments, R1.1 is independently —SOn1R1D. In embodiments, R1D is independently hydrogen. In embodiments, R1D is independently unsubstituted C1-C4 alkyl. In embodiments, R1D is independently unsubstituted C1-C4 haloalkyl. In embodiment, n1 is 0. In embodiment, n1 is 1. In embodiment, n1 is 2. In embodiments, R1.1 is independently —SF5. In embodiments, R1.1 is independently unsubstituted 5 to 6 membered heteroaryl. In embodiments, R1.1 is independently pyrazolyl. In embodiments, R1.1 is independently pyrrolyl. In embodiments, R1.1 is independently pyridazinyl. In embodiments, R1.1 is independently triazinyl. In embodiments, R1.1 is independently pyrimidinyl. In embodiments, R1.1 is independently imidazolyl. In embodiments, R1 is independently pyrazinyl. In embodiments, R1.1 is independently purinyl. In embodiments, R1 is independently oxazolyl. In embodiments, R1.1 is independently isoxazolyl. In embodiments, R1.1 is independently thiazolyl. In embodiments, R1.1 is independently isothiazolyl. In embodiments, R1.1 is independently furyl. In embodiments, R1.1 is independently thienyl. In embodiments, R1.1 is independently pyridyl. In embodiments, R1.1 is independently pyrimidyl.
In embodiments, R1.1 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, —CN, —SR1D, —SO2R1D—SO2NR1AR1B, —C(O)R1C, —C(O)—OR1C, —OR1D, —SF5, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R1.1 is independently —CF3, —CHF2, or —CH2F. In embodiments, R1.1 is independently —OCF3, —OCH2F, or —OCHF2. In embodiments, R1.1 is independently hydrogen. In embodiments, R1.1 is independently-Br. In embodiments, R1.1 is independently —Cl. In embodiments, R1.1 is independently-F. In embodiments, R1.1 is independently halogen. In embodiments, R1.1 is independently —OCF3. In embodiments, R1.1 is independently —OCF2CF3. In embodiments, R11 is independently unsubstituted C1-C4 haloalkoxy.
In embodiments, R1.2 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, substituted or unsubstituted C1-C8 alkyl, or substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R12 is hydrogen or halogen. In embodiments, R1.2 is independently —CF3, —CHF2, or —CH2F. In embodiments, R12 is independently —OCF3, —OCH2F, or —OCHF2. In embodiments, R1.2 is independently hydrogen. In embodiments, R12 is independently-Br. In embodiments, R1.2 is independently —Cl. In embodiments, R12 is independently-F. In embodiments, R1.2 is independently halogen. In embodiments, R12 is independently —OCF3. In embodiments, R1.2 is independently —OCF2CF3. In embodiments, R1.2 is independently unsubstituted C1-C4 haloalkoxy.
In embodiments, R1.2 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, —CN, —SR1D, —SO2R1D—SO2NR1AR1B, —C(O)R1C, —C(O)—OR1C, —OR1D, —SF5, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R1.2 is independently —CF3, —CHF2, or —CH2F. In embodiments, R1.2 is independently —OCF3, —OCH2F, or —OCHF2. In embodiments, R1.2 is independently hydrogen. In embodiments, R1.2 is independently-Br. In embodiments, R1.2 is independently —Cl. In embodiments, R12 is independently-F. In embodiments, R1.2 is independently halogen. In embodiments, R1.2 is independently —OCF3. In embodiments, R1.2 is independently —OCF2CF3. In embodiments, R1.2 is independently unsubstituted C1-C4 haloalkoxy.
In embodiments, R1.3 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, —CN, —SR1D, —SO2R1D—SO2NR1AR1B, —C(O)R1C, —C(O)—OR1C, —OR1D, —SF5, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R1.3 is independently —CF3, —CHF2, or —CH2F. In embodiments, R1.3 is independently —OCF3, —OCH2F, or —OCHF2. In embodiments, R1.3 is independently hydrogen. In embodiments, R1.3 is independently-Br. In embodiments, R1.3 is independently —Cl. In embodiments, R13 is independently-F. In embodiments, R1.3 is independently halogen. In embodiments, R1.3 is independently —OCF3. In embodiments, R1.3 is independently —OCF2CF3. In embodiments, R1.3 is independently unsubstituted C1-C4 haloalkoxy.
In embodiments, R1.4 is independently hydrogen,
halogen, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, or unsubstituted isobutoxy.
In embodiments, R1.4 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, substituted or unsubstituted C1-C8 alkyl, or substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R1.4 is hydrogen or halogen. In embodiments, R1.4 is independently —CF3, —CHF2, or —CH2F. In embodiments, R1.4 is independently —OCF3, —OCH2F, or —OCHF2. In embodiments, R1.4 is independently hydrogen. In embodiments, R1.4 is independently-Br. In embodiments, R1.4 is independently —Cl. In embodiments, R1.4 is independently-F. In embodiments, R1.4 is independently halogen. In embodiments, R1.4 is independently —OCF3. In embodiments, R1.4 is independently —OCF2CF3. In embodiments, R1.4 is independently unsubstituted C1-C4 haloalkoxy.
In embodiments, R1.5 is independently hydrogen,
halogen, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, or unsubstituted isobutoxy.
In embodiments, R1.5 is independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, —CN, —SR1D, —SO2R1D—SO2NR1AR1B, —C(O)R1C, —C(O)—OR1C, —OR1D, —SF5, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R1.5 is independently —CF3, —CHF2, or —CH2F. In embodiments, R15 is independently —OCF3, —OCH2F, or —OCHF2. In embodiments, R1.5 is independently hydrogen. In embodiments, R1.5 is independently-Br. In embodiments, R1.5 is independently —Cl. In embodiments, R1.5 is independently-F. In embodiments, R1.5 is independently halogen. In embodiments, R1.5 is independently —OCF3. In embodiments, R1.5 is independently —OCF2CF3. In embodiments, R1.5 is independently unsubstituted C1-C4 haloalkoxy.
In embodiments, R1 and R1.2 are independently hydrogen, halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, or unsubstituted C1-C8 alkyl. In embodiments, R1.1 is independently hydrogen, halogen, or —OCF3; and R1.2 is independently hydrogen, halogen, or —OCF3. In embodiments, R1.1 is independently hydrogen, —F, or —OCF3; and R1.2 is independently hydrogen, —F, or —OCF3. In embodiments, R1.1 is hydrogen and R12 is hydrogen, halogen, or —OCF3. In embodiments, R1.1 is hydrogen and R12 is —OCF3. In embodiments, R1.1 is independently —OCF3; and R12 is independently hydrogen, halogen, or —OCF3. In embodiments, R1.1 is independently —OCF3 and R1.2 is independently hydrogen. In embodiments, R1.1 is independently —OCF3; and R12 is independently halogen. In embodiments, R1.1 is independently —OCF3; and R1.2 is independently-F. In embodiments, R1.1 is independently —OCF3; and R1.2 is independently —OCF3.
In embodiments, two adjacent R1 substituents are joined to form a substituted or unsubstituted 5 to 6 membered heterocycloalkyl.
In embodiments, R1 is independently halogen, —CF3, —CHF2, —CH2F, —OCF3, —OCH2F, —OCHF2, —SCF3, —SCH2F, —SCHF2, —CN, —SR1D, —SO2R1D—SO2NR1AR1B, —NHC(O)NR1AR1B, —N(O)2, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O)NR1AR1B, —OR1D, —NR1ASO 2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted 5 to 6 membered heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted 5 to 6 membered heterocycloalkyl.
In embodiments, R1 is independently —OH, —OCH3, —OCH2CH3, —OCH2CH2CH3, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —F, —Cl, —Br, —I, —CF3, —CCl3, —CBr3, —Cl3, —OCH2CF3, —OCH2CCl3, —OCH2CBr3, —OCH2Cl3, —SF5, —CF2CF3, —SCH3, —SCH2CH3, —SCF3, —SCCl3, —SCBr3, —SCI3, —SOCH3, —SO2CH3, —SOCF3, —SO2CF3, —CH2CN, —CN,
In embodiments, R1 is independently —OH, —CH3, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2OH, —F, —Cl, —Br, —I, —OCF3, —OCHF2, —OCH2CF3, —SF5, —CF2CF3, —SCH3, —SCF3, —SOCH3, —SO2CH3, —SOCF3, —SO2CF3, —CH2CN, —CN, —CF3,
In embodiments, R1 is independently-OH. In embodiments, R1 is independently —OCH3. In embodiments, R1 is independently —OCH2CH3. In embodiments, R1 is independently —OCH2CH2CH3. In embodiments, R1 is independently —OCCl3. In embodiments, R1 is independently —OCF3. In embodiments, R1 is independently —OCBr3. In embodiments, R1 is independently —OCl3. In embodiments, R1 is independently —OCHCl2. In embodiments, R1 is independently —OCHBr2. In embodiments, R1 is independently —OCHI2. In embodiments, R1 is independently —OCHF2. In embodiments, R1 is independently —OCH2Cl. In embodiments, R1 is independently —OCH2Br. In embodiments, R1 is independently —OCH2I. In embodiments, R1 is independently —OCH2F. In embodiments, R1 is independently-F. In embodiments, R1 is independently —Cl. In embodiments, R1 is independently-Br. In embodiments, R1 is independently —I. In embodiments, R1 is independently —CF3. In embodiments, R1 is independently —CCl3. In embodiments, R1 is independently —CBr3. In embodiments, R1 is independently —Cl3. In embodiments, R1 is independently —OCH2CF3. In embodiments, R1 is independently —OCH2CCl3. In embodiments, R1 is independently —OCH2CBr3. In embodiments, R1 is independently —OCH2Cl3. In embodiments, R1 is independently —SF5. In embodiments, R1 is independently —CF2CF3. In embodiments, R1 is independently —SCH3. In embodiments, R1 is independently —SCH2CH3. In embodiments, R1 is independently —SCF3. In embodiments, R1 is independently —SCCl3. In embodiments, R1 is independently —SCBr3. In embodiments, R1 is independently —SCl3. In embodiments, R1 is independently —SOCH3. In embodiments, R1 is independently —SO2CH3. In embodiments, R1 is independently —SOCF3. In embodiments, R1 is independently —SO2CF3. In embodiments, R1 is independently —CH2CN. In embodiments, R1 is independently —CN. In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1 is independently
In embodiments, R1.1 is independently-OH. In embodiments, R1.1 is independently —OCH3. In embodiments, R1.1 is independently —OCH2CH3. In embodiments, R1.1 is independently —OCH2CH2CH3. In embodiments, R1.1 is independently —OCCl3. In embodiments, R1.1 is independently —OCF3. In embodiments, R1.1 is independently —OCBr3. In embodiments, R1.1 is independently —OCl3. In embodiments, R1.1 is independently —OCHCl2. In embodiments, R1.1 is independently —OCHBr2. In embodiments, R1.1 is independently —OCHI2. In embodiments, R1.1 is independently —OCHF2. In embodiments, R1.1 is independently —OCH2Cl. In embodiments, R1.1 is independently —OCH2Br. In embodiments, R1.1 is independently —OCH2I. In embodiments, R1.1 is independently —OCH2F. In embodiments, R1.1 is independently-F. In embodiments, R1.1 is independently —Cl. In embodiments, R1.1 is independently-Br. In embodiments, R1.1 is independently —I. In embodiments, R1.1 is independently —CF3. In embodiments, R1.1 is independently —CCl3. In embodiments, R1.1 is independently —CBr3. In embodiments, R1.1 is independently —Cl3. In embodiments, R1.1 is independently —OCH2CF3. In embodiments, R1.1 is independently —OCH2CCl3. In embodiments, R1.1 is independently —OCH2CBr3. In embodiments, R1.1 is independently —OCH2Cl3. In embodiments, R1.1 is independently —SF5. In embodiments, R1.1 is independently —CF2CF3. In embodiments, R1.1 is independently —SCH3. In embodiments, R1.1 is independently —SCH2CH3. In embodiments, R1.1 is independently —SCF3. In embodiments, R1.1 is independently —SCCl3. In embodiments, R1.1 is independently —SCBr3. In embodiments, R1.1 is independently —SCl3. In embodiments, R1.1 is independently —SOCH3. In embodiments, R1.1 is independently —SO2CH3. In embodiments, R1.1 is independently —SOCF3. In embodiments, R1.1 is independently —SO2CF3. In embodiments, R1.1 is independently —CH2CN. In embodiments, R1 is independently —CN. In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
_In embodiments, R1.1 is independently
In embodiments, R1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.1 is independently
In embodiments, R1.2 is independently-OH. In embodiments, R1.2 is independently —OCH3. In embodiments, R1.2 is independently —OCH2CH3. In embodiments, R1.2 is independently —OCH2CH2CH3. In embodiments, R1.2 is independently —OCCl3. In embodiments, R1.2 is independently —OCF3. In embodiments, R1.2 is independently —OCBr3. In embodiments, R1.2 is independently —OCl3. In embodiments, R1.2 is independently —OCHCl2. In embodiments, R1.2 is independently —OCHBr2. In embodiments, R1.2 is independently —OCHI2. In embodiments, R1.2 is independently —OCHF2. In embodiments, R1.2 is independently —OCH2Cl. In embodiments, R1.2 is independently —OCH2Br. In embodiments, R1.2 is independently —OCH2I. In embodiments, R1.2 is independently —OCH2F. In embodiments, R1.2 is independently-F. In embodiments, R1.2 is independently —Cl. In embodiments, R1.2 is independently-Br. In embodiments, R1.2 is independently —I. In embodiments, R1.2 is independently —CF3. In embodiments, R1.2 is independently —CCl3. In embodiments, R1.2 is independently —CBr3. In embodiments, R1.2 is independently —Cl3. In embodiments, R1.2 is independently —OCH2CF3. In embodiments, R1.2 is independently —OCH2CCl3. In embodiments, R1.2 is independently —OCH2CBr3. In embodiments, R1.2 is independently —OCH2Cl3. In embodiments, R1.2 is independently —SF5. In embodiments, R1.2 is independently —CF2CF3. In embodiments, R1.2 is independently —SCH3. In embodiments, R1.2 is independently —SCH2CH3. In embodiments, R1.2 is independently —SCF3. In embodiments, R1.2 is independently —SCCl3. In embodiments, R1.2 is independently —SCBr3. In embodiments, R1.2 is independently —SCl3. In embodiments, R1.2 is independently —SOCH3. In embodiments, R1.2 is independently —SO2CH3. In embodiments, R1.2 is independently —SOCF3. In embodiments, R1.2 is independently —SO2CF3. In embodiments, R1.2 is independently —CH2CN. In embodiments, R is independently —CN. In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.2 is independently
In embodiments, R1.3 is independently-OH. In embodiments, R1.3 is independently —OCH3. In embodiments, R1.3 is independently —OCH2CH3. In embodiments, R1.3 is independently —OCH2CH2CH3. In embodiments, R1.3 is independently —OCCl3. In embodiments, R1.3 is independently —OCF3. In embodiments, R1.3 is independently —OCBr3. In embodiments, R1.3 is independently —OCl3. In embodiments, R1.3 is independently —OCHCl2. In embodiments, R1.3 is independently —OCHBr2. In embodiments, R1.3 is independently —OCHI2. In embodiments, R1.3 is independently —OCHF2. In embodiments, R1.3 is independently —OCH2Cl. In embodiments, R1.3 is independently —OCH2Br. In embodiments, R1.3 is independently —OCH2I. In embodiments, R1.3 is independently —OCH2F. In embodiments, R1.3 is independently-F. In embodiments, R13 is independently —Cl. In embodiments, R1.3 is independently-Br. In embodiments, R1.3 is independently —I. In embodiments, R1.3 is independently —CF3. In embodiments, R1.3 is independently —CCl3. In embodiments, R1.3 is independently —CBr3. In embodiments, R1.3 is independently —Cl3. In embodiments, R1.3 is independently —OCH2CF3. In embodiments, R1.3 is independently —OCH2CCl3. In embodiments, R1.3 is independently —OCH2CBr3. In embodiments, R1.3 is independently —OCH2Cl3. In embodiments, R1.3 is independently —SF5. In embodiments, R1.3 is independently —CF2CF3. In embodiments, R1.3 is independently —SCH3. In embodiments, R1.3 is independently —SCH2CH3. In embodiments, R1.3 is independently —SCF3. In embodiments, R1.3 is independently —SCCl3. In embodiments, R1.3 is independently —SCBr3. In embodiments, R1.3 is independently —SCl3. In embodiments, R1.3 is independently —SOCH3. In embodiments, R1.3 is independently —SO2CH3. In embodiments, R1.3 is independently —SOCF3. In embodiments, R1.3 is independently —SO2CF3. In embodiments, R1.3 is independently —CH2CN. In embodiments, R1.3 is independently —CN. In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.3 is independently
In embodiments, R1.4 is independently-OH. In embodiments, R1.4 is independently —OCH3. In embodiments, R1.4 is independently —OCH2CH3. In embodiments, R1.4 is independently —OCH2CH2CH3. In embodiments, R1.4 is independently —OCCl3. In embodiments, R1.4 is independently —OCF3. In embodiments, R1.4 is independently —OCBr3. In embodiments, R1.4 is independently —OCl3. In embodiments, R1.4 is independently —OCHCl2. In embodiments, R1.4 is independently —OCHBr2. In embodiments, R1.4 is independently —OCHI2. In embodiments, R1.4 is independently —OCHF2. In embodiments, R1.4 is independently —OCH2Cl. In embodiments, R1.4 is independently —OCH2Br. In embodiments, R1.4 is independently —OCH2I. In embodiments, R1.4 is independently —OCH2F. In embodiments, R1.4 is independently-F. In embodiments, R1.4 is independently —Cl. In embodiments, R1.4 is independently-Br. In embodiments, R1.4 is independently —I. In embodiments, R1.4 is independently —CF3. In embodiments, R1.4 is independently —CCl3. In embodiments, R1.4 is independently —CBr3. In embodiments, R1.4 is independently —Cl3. In embodiments, R1.4 is independently —OCH2CF3. In embodiments, R1.4 is independently —OCH2CCl3. In embodiments, R1.4 is independently —OCH2CBr3. In embodiments, R1.4 is independently —OCH2Cl3. In embodiments, R1.4 is independently —SF5. In embodiments, R1.4 is independently —CF2CF3. In embodiments, R1.4 is independently —SCH3. In embodiments, R1.4 is independently —SCH2CH3. In embodiments, R1.4 is independently —SCF3. In embodiments, R1.4 is independently —SCCl3. In embodiments, R1.4 is independently —SCBr3. In embodiments, R1.4 is independently —SCl3. In embodiments, R1.4 is independently —SOCH3. In embodiments, R1.4 is independently —SO2CH3. In embodiments, R1.4 is independently —SOCF3. In embodiments, R1.4 is independently —SO2CF3. In embodiments, R1.4 is independently —CH2CN. In embodiments, R1.4 is independently —CN. In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R14 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.4 is independently
In embodiments, R1.5 is independently-OH. In embodiments, R1.5 is independently —OCH3. In embodiments, R15 is independently —OCH2CH3. In embodiments, R1.5 is independently —OCH2CH2CH3. In embodiments, R1.5 is independently —OCCl3. In embodiments, R1.5 is independently —OCF3. In embodiments, R1.5 is independently —OCBr3. In embodiments, R1.5 is independently —OCl3. In embodiments, R1.5 is independently —OCHCl2. In embodiments, R1.5 is independently —OCHBr2. In embodiments, R1.5 is independently —OCHI2. In embodiments, R1.5 is independently —OCHF2. In embodiments, R1.5 is independently —OCH2Cl. In embodiments, R1.5 is independently —OCH2Br. In embodiments, R1.5 is independently —OCH2I. In embodiments, R1.5 is independently —OCH2F. In embodiments, R1.5 is independently-F. In embodiments, R1.5 is independently —Cl. In embodiments, R1.5 is independently-Br. In embodiments, R1.5 is independently —I. In embodiments, R1.5 is independently —CF3. In embodiments, R1.5 is independently —CCl3. In embodiments, R1.5 is independently —CBr3. In embodiments, R1.5 is independently —Cl3. In embodiments, R1.5 is independently —OCH2CF3. In embodiments, R1.5 is independently —OCH2CCl3. In embodiments, R1.5 is independently —OCH2CBr3. In embodiments, R1.5 is independently —OCH2Cl3. In embodiments, R1.5 is independently —SF5. In embodiments, R1.5 is independently —CF2CF3. In embodiments, R1.5 is independently —SCH3. In embodiments, R1.5 is independently —SCH2CH3. In embodiments, R1.5 is independently —SCF3. In embodiments, R1.5 is independently —SCCl3. In embodiments, R1.5 is independently —SCBr3. In embodiments, R1.5 is independently —SCl3. In embodiments, R1.5 is independently —SOCH3. In embodiments, R1.5 is independently —SO2CH3. In embodiments, R1.5 is independently —SOCF3. In embodiments, R1.5 is independently —SO2CF3. In embodiments, R1.5 is independently —CH2CN. In embodiments, R1.5 is independently —CN. In embodiments, R1.5 is independently
In embodiments, R5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R1.5 is independently
In embodiments, R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2 is independently, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2 is independently R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2 is independently unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or to 6 membered heteroaryl).
In embodiments, R2A, R2B, R2C, and RD are independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A, R2B, R2C, and R2D are independently hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2A is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2B is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2B is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2C is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2C is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2D is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2D is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2A, R2B, R2C, and RD are independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A, R2B, R2C, and R2D are independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —C H2I, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A, R2B, R2C, and R2D are independently hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form an R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl) or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or to 6 membered heterocycloalkyl) or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2A is independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2A is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —C H2I, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2A is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2B is independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2B is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —C H2I, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2B is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form an R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl) or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl). In embodiments, R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form an unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl) or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2C is independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2C is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —C H2I, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2C is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2D is independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2D is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —C H2I, —CN, —COOH, —CONH2, R20-substituted or unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), R20-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), R20-substituted or unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), R20-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), R20-substituted or unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or R20-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2′ is independently
hydrogen, —CF3, —CBr3, —CCl3, —Cl3, —CHF2, —CHBr2, —CHCl2, —CHI2, —CH2F, —CH2Br, —CH2Cl, —CH2I, —CN, —COOH, —CONH2, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered heterocycloalkyl, 3 to 6 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C12 aryl, C6-C10 aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered heteroaryl, 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
In embodiments, R2 is independently substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, R2 is independently substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R2 is independently substituted or unsubstituted C1-C8 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R2 is independently substituted C1-C8 alkyl or substituted 2 to 5 membered heteroalkyl. In embodiments, R2 is independently R20-substituted or unsubstituted C1-C8 alkyl or R20-substituted or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R2 is independently R20-substituted C1-C8 alkyl or R20-substituted 2 to 5 membered heteroalkyl. In embodiments, R2 is independently R20-substituted C1-C8 alkyl or R20-substituted 2 to 5 membered heteroalkyl; wherein R20 is substituted or unsubstituted 5 to 6 membered heterocycloalkyl or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R2 is independently R20-substituted C1-C8 alkyl; wherein R20 is substituted or unsubstituted 5 to 6 membered heterocycloalkyl or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R2 is independently R20-substituted 2 to 5 membered heteroalkyl; wherein R20 is substituted or unsubstituted 5 to 6 membered heterocycloalkyl or substituted or unsubstituted 5 to 6 membered heteroaryl. In embodiments, R2 is independently unsubstituted C1-C8 alkyl or unsubstituted 2 to 5 membered heteroalkyl. In embodiments, R2 is independently unsubstituted C1-C8 alkyl. In embodiments, R2 is independently unsubstituted 2 to 5 membered heteroalkyl.
In embodiments, R2 is hydrogen.
In embodiments, R16 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
In embodiments, R17 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
In embodiments, R18 is independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
In embodiments, R19 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
In embodiments, each R16A, R16B, R17A, R17B, R18A, R8B, R19A, and R19B, is independently hydrogen, —CX3, —CN, —COOH, —CONH2, —CHX2, —CH2X, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; each X, X16, X17, X18 and X19 is independently-F, —Cl, —Br, or —I; the symbols n16, n17, n18, n19, v16, v17, v18, and v19 are independently and integer from 0 to 4; and the symbols m16, m17, m18 and m19 are independently and integer between 1 and 2. In embodiments, the symbols v16, v17, v18, and v19 are independently 1 or 2. In embodiments, the symbols m16, m17, m18 and m19 are independently 1 or 2.
In embodiments, each R16A, R16B, R17A, R17B, R18A, R18B, R9A, and R19B, is independently hydrogen, —CX3, —CN, —COOH, —CONH2, —CHX2, —CH2X, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; each X, X16, X17, X18 and X19 is independently-F, —Cl, —Br, or —I; the symbols n16, n17, n18, n19, v16, v17, v18, and v19 are independently and integer from 0 to 4; the symbols v16, v17, v18, and v19 are independently 1 or 2; and the symbols m16, m17, m18 and m19 are independently 1 or 2.
In embodiments, X1 is-F. In embodiments, X1 is —Cl. In embodiments, X1 is-Br. In embodiments, X1 is —I. In embodiments, X2 is-F. In embodiments, X2 is —Cl. In embodiments, X2 is-Br. In embodiments, X2 is —I. In embodiments, X16 is-F. In embodiments, X16 is —Cl. In embodiments, X16 is-Br. In embodiments, X16 is —I. In embodiments, X17 is-F. In embodiments, X17 is —Cl. In embodiments, X17 is-Br. In embodiments, X17 is —I. In embodiments, X18 is-F. In embodiments, X18 is —Cl. In embodiments, X18 is-Br. In embodiments, X18 is —I. In embodiments, X19 is-F. In embodiments, X19 is —Cl. In embodiments, X19 is-Br. In embodiments, X19 is —I. In embodiments, X is-F. In embodiments, X is —Cl. In embodiments, X is-Br. In embodiments, X is —I.
In embodiments, z1 is an integer from 0 to 5. In embodiments, z1 is an integer from 0 to 2. In embodiments, z1 is 0. In embodiments, z1 is 1. In embodiments, z1 is 2. In embodiments, z1 is 3. In embodiments, z1 is 4. In embodiments, z1 is 5. In embodiments, z2 is an integer from 0 to 8. In embodiments, z2 is an integer from 0 to 2. In embodiments, z2 is 0. In embodiments, z2 is 1. In embodiments, z2 is 2. In embodiments, z2 is 3. In embodiments, z2 is 4. In embodiments, z2 is 5. In embodiments, z2 is 6. In embodiments, z2 is 7. In embodiments, z2 is 8. In embodiments, z26 is 0. In embodiments, z26 is 1. In embodiments, z26 is 2. In embodiments, z26 is 3. In embodiments, z26 is 4. In embodiments, z26 is 5. In embodiments, n1 is 0. In embodiments, n1 is 1. In embodiments, n1 is 2. In embodiments, n1 is 3. In embodiments, n1 is 4. In embodiments, m1 is 1. In embodiments, m1 is 2. In embodiments, v1 is 1. In embodiments, v1 is 2. In embodiments, n2 is 0. In embodiments, n2 is 1. In embodiments, n2 is 2. In embodiments, n2 is 3. In embodiments, n2 is 4. In embodiments, m2 is 1. In embodiments, m2 is 2. In embodiments, v2 is 1. In embodiments, v2 is 2. In embodiments, n16 is 0. In embodiments, n16 is 1. In embodiments, n16 is 2. In embodiments, n16 is 3. In embodiments, n16 is 4. In embodiments, m16 is 1. In embodiments, m16 is 2. In embodiments, v16 is 1. In embodiments, v16 is 2. In embodiments, n17 is 0. In embodiments, n17 is 1. In embodiments, n17 is 2. In embodiments, n17 is 3. In embodiments, n17 is 4. In embodiments, m17 is 1. In embodiments, m17 is 2. In embodiments, v17 is 1. In embodiments, v16 is 2. In embodiments, n18 is 0. In embodiments, n18 is 1. In embodiments, n18 is 2. In embodiments, n18 is 3. In embodiments, n18 is 4. In embodiments, m18 is 1. In embodiments, m18 is 2. In embodiments, v18 is 1. In embodiments, v18 is 2. In embodiments, n19 is 0. In embodiments, n19 is 1. In embodiments, n19 is 2. In embodiments, n19 is 3. In embodiments, n19 is 4. In embodiments, m19 is 1. In embodiments, m19 is 2. In embodiments, v19 is 1. In embodiments, v19 is 2.
In embodiments, R1 is independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SR1D, —SCX13, —SCH2X1, —SCHX12, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted C1-C6 alkyl, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted 2 to 6 membered heteroalkyl, or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, a substituted R1 (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1 is substituted, it is substituted with at least one substituent group. In embodiments, when R1 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R1.2 is independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SR1D, —SCX13, —SCH2X1, —SCHX12, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted C1-C6 alkyl, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted 2 to 6 membered heteroalkyl, or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, a substituted R1.2 (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1.2 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1.2 is substituted, it is substituted with at least one substituent group. In embodiments, when R1.2 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R12 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R1.3 is independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SR1D, —SCX13, —SCH2X1, —SCHX12, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted C1-C6 alkyl, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted 2 to 6 membered heteroalkyl, or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted 5 to 6 membered heteroaryl.
In embodiments, a substituted R1.3 (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1.3 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1.3 is substituted, it is substituted with at least one substituent group. In embodiments, when R1.3 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1.3 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R1.4 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1B, —N(O)m1, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O) NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, —N3, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R1 4 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1.4 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1.4 is substituted, it is substituted with at least one substituent group. In embodiments, when R1.4 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1.4 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R1.5 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1B, —N(O)m1, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O) NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, —N3, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R15 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R15 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R15 is substituted, it is substituted with at least one substituent group. In embodiments, when R15 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R15 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R16 is independently hydrogen,
halogen, —CX163, —CHX162, —CH2X16, —CN, —SOn16R16A, —SOv16NR16AR16B, —NHNR16AR16B, —ONR16AR16B, —NHC(O)NHNR16AR16B, —NHC(O)NR16AR16B, —N(O)m16, —NR16AR16B, —C(O)R16A, —C(O)—OR16A, —C(O)NR16AR16B, —OR16A, —NR16ASO2R16B, —NR16AC(O)R16B, —NR16AC(O)OR16B, —NR16AOR16B, —OCX163, —OCHX162, —OCH2X16, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R16 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16 is substituted, it is substituted with at least one substituent group. In embodiments, when R16 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R17 is independently hydrogen,
halogen, —CX173, —CHX172, —CH2X17, —CN, —SOn17R17A, —SOv17NR17AR17B, —NHNR17AR17B, —ONR17AR17B, —NHC(O)NHNR17AR17B, —NHC(O)NR17AR17B, —N(O)m17, —NR17AR17B, —C(O)R17A, —C(O)—OR17A, —C(O)NR17AR17B, —OR17A, —NR17ASO2R17B, —NR17AC(O)R17B, —NR17AC(O)OR17B, —NR17AOR17B, —OCX173, —OCHX172, —OCH2X17, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R17 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17 is substituted, it is substituted with at least one substituent group. In embodiments, when R17 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R18 is independently hydrogen, halogen, —CX183, —CHX182, —CH2X18, —CN, —SOn18R18A, —SOv18NR18AR18B, —NHNR18AR18B, —ONR18AR18B, —NHC(O)NHNR18AR18B, —NHC(O)NR18AR18B, —N(O)m18, —NR18AR8B, —C(O)R18A, —C(O)—OR18A, —C(O)NR18AR18B, —OR18A, —NR18ASO2R18B, —NR18AC(O)R18B, —NR18AC(O)OR18B, —NR18AOR18B, —OCX183, —OCHX182, —OCH2X18, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R18 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18 is substituted, it is substituted with at least one substituent group. In embodiments, when R18 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R19 is independently hydrogen,
halogen, —CX193, —CHX192, —CH2X19, —CN, —SOn19R19A, —SOv19NR19AR19B, —NHNR19AR19B, —ONR19AR19B, —NHC(O)NHNR19AR19B —NHC(O)NR19AR19B, —N(O)m19, —NR9AR19B, —C(O)R19A, —C(O)—OR19A —C(O)NR19AR19B, —OR19A, —NR19ASO2R19B, —NR19AC(O)R19B, —NR19AC(O)OR19B, —NR19AOR19B, —OCX193, —OCHX192, —OCH2X19, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R19 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19 is substituted, it is substituted with at least one substituent group. In embodiments, when R19 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R16A is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R16A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16A is substituted, it is substituted with at least one substituent group. In embodiments, when R16A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16A is substituted, it is substituted with at least one lower substituent group.
In embodiments, R16B is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R16B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R16B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R16B is substituted, it is substituted with at least one substituent group. In embodiments, when R16B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R16B is substituted, it is substituted with at least one lower substituent group.
In embodiments, R17A is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R17A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17A is substituted, it is substituted with at least one substituent group. In embodiments, when R17A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17A is substituted, it is substituted with at least one lower substituent group.
In embodiments, R17B is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R17B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17B is substituted, it is substituted with at least one substituent group. In embodiments, when R17B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17B is substituted, it is substituted with at least one lower substituent group.
In embodiments, R18A is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R18A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18A is substituted, it is substituted with at least one substituent group. In embodiments, when R18A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R18A is substituted, it is substituted with at least one lower substituent group.
In embodiments, R8B is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R18B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R18B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R18B is substituted, it is substituted with at least one substituent group. In embodiments, when R18B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R8B is substituted, it is substituted with at least one lower substituent group.
In embodiments, R19A is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R19A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19A is substituted, it is substituted with at least one substituent group. In embodiments, when R19A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19A is substituted, it is substituted with at least one lower substituent group.
In embodiments, R19B is independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted R19B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R19B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R19B is substituted, it is substituted with at least one substituent group. In embodiments, when R19B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R19B is substituted, it is substituted with at least one lower substituent group.
In embodiments, R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered) or substituted (e.g., substituted with at least one substituent group, size-limited substituent group, or lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is:
In embodiments, the compound is useful as a comparator compound. In embodiments, the comparator compound can be used to assess the activity of a test compound in an assay (e.g., an assay as described herein, for example in the examples section, figures, or tables).
In embodiments, the compound is a compound described herein (e.g., in an aspect, embodiment, example, table, figure, or claim).
In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient. In embodiments, the compound as described herein is included in a therapeutically effective amount.
In embodiments of the pharmaceutical compositions, the compound, or pharmaceutically acceptable salt thereof, is included in a therapeutically effective amount.
In embodiments of the pharmaceutical compositions, the pharmaceutical composition includes a second agent (e.g. therapeutic agent). In embodiments of the pharmaceutical compositions, the pharmaceutical composition includes a second agent (e.g. therapeutic agent) in a therapeutically effective amount. In embodiments of the pharmaceutical compositions, the second agent is an agent for treating cancer. In embodiments, the second agent is an anti-cancer agent. In embodiments, the second agent is a chemotherapeutic. In embodiments, the second agent is an anti-inflammatory agent. In embodiments, the administering does not include administration of any active agent other than the recited active agent (e.g., a compound described herein).
In an aspect is provided a method of inhibiting Taspase1 protein activity, the method including contacting the Taspase1 protein with a compound as described herein.
In an aspect is provided a method of treating cancer, the method including administering to a subject in need thereof an effective amount of a compound as described herein. In embodiments, the cancer is glioblastoma, bladder, kidney, liver, pancreatic, melanoma, leukemia, lymphoma, ovarian cancer, renal cancer, colon cancer, prostate cancer, lung cancer, brain cancer, or breast cancer. In embodiments, the cancer is glioblastoma. In embodiments, the cancer is bladder cancer. In embodiments, the cancer is kidney cancer. In embodiments, the cancer is liver cancer. In embodiments, the cancer is pancreatic cancer. In embodiments, the cancer is melanoma. In embodiments, the cancer is leukemia. In embodiments, the cancer is lymphoma. In embodiments, the cancer is ovarian cancer. In embodiments, the cancer is renal cancer. In embodiments, the cancer is colon cancer. In embodiments, the cancer is prostate cancer. In embodiments, the cancer is lung cancer. In embodiments, the cancer is brain cancer. In embodiments, the cancer is breast cancer.
In embodiments, the cancer is colorectal cancer. In embodiments, the cancer is liver cancer. In embodiments, the cancer is hepatocellular cancer. In embodiments, the cancer is breast cancer. In embodiments, the cancer is estrogen receptor positive breast cancer. In embodiments, the cancer is estrogen receptor (ER) negative breast cancer. In embodiments, the cancer is tamoxifen resistant breast cancer. In embodiments, the cancer is HER2 negative breast cancer. In embodiments, the cancer is HER2 positive breast cancer. In embodiments, the cancer is low grade (well differentiated) breast cancer. In embodiments, the cancer is intermediate grade (moderately differentiated) breast cancer. In embodiments, the cancer is high grade (poorly differentiated) breast cancer. In embodiments, the cancer is stage 0 breast cancer. In embodiments, the cancer is stage I breast cancer. In embodiments, the cancer is stage II breast cancer. In embodiments, the cancer is stage III breast cancer. In embodiments, the cancer is stage IV breast cancer. In embodiments, the cancer is triple negative breast cancer.
In embodiments, the cancer is sensitive to Taspase1 inhibition as determined using techniques known in the art (e.g., a screening assay).
In embodiments, the method includes administering a second agent (e.g. therapeutic agent). In embodiments, the method includes administering a second agent (e.g. therapeutic agent) in a therapeutically effective amount. In embodiments, the second agent is an agent for treating cancer. In embodiments, the second agent is an anti-cancer agent. In embodiments, the second agent is a chemotherapeutic. In embodiments, the second agent is an anti-inflammatory agent.
In an aspect is provided a method of inhibiting Taspase1 protein activity, the method including: contacting the Taspase1 protein with a compound described herein.
In an aspect is provided a Taspase1 protein covalently bonded to a compound as described herein. In embodiments, the compound is bonded (e.g., covalently bonded) to a cysteine residue of the protein.
In an aspect is provided a Taspase protein covalently bonded to a portion of a compound as described herein.
Where the compound covalently binds to the Taspase1, a Taspase1 protein (e.g., human Taspase1) covalently bonded to a Taspase1 inhibitor is formed (also referred to herein as a “Taspase1-compound adduct”), as described below. In embodiments, the resulting covalent bond is reversible. Where the resulting covalent bond is reversible, the bonding reverses upon denaturation of the protein. Thus, in embodiments, the reversibility of a covalent bond between the compound and the Taspase1 upon denaturation of the Taspase1 avoids or decreases autoimmune response in a subject subsequent to administration of the compound (relative to irreversibility).
In embodiments, the Taspase1 protein (e.g., human Taspase1) is covalently bonded to a Taspase1 inhibitor (e.g., compound described herein or a portion of a compound described herein). In embodiments, the Taspase1 protein (e.g., human Taspase1) is irreversibly covalently bonded to a Taspase1 inhibitor (e.g., compound described herein or a portion of a compound described herein). In embodiments, the Taspase1 protein (e.g., human Taspase1) is reversibly covalently bonded to a Taspase1 inhibitor (e.g., compound described herein or a portion of a compound described herein). In embodiments, the Taspase1 protein (e.g., human Taspase1) is covalently bonded to a portion of a Taspase1 inhibitor (e.g., compound described herein). In embodiments, the Taspase1 protein (e.g., human Taspase1) is irreversibly covalently bonded to a portion of a Taspase1 inhibitor (e.g., compound described herein). In embodiments, the Taspase1 protein (e.g., human Taspase1) is reversibly covalently bonded to a portion of a Taspase1 inhibitor (e.g., compound described herein). In embodiments, the Taspase1 inhibitor (e.g., compound described herein) is bonded to a cysteine residue (e.g., Cys293 of human Taspase1 or cysteine corresponding to Cys293 of human Taspase1) of the Taspase1 protein (e.g., human Taspase1).
In embodiments, the Taspase1 protein covalently bonded to a Taspase1 inhibitor or compound described herein is the product of a reaction between the Taspase1 protein and a Taspase1 inhibitor or compound described herein. It will be understood that the covalently bonded Taspase1 protein and Taspase1 inhibitor (e.g., compound described herein) are the remnants of the reactant Taspase1 protein and Taspase1 inhibitor or compound, wherein each reactant now participates in the covalent bond between the Taspase1 protein and Taspase1 inhibitor or compound. In embodiments of the covalently bonded Taspase1 protein and compound described herein, the remnant of the E substituent is a linker including a covalent bond between the Taspase1 protein and the remainder of the compound described herein. It will be understood by a person of ordinary skill in the art that when a Taspase1 protein is covalently bonded to a Taspase1 inhibitor (e.g., compound described herein), the Taspase1 inhibitor (e.g., compound described herein) forms a remnant of the pre-reacted Taspase1 inhibitor (e.g., compound described herein) wherein a bond connects the remnant of the Taspase1 inhibitor (e.g., compound described herein) to the remnant of the Taspase1 protein (e.g., cysteine sulfur, sulfur of amino acid corresponding to C293 of human Taspase1, sulfur of C293 of human Taspase1). The remnant of the Taspase1 inhibitor (compound described herein) may also be called a portion of the Taspase1 inhibitor. In embodiments, the remnant of the electrophilic moiety (e.g., R3) substituent is a linker selected from a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(O)NH—, —C(O)O—, —OC(O)—, —CH2NH—, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted arylene (e.g., C6-C10 or phenyl), or substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
Embodiment P1. A compound having the formula:
wherein,
R1 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1B, —N(O)m1, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O) NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is substituted or unsubstituted alkylene;
R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R2 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is independently —CN,
wherein R16 is independently hydrogen, halogen, —CX163, —CHX162, —CH2X16, —CN, —SOn16R16A, —SOv16NR16AR16B, —NHNR16AR16B, —ONR16AR16B, —NHC(O)NHNR16AR16B, —NHC(O)NR16AR16B, —N(O)m16, —NR16AR16B C(O)R16A, —C(O)—OR16A, —C(O)NR16AR16B, —OR16A, —NR16ASO2R16B, —NR1AC(O)R16B, —NR16AC(O)OR16B, —NR16AOR16B, —OCX163, —OCHX162, —OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R17 is independently hydrogen,
halogen, —CX173, —CHX172, —CH2X17, —CN, —SOn17R17A, —SOv17NR17AR17B, —NHNR17AR17B, —ONR17AR17B, —NHC(O)NHNR17AR17B, —NHC(O)NR17AR17B, —N(O)m17, —NR17AR17B, —C(O)R17A, —C(O)—OR17A, —C(O)NR17AR17B, —OR17A, —NR17ASO2R17B, —NR17AC(O)R17B, —NR17AC(O)OR17B, —NR17AOR17B, —OCX173, —OCHX172, —OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R18 is independently hydrogen,
halogen, —CX183, —CHX182, —CH2X18, —CN, —SOn18R18A, —SOv18NR18AR18B, —NHNR18AR18B, —ONR18AR18B, —NHC(O)NHNR18AR18B, —NHC(O)NR18AR18B, —N(O)m18, —NR18AR8B, —C(O)R18A, —C(O)—OR18A, —C(O)NR18AR18B, —OR18A, —NR18ASO2R18B, —NR18AC(O)R18B, —NR18AC(O)OR18B, —NR18AOR18B, —OCX183, —OCHX182, —OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R19 is independently hydrogen,
halogen, —CX193, —CHX192, —CH2X19, —CN, —SOn19R19A, —SOv19NR19AR19B, —NHNR19AR19B, —ONR19AR19B, —NHC(O)NHNR19AR19B, —NHC(O)NR19AR19B, —N(O)m19, —NR19AR19B C(O)R19A, —C(O)—OR19A —C(O)NR19AR19B, —OR19A, —NR19ASO2R19B, —NR19AC(O)R19B, —NR19AC(O)OR19B, —NR19AOR19B, —OCX193, —OCHX192, —OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R16A, R16B, R17A, R17B, R18A, R18B, R19A, and R19B are independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X, X1, X2, X16, X17, X18, and X19 are independently —F, —Cl, —Br, or —I;
n1, n2, n16, n17, n18, and n19 are independently an integer from 0 to 4;
m1, m2, m16, m17, m18, m19, v1, v2, v16, v17, v18, and v19 are independently 1 or 2;
z1 is an integer from 0 to 5; and
z2 is an integer from 0 to 8.
Embodiment P2. The compound of embodiment P1, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
R2.1 is independently hydrogen, oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2,
—NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl; R3 is independently —CN,
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl;
R1A, R1B, and R1D are independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and
X is independently —F, —Cl, —Br, or —I.
Embodiment P3. The compound of embodiments P1 to P2, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl 3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
R2.1 is independently hydrogen, oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2,
—NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl;
R3 is independently —CN,
and
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted C6 aryl.
Embodiment P4. The compound of one of embodiments P1 to P3, wherein R2.1 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
Embodiment P5. The compound of embodiments P1 to P3, having the formula:
wherein,
R2.1 is independently —CH2O—CH2CCH, —CH2O—CH2CN, —CH2O—CH2-heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
Embodiment P6. The compound of one of embodiments P1 to P3, wherein R2.1 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl.
Embodiment P7. The compound of one of embodiments P1 to P3, wherein R2.1 is independently hydrogen, R20-substituted or unsubstituted C1-C6 alkyl, or R20-substituted or unsubstituted 2 to 6 membered heteroalkyl;
R20 is independently —OH, R21-substituted or unsubstituted 5 to 6 membered heterocycloalkyl or
R21-substituted or unsubstituted 5 to 6 membered heteroaryl; and
R21 is independently oxo.
Embodiment P8. The compound of embodiment P1, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
L2 is unsubstituted C1-C6 alkylene;
R3 is independently —CN,
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl;
R1A, R1B, and R1D are independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and
X is independently —F, —Cl, —Br, or —I.
Embodiment P9. The compound of embodiments P1 and P8, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl 3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
L2 is unsubstituted C1-C6 alkylene;
R3 is independently —CN,
and
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted C6 aryl.
Embodiment P10. The compound of embodiment P9, wherein L2 is unsubstituted n-propylene or unsubstituted n-butylene.
Embodiment P11. The compound of embodiments P1 or P10, wherein R1.1 is independently
hydrogen, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —O CH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl3, —SCHCl2, —SCH2 Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, alkenyl, alkynyl, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, unsubstituted isobutoxy, or unsubstituted pyrazolyl;
R1.2 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, or unsubstituted C1-C4 alkyl; and
R1.3 is independently hydrogen,
halogen, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OC H2Br, —OCH2I, —OCH2F, —CN, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, or unsubstituted isobutoxy.
Embodiment P12. The compound of embodiments P1 or P10, wherein
R1.1 is independently hydrogen, —OCF3, —CN, —SCH3, —SCF3, —SOCH3, —SO2CH3, —NHCH3, —SF5, unsubstituted C2-C4 alkenyl, unsubstituted C2-C4 alkynyl, unsubstituted isopropoxy, or unsubstituted pyrazolyl;
R1.2 is independently hydrogen, —F, —Br, or —CF3; and
R1.3 is independently hydrogen, —F, or —OCF3.
Embodiment P13. The compound of one of embodiments P1 to P12, wherein
R3 is independently —CN.
Embodiment P14. The compound of one of embodiments P1 to P12, wherein
R3 is independently
Embodiment P15. The compound of one of embodiments P1 to P12, wherein
R3 is independently
Embodiment P16. The compound of one of embodiments P1 to P12, wherein
R3 is independently
Embodiment P17. The compound of one of embodiments P1 to P12, wherein
R3 is independently
Embodiment P18. The compound of one of embodiments P1 to P17, wherein
R16 is hydrogen;
R17 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl; and
R18 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl.
Embodiment P19. The compound of one of embodiments P1 to P17, wherein
R16 is hydrogen;
R17 is independently hydrogen or unsubstituted C1-C4 alkyl; and
R18 is independently hydrogen or unsubstituted C1-C4 alkyl.
Embodiment P20. The compound of one of embodiments P1 to P17, wherein
R16 is hydrogen;
R17 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl; and
R18 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl.
Embodiment P21. The compound of one of embodiments P1 to P17, wherein
R16 is hydrogen;
R17 is independently hydrogen or unsubstituted methyl; and
R18 is independently hydrogen or unsubstituted methyl.
Embodiment P22. The compound of one of embodiments P1 to P17, wherein
R16, R17 and R18 are hydrogen.
Embodiment P23. A pharmaceutical composition comprising the compound of any one of embodiments P1 to P22 and a pharmaceutically acceptable excipient.
Embodiment P24. A method of inhibiting Taspase1 protein activity, said method comprising: contacting the Taspase1 protein with a compound of one of embodiments P1 to P22.
Embodiment P25. A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of one of embodiments P1 to P22.
Embodiment P26. The method of embodiment P25, wherein the cancer is glioblastoma, melanoma, leukemia, lymphoma, ovarian cancer, renal cancer, colon cancer, prostate cancer, lung cancer, brain cancer, or breast cancer.
Embodiment P27. The method of embodiment P25, wherein the cancer is sensitive to Taspase1 inhibition.
Embodiment P28. A Taspase1 protein covalently bonded to a compound of one of embodiments P1 to P22.
Embodiment P29. The Taspase1 protein of embodiment P28, wherein the compound is bonded to a cysteine residue of the protein.
Embodiment P30. A Taspase protein covalently bonded to a portion of a compound of one of embodiments P1 to P22.
Embodiment 1. A compound having the formula:
R1 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NHC(O)NR1CNR1AR1B, —NHC(O)NR1AR1B, —N(O)m1, —NR1AR1B, —C(O)R1C, —C(O)—OR1C, —C(O) NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R1 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is substituted or unsubstituted alkylene;
R2 is independently oxo, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NHC(O)NR2CNR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O) NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two R2 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is independently —CN,
wherein R16 is independently hydrogen, halogen, —CX163, —CHX162, —CH2X16, —CN, —SOn16R16A, —SOv16NR16AR16B, —NHNR16AR16B, —ONR16AR16B, —NHC(O)NHNR16AR16B, —NHC(O)NR16AR16B, —N(O)m16, —NR16AR16B C(O)R6A, —C(O)—OR16A, —C(O)NR16AR16B, —OR16A, —NR16ASO2R16B, —NR16AC(O)R16B, —NR16AC(O)OR16B, —NR16AOR16B, —OCX163, —OCHX162, —OCH2X16, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R17 is independently hydrogen,
halogen, —CX173, —CHX172, —CH2X17, —CN, —SOn17R17A, —SOv17NR17AR17B, —NHNR17AR17B, —ONR17AR17B, —NHC(O)NHNR17AR17B, —NHC(O)NR17AR17B, —N(O)m17, —NR17AR17B, —C(O)R17A, —C(O)—OR17A, —C(O)NR17AR17B, —OR17A, —NR17ASO2R17B, —NR17AC(O)R17B, —NR17AC(O)OR17B, —NR17AOR17B, —OCX173, —OCHX172, —OCH2X17, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R18 is independently hydrogen,
halogen, —CX183, —CHX182, —CH2X18, —CN, —SOn118R8A, —SOv18NR18AR18B, —NHNR18AR18B, —ONR18AR18B, —NHC(O)NHNR18AR18B,
—NHC(O)NR18AR18B, —N(O)m18, —NR18AR8B, —C(O)R18A, —C(O)—OR18A, —C(O)NR18AR18B, —OR18A, —NR18ASO2R18B, —NR18AC(O)R18B, —NR18AC(O)OR18B, —NR18AOR18B, —OCX183, —OCHX182, —OCH2X18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R19 is independently hydrogen,
halogen, —CX193, —CHX192, —CH2X19, —CN, —SOn19R19A, —SOv19NR19AR19B, —NHNR9AR19B, —ONR19AR19B, —NHC(O)NHNR19AR19B,
—NHC(O)NR19AR19B, —N(O)m19, —NR19AR19B, —C(O)R19A, —C(O)—OR19A —C(O)NR19AR19B, —OR19A, —NR19ASO2R19B, —NR19AC(O)R19B, —NR19AC(O)OR19B, —NR19AOR19B, —OCX193, —OCHX192, —OCH2X19, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R16A, R16B, R17A, R17B, R18A, R18B, R19A, and R19B are independently hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R19A and R19B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
X, X1, X2, X16, X17, X18, and X19 are independently —F, —Cl, —Br, or —I;
n1, n2, n16, n17, n18, and n19 are independently an integer from 0 to 4;
m1, m2, m16, m17, m18, m19, v1, v2, v16, v17, v18, and v19 are independently 1 or 2;
z1 is an integer from 0 to 5; and
z2 is an integer from 0 to 8.
Embodiment 2. The compound of embodiment 1, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
R2.1 is independently hydrogen, oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl;
R3 is independently —CN,
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl;
R1A, R1B, and R1D are independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and
X is independently —F, —Cl, —Br, or —I.
Embodiment 3. The compound of one of embodiments 1 to 2, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl 3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
R2.1 is independently hydrogen, oxo, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2,
—NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —N3, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl;
R3 is independently —CN,
and
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted C6 aryl.
Embodiment 4. The compound of one of embodiments 1 to 3, wherein
R2.1 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
Embodiment 5. The compound of one of embodiments 1 to 3, having the formula:
wherein,
R2.1 is independently —CH2O—CH2CCH, —CH2O—CH2CN, —CH2O—CH2-heterocycloalkyl, substituted or unsubstituted C6-C12 aryl, or substituted or unsubstituted 5 to 12 membered heteroaryl.
Embodiment 6. The compound of one of embodiments 1 to 3, wherein
R2.1 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted 2 to 6 membered heteroalkyl.
Embodiment 7. The compound of one of embodiments 1 to 3, wherein
R2.1 is independently hydrogen, R20-substituted or unsubstituted C1-C6 alkyl, or R20-substituted or unsubstituted 2 to 6 membered heteroalkyl;
R20 is independently —OH, R21-substituted or unsubstituted 5 to 6 membered heterocycloalkyl or R21-substituted or unsubstituted 5 to 6 membered heteroaryl; and
R21 is independently oxo.
Embodiment 8. The compound of embodiment 1, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —NR1AR1B, —OR1D, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
L2 is unsubstituted C1-C6 alkylene;
R3 is independently —CN,
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C7 cycloalkyl, or substituted or unsubstituted C6-C12 aryl;
R1A, R1B, and R1D are independently
hydrogen, —CX3, —CHX2, —CH2X, —CN, —OH, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and
X is independently —F, —Cl, —Br, or —I.
Embodiment 9. The compound of embodiments 1 or 8, having the formula:
wherein,
R1.1, R1.2, and R1.3 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCl3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl 3, —SCHCl2, —SCH2Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2 to 6 membered heteroalkyl, or substituted or unsubstituted 5 to 6 membered heteroaryl;
L2 is unsubstituted C1-C6 alkylene;
R3 is independently —CN, R
and
R16, R17, and R18 are independently hydrogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —O CHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, —CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted C6 aryl.
Embodiment 10. The compound of embodiment 9, wherein L2 is unsubstituted n-propylene or unsubstituted n-butylene.
Embodiment 11. The compound of embodiments 2 or 10, wherein
R1.1 is independently
hydrogen, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —O CH2Br, —OCH2I, —OCH2F, —CN, —SH, —SCH3, —SCF3, —SCHF2, —SCH2F, —SCCl3, —SCHCl2, —SCH2 Cl, —SCBr3, —SCHBr2, —SCH2Br, —SCl3, —SCHI2, —SCH2I, —SOCH3, —SO2CH3, —NH2, —NHCH3, —OH, —SF5, alkenyl, alkynyl, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, unsubstituted isobutoxy, or unsubstituted pyrazolyl;
R1.2 is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —Cl3, CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, or unsubstituted C1-C4 alkyl; and
R1.3 is independently hydrogen,
halogen, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OC H2Br, —OCH2I, —OCH2F, —CN, unsubstituted methoxy, unsubstituted ethoxy, unsubstituted n-propoxy, unsubstituted isopropoxy, unsubstituted n-butoxy, unsubstituted t-butoxy, unsubstituted sec-butoxy, or unsubstituted isobutoxy.
Embodiment 12. The compound of embodiments 2 or 10, wherein
R1.1 is independently hydrogen, —OCF3, —CN, —SCH3, —SCF3, —SOCH3, —SO2CH3, —NHCH3, —SF5, unsubstituted C2-C4 alkenyl, unsubstituted C2-C4 alkynyl, unsubstituted isopropoxy, or unsubstituted pyrazolyl;
R1.2 is independently hydrogen, —F, —Br, or —CF3; and
R1.3 is independently hydrogen, —F, or —OCF3.
Embodiment 13. The compound of one of embodiments 1 to 12, wherein
R3 is independently —CN.
Embodiment 14. The compound of one of embodiments 1 to 12, wherein
R3 is independently R
Embodiment 15. The compound of one of embodiments 1 to 12, wherein
R3 is independently
Embodiment 16. The compound of one of embodiments 1 to 12, wherein
R3 is independently
Embodiment 17. The compound of one of embodiments 1 to 12, wherein
R3 is independently
Embodiment 18. The compound of one of embodiments 1 to 17, wherein
R16 is hydrogen;
R17 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl; and
R18 is independently hydrogen, unsubstituted C1-C4 alkyl, or unsubstituted C3-C6 cycloalkyl.
Embodiment 19. The compound of one of embodiments 1 to 17, wherein
R16 is hydrogen;
R17 is independently hydrogen or unsubstituted C1-C4 alkyl; and
R18 is independently hydrogen or unsubstituted C1-C4 alkyl.
Embodiment 20. The compound of one of embodiments 1 to 17, wherein
R16 is hydrogen;
R17 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl; and
R18 is independently hydrogen, unsubstituted methyl, or unsubstituted cyclopropyl.
Embodiment 21. The compound of one of embodiments 1 to 17, wherein
R16 is hydrogen;
R17 is independently hydrogen or unsubstituted methyl; and
R18 is independently hydrogen or unsubstituted methyl.
Embodiment 22. The compound of one of embodiments 1 to 17, wherein
R16, R17 and R18 are hydrogen.
Embodiment 23. The compound of embodiment 1, having the formula:
Embodiment 24. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 23 and a pharmaceutically acceptable excipient.
Embodiment 25. A method of inhibiting Taspase1 protein activity, said method comprising: contacting the Taspase1 protein with a compound of one of embodiments 1 to 23.
Embodiment 26. A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of one of embodiments 1 to 23.
Embodiment 27. The method of embodiment 26, wherein the cancer is glioblastoma, melanoma, leukemia, lymphoma, ovarian cancer, renal cancer, colon cancer, prostate cancer, lung cancer, brain cancer, or breast cancer.
Embodiment 28. The method of embodiment 26, wherein the cancer is sensitive to Taspase1 inhibition.
Embodiment 29. A Taspase1 protein covalently bonded to a compound of one of embodiment 1 to 23.
Embodiment 30. The Taspase1 protein of embodiment 29, wherein the compound is bonded to a cysteine residue of the protein.
Embodiment 31. A Taspase protein covalently bonded to a portion of a compound of one of embodiments 1 to 23.
Embodiment 32. A compound of any one of embodiments 1 to 23, or a pharmaceutically acceptable salt thereof, for use in a method of treating cancer, comprising administering to a subject in need thereof an effective amount of the compound.
Embodiment 33. A compound for the use of embodiment 32, wherein the cancer is glioblastoma, melanoma, leukemia, lymphoma, ovarian cancer, renal cancer, colon cancer, prostate cancer, lung cancer, brain cancer, or breast cancer.
Embodiment 34. A compound for the use of embodiment 32, wherein the cancer is sensitive to Taspase1 inhibition.
Taspase1 is a unique protease, first characterized by Professor James Hsieh, that contains a threonine residue as the active site nucleophile and cleaves substrates after an aspartate residue.3,4. It is overexpressed in numerous liquid and solid malignancies and has been termed a ‘non-oncogene addiction’protease.1,2 Major substrates of Taspase1 include the master cell, epigenetic regulatory proteins MLL and the transcription factor (TF) IIA family of nuclear proteins that regulate the cell cycle.5,6 Loss of Taspase1 disrupts proliferation of human cancer cell lines in vitro and reduces growth of tumor xenograft models of several aggressive tumor types. Taspase1 is overexpressed in multiple cancer cell lines and loss of Taspase1 sensitizes glioblastoma and melanoma cells to chemotherapy-induced apoptosis.7 Other evidence points to a key role of Taspase1 in invasion and metastasis via proteolysis of MLL in HepG2 hepatocellular carcinoma metastasis models in vitro and in vivo.8 Loss of Taspase1 strongly inhibits development of HER2-driven breast tumors and EGFR-driven lung cancer (including drug-resistant, EGFR-T790M mutant tumors). Thus, growth factor-driven, drug-resistant cancers represent promising clinical indications for Taspase1 inhibitors.
An alternative hit-finding approach using a tethering screen, inspired by successful lead compounds targeting KRAS G12C,9,10 to target selective covalent modification of a noncatalytic cysteine residue in the Taspase1 substrate-binding groove was accompanied by expanded protein crystallography efforts to drive a structure-based design optimization strategy. This approach produced the first and only known potent Taspase1 inhibitors.
The iterative process of chemical optimization and biological testing has led to the discovery of 21 covalent inhibitors with biochemical IC50<100 nM and increased cell-based potency, now enabling studies of Taspase1 inhibition in cell lines that represent clinically-relevant models.
Designs for Taspase1 inhibitors have benefited from X-ray co-structures that describe the binding modes of inhibitors, yielding molecules with improved on-target cellular efficacy, including inhibition of proliferation.
Crystallography efforts have supported structure-based drug design with co-crystal structures of inhibitors (both covalent and non-covalent) bound to truncated Taspase1 as either a 2-chain or single-chain circularly permuted protein, informing the SAR strategy by identifying regions where additional interactions might increase potency.
Warhead-bearing piperazine compounds that display ˜20 nM Taspase1 inhibition have been shown to exhibit on-mechanism cellular activity. Mass spectrometry-based tethering assays confirmed specific, concentration dependent covalent modification of the enzyme at C293. Most inhibitors show minimal inhibition of a Taspase1 mutant lacking the targeted cysteine (C293A), indicating that a large portion of the potency is due to covalency. Despite this, specific SAR trends demonstrate that binding site interactions effectively modulate inhibition. A primary optimization objective has been to increase pocket occupation and thus reduce reliance on the reactive vinyl sulfonamide warhead. This has been substantially guided by the available co-crystal structures of inhibitors bound to Taspase1 adjacent to the catalytic threonine (T234).
In parallel with the efforts to optimize binding interactions, the team has undertaken a concerted effort to explore less reactive chemical moieties used in approved drugs and clinical candidates. New electrophiles were designed to provide appropriate spacing to react with Cys293, or the catalytic Threonine and were evaluated using piperazine substitutions known to enable potent Taspase1 inhibition. No compounds intended to interact covalently with the catalytic Threonine have yet shown inhibition of Taspase1, but compounds with alternative Cysteine-reactive warheads have demonstrated low micromolar inhibition of the enzyme.
The most potent covalent inhibitors approach the enzymatic assay sensitivity limits. To extend that assay, compounds are also tested in the presence of 6.6 mM GSH as a non-specific, but physiologically relevant, thiol competitor. Selected analogs, notably those with piperazine substitutions (SMDC128), exhibit a smaller drop-off in the presence of 6.6 mM GSH, predicting less sensitivity to intracellular antioxidants and the prospect for better cellular activity.
An additional 30 compounds in the series were shown to exhibit dose-dependent activity (EC50 less than 40 μM) in a cell-based assay that monitors cleavage of a Taspase1 substrate (
The ratio of cell to biochemical potency can vary, possibly due to reaction of the vinyl sulfonamide warhead with cytosolic components such as GSH. We have reduced the gap between enzyme and cell-based activity with analogs such as SMDC069, with a ˜30-fold ratio of cellular to biochemical potency compared to the ˜200 fold drop-off with SMDC689.
Using compounds with increased on-target cellular activity assay, it is now feasible to examine inhibition of cell growth. Taspase1 shRNA knockdown produces target-specific cell growth reduction in specific cancer cell lines. We tested whether inhibitors could phenocopy these results by treating cell monolayers with varying doses of SMDC069, SMDC689, and an inactive control, with the same warhead.
In vitro experiments showed that electrophilic piperazine compounds have uniformly excellent solubility and permeability, with no efflux liability. Most examples showed moderate to good microsomal stability. Taken together with the improved cellular data, this suggests a promising profile for discovering future inhibitors worthy of testing in vivo.
We propose to further optimize the current covalent and non-covalent scaffolds using new structural information, particularly co-crystal structures of compounds bound to full-length Taspase 1, to build in non-covalent interactions and decrease reactivity through use of alternative warheads. In the future we plan to further improve cell-based potency over our current best-in-class inhibitors, retain acceptable solubility, permeability and microsomal stability properties and begin evaluating optimized compounds in POC in vivo models reported above to be Taspase sensitive.
[4-(trifluoromethoxy)phenyl]prop-2-enenitrile: By the procedure of the cited reference (applies to parts 1 and 2), Sodium hydride 60% dispersion in mineral oil (0.558 g, 14.0 mmol 1.00 eq) was dissolved in dry Tetrahydrofuran (17 ml) and stirred in an ice bath under dry Argon. Diethyl cyanomethyl phosphonate (2.25 ml, 14.0 mmol, 1.00 eq) was added. 4-(Trifluoromethoxy)benzaldehyde (1.99 ml, 14.0 mmol, 1.00 eq) was added as a solution in Tetrahydrofuran (5 ml). The reaction was stirred and allowed to warm to room temperature overnight. The reaction was quenched with water and the reaction mixture was partitioned between water and Ethyl acetate with the water layer extracted twice. The combined organic layer was organics were dried with brine and Sodium sulfate, decanted, concentrated to afford a residue which was dissolved in 10:1 hexane ether and hexane was added until 20:1 when crystallization afforded pure intermediate (1.18 g, 5.55 mmol) 39% yield which was used directly in the next reaction. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 5.88 (d, J=16.58 Hz, 1H) 7.26 (d, J=8.67 Hz, 2H) 7.40 (d, J=16.58 Hz, 1H) 7.45-7.55 (m, 2H).
3-[4-(trifluoromethoxy)phenyl]propan-1-amine: Lithium aluminum hydride (304 mg, 8.02 mmol, 3.20 eq) was suspended in dry diethyl ether (15 ml) with stirring under dry argon. This was heated to 50° C. and a solution of [4-(trifluoromethoxy)phenyl]prop-2-enenitrile (534 mg, 2.51 mmol, 1 eq) in diethyl ether (5 ml) was added dropwise with a syringe. Heating was continued for 1.5 hours, the reaction was cooled to room temperature and stirred overnight. The reaction was quenched by slow addition of water (5 ml) in an ice bath followed by 1M NaOH (10 ml). The mixture was vigorously stirred with Ethyl acetate for 0.5 hours, partitioned and the water layer was extracted twice more with Ethyl acetate. The combined organics were dried with brine then sodium sulfate, filtered and concentrated to afford crude 3-[4-(trifluoromethoxy)phenyl]propan-1-amine (481 mg, 2.19 mmol) 87% yield, crude which was used crude in the next step. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.64-1.76 (m, 2H) 2.55-2.63 (m, 2H) 2.66 (t, J=7.06 Hz, 2H) 7.03-7.11 (m, 2H) 7.11-7.17 (m, 2H).
[4-(trifluoromethoxy)phenyl]propyl}ethene-1-Sulfonamide (SMDC714): 3-[4-(trifluoromethoxy)phenyl]propan-1-amine (74.1 mg, 0.385 mmol, 1.00 eq) was dissolved in DCM (4 mL) and cooled to 0° C. The reaction mixture was treated with trimethylamine (2.00 equiv). To it was added 98.0% 2-Chloroethanesulfonyl chloride (1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated and loaded on a 12 g Silicycle cartridge in a gradient of Ethyl acetate 0-30% in Hexane to afford the product (34.8 mg, 0.113 mmol) 29% yield. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.79-1.94 (m, 2H) 2.63-2.73 (m, 2H) 3.04 (q, J=6.84 Hz, 2H) 4.68 (t, J=5.93 Hz, 1H) 5.94 (d, J=9.80 Hz, 1H) 6.23 (d, J=16.58 Hz, 1H) 6.51 (dd, J=16.48, 9.89 Hz, 1H) 7.08-7.16 (m, 2H) 7.16-7.24 (m, 2H); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 31.45, 31.99, 42.33, 121.10, 122.20, 126.89, 129.66, 135.76, 139.63, 147.62; 19 F NMR (282 MHz, METHANOL-d4) δ ppm −57.93 (s, 1 F); LCMS (ESI+) m/z 310.30 (M+H+).
1-(Ethenesulfonyl)piperazine hydrochloride: N-Boc piperazine (10.0 g, 53.7 mmol, 1.0 eq), was dissolved in CH2Cl2 (400 mL, 0.13 M), and Et3N (20 mL, 214 mmol, 4.0 eq) was added. The mixture was cooled to 0° C. in an ice bath and 2-chloroethane sulfonyl chloride (7.86 mL, 75.2 mmol, 1.4 eq) was added. After addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 16 hours. The reaction was diluted with H2O and extracted with CH2Cl2 (×3). The combined organic layers were washed with saturated aqueous NaCl, dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified on silica (0-70% gradient of EtOAc in Hexanes). 1H NMR (400 MHz, MeOD): δ 6.64 (dd, 1H, J=10.0, 16.5 Hz), 6.19 (d, 1H, J=16.5 Hz), 6.13 (d, 1H, J=10.0 Hz), 3.52 (4H, t, J=4.78 Hz), 3.10 (4H, t, J=5.2 Hz), 1.46 (s, 9H).
This material was dissolved in THE (˜200 mL) and 4 M HCl in dioxane was added (134 mL, 537 mmol, 10 eq) and the reaction was allowed to stir overnight at room temperature. The reaction mixture was then concentrated in vacuo and dried under low pressure to give 9.11 g (80% yield over 2 steps) of 1-(ethenesulfonyl)piperazine hydrochloride as an off-white powder, which was used without further purification. 1H NMR (400 MHz, MeOD): δ 6.72 (dd, 1H, J=10.0, 16.5 Hz), 6.27 (d, 1H, J=16.5 Hz), 6.21 (d, 1H, J=10.0 Hz), 3.44-3.40 (m, 4H), 3.36-3.30 (m, 4H); MS (ES): m/z 177.1 [M+H]+
1-(ethenesulfonyl)-4-{[4-(trifluoromethoxy)phenyl]methyl}piperazine (SMDC967): 1-(ethenesulfonyl)piperazine hydrochloride (122 mg, 0.6 mmol, 1.0 equiv.) was suspended in a septum-capped 20 vial in ordinary non-dried reagent grade acetonitrile (3 ml), potassium carbonate (159 mg, 1.1 mmol, 2.0 equiv.) was added, followed by 4-(Trifluoromethoxy)benzyl bromide (97 ul, 0.6 mmol, 1.0 equiv.). The reaction mixture was stirred at room temperature for 2 hours, filtered through celite, concentrated, dissolved in a small amount dichloromethane and eluted on a 12 g Silicycle cartridge in a gradient of Ethyl Acetate 0-100% in Hexane. The product was further purified by HPLC 30-80% Methanol (0.05% Formic acid both) in water over 12 min 18 min total, to afford the product (49 mg, 0.1 mmol) 24% yield as a clear oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.39-2.72 (m, 4H) 3.10-3.27 (m, 4H) 3.55 (s, 2H) 6.06 (d, J=9.98 Hz, 1H) 6.25 (d, J=16.58 Hz, 1H) 6.44 (dd, J=16.58, 9.80 Hz, 1H) 7.17 (m, J=8.29 Hz, 2H) 7.34 (m, J=8.29 Hz, 2H), 19F NMR (282 MHz, CHLOROFORM-d) δ ppm 57.87 (s, 1 F) 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 45.62 (s, 1 C) 52.21 (s, 1 C) 61.68 (s, 1 C) 76.58 (s, 1 C) 77.43 (s, 1 C) 120.89 (s, 1 C) 128.92 (s, 1C) 130.18 (s, 1 C) 132.13 (s, 1 C) 136.38 (s, 1 C); LCMS (ESI+) m/z 351.1 (M+H+).
1-(Ethenesulfonyl)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazine (SMDC689) (2): 3-Fluoro-4-(trifluoromethoxy)benzaldehyde (78 mg, 0.392 mmol, 1.0 eq.) and 1 (100 mg, 0.47 mmol, 1.2 eq) were dissolved in dichloroethane (2.5 mL, 0.16 M). NaBH(OAc)3 was added, and the reaction was allowed to stir overnight at room temperature. After confirmation of product formation by LC/MS, the reaction was quenched with 2 M NaOH, then extracted with CH2Cl2 (×3). The combined organic layers were then washed with saturated aqueous NaCl, dried over MgSO4, and concentrated in vacuo. The crude residue was dissolved in MeOH and purified by HPLC to give 66.1 mg (45.6% yield) of the desired product. 1H NMR (400 MHz, CDCl3): δ 7.40-7.37 (m, 2H), 7.32 (d, 1H, J=8.0 Hz), 6.44 (dd, 1H, J=9.8, 16.5 Hz), 6.29 (d, 1H, J=16.5 Hz), 6.15 (d, 1H, J=9.8 Hz), 4.15 (s, 1H), 3.57 (bs, 4H), 3.22 (bs, 4H); 13C NMR (100 MHz, CDCl3): δ 42.84, 51.23, 59.64, 120.37 (q, J=249, 518), 120.25 (d, J=20 Hz), 124.56, 127.57 (d, J=2 Hz), 128.69 (d, 7 Hz), 130.98, 131.55, 138.16 (d, 12 Hz), 154.56 (d, J=255 Hz); DEPT-135 (100 MHz, CDCl3): δ 42.74 (CH2), 51.14 (CH2), 59.56 (CH2), 120.15 (d, J=19 Hz, CH), 124.47 (CH), 127.46 (d, J=4 Hz, CH), 130.88 (CH2), 131.46 (CH); MS (ES) m/z 369.3 [M+H]+.
1-(3-(Trifluoromethoxy)benzyl)-4-(vinyl sulfonyl)piperazine (SMDC723): To 100 mg of 1 (100 mg, 0.47 mmol) in dichloroethane (4.0 mL) was added 3-(trifluoromethoxy)benzaldehyde (70 μL, 0.56 mmol) followed by NaBH(OAc)3 (350 mg, 1.61 mmol). The reaction vessel capped, purged with Argon, and stirred for 1.5 h at rt. The reaction solution was then diluted with CH2Cl2 (20 mL) and washed with 1 M aqueous NaOH (15 mL). The aqueous layer was then extracted 3× with CH2Cl2 (20 mL). The combined organics were then washed with brine and dried with MgSO4. The crude product was absorbed onto celite and purified on a C18 column with 0-50% water (0.1 TFA): MeCN to afford 1-(3-(trifluoromethoxy)benzyl)-4-(vinyl sulfonyl)piperazine (33.5 mg, 20%).1H NMR (400 MHz; MeOD): δ 7.64-7.60 (m, 1H), 7.54-7.51 (m, 2H), 7.45 (d, J=8.2 Hz, 1H), 6.71 (dd, J=16.6, 10.0 Hz, 1H), 6.28 (d, J=16.6 Hz, 1H), 6.22 (d, J=10.0 Hz, 1H), 4.38 (s, 2H), 3.44 (bs, 4H), 3.33 (bs, 4H); 13C NMR (100 MHz, CDCl3): δ 42.76, 51.22, 60.24, 120.38 (q, J=171, 343 Hz), 123.00, 123.51, 129.43, 129.76, 131.03, 131.25, 131.48, 149.84; DEPT-135 (100 MHz, CDCl3): δ 42.67 (CH2), 51.13 (CH2), 60.14 (CH2), 122.89 (CH), 123.41 (CH), 129.32 (CH), 130.90 (CH2), 131.15 (CH), 131.41 (CH); MS (ES) m/z 351.0 [M+H]+.
tert-butyl (3S)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate: 1-benzyl 4-tert-butyl (25)-2-(2-methoxy-2-oxoethyl)piperazine-1,4-dicarboxylate (1.23 g, 3.13 mmol, 1 eq) was dissolved in Ethanol (116 ml) and Palladium 10% in Carbon (465 mg) was added. The flask was fitted with a balloon adaptor, evacuated, and purged with hydrogen 3 times. The reaction mixture was then stirred under hydrogen for 2 hours, then filtered through celite and concentrated to afford a sooty-colored oil which was used in the next step. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.93-10.19 (brs, 1H) 4.05-4.28 (m, 1H) 3.93-4.06 (m, 1H) 3.72 (s, 2H) 3.69-3.78 (m, 1H) 3.53-3.63 (m, 1H) 3.19-3.54 (m, 1H) 3.07-3.18 (m, 1H) 2.95-3.06 (m, 1H) 2.69-2.85 (m, 1H) 1.43 (s, 5H).
tert-butyl (3 S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate: tert-butyl (3S)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate (509 mg, 1.97 mmol, 1 eq) was reacted with 3-fluoro-(trifluoromethoxy)benzaldehyde (0.341 ml, 1.97 mmol, 1 eq) in DCE (15 mL). Half an hour later, sodium triacetoxyborohydride (1.4 equiv.) was added to the above reaction mixture. The reaction mixture was monitored by LCMS and TLC. Next day, 12 h later, 100 mg more sodium triacetoxyborohydride was added to push the reaction mixture to the completion. 12 h later, the reaction mixture was treated with sat. 10% saturated solution of sodium bicarbonate solution (100 mL). Then the organic layer was extracted with dichloromethane (2×80 mL), the combined layers was washed with water (2×100 mL), dried over Na2SO4, and concentrated under reduced pressure to afford a residue which was purified on a 25 g Silicycle cartridge in a gradient of 0-100% Ethyl acetate in hexane to afford a product (546 mg, 1.21 mmol) 61% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.08-7.22 (m, 1H) 6.94-7.07 (m, 1H) 3.61 (br. s, 2H) 3.49-3.79 (m, 4H) 2.92-3.48 (m, 3H) 2.34-2.58 (m, 2H) 2.13-2.34 (m, 1H) 1.37 (s, 6H) 1.25-1.47 (m, 6H) 1.25-1.47 (m, 6H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 172.06 (s, 1 C) 155.56 (s, 1 C) 154.59 (s, 1 C) 153.05 (s, 1 C) 139.86 (s, 1 C) 134.97 (s, 1 C) 124.04 (s, 1 C) 123.21 (s, 1 C) 121.57 (s, 1 C) 118.99 (s, 1 C) 116.66 (s, 1 C) 79.54 (s, 1 C) 57.11 (s, 1 C) 55.31 (s, 1 C) 51.45 (s, 1 C) 47.50 (s, 1C) 46.83 (s, 1 C) 42.39 (s, 1 C) 29.93 (s, 1 C) 28.03 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −59.04 (d, J=4.09 Hz, 3 F) 129.27-−129.16 (m, 1 F); LCMS (ESI+) m/z 451.16 (M+H+)
tert-butyl (3 S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-hydroxyethyl) piperazine-1-carboxylate: Lithium aluminum hydride (54 mg, 1.42 mmol, 1.33 eq) was stirred in dry Tetrahydrofuran (15 ml) under dry argon with stirring. To this was added a solution of tert-butyl (3 S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate (480 mg, 1.07 mmol, 1.00 eq) in 10 ml tetrahydrofuran via syringe over a 3 minute period at room temperature. The reaction was monitored to be complete by TLC. If not complete a small amount of LiAlH4 may be added. The reaction was then cooled in an icebath with rapid stirring quenched by careful addition of 1.5 ml water, then 5 ml 2M NaOH, then 3 ml more water. The resulting mixture was filtered through celite then extracted twice with Diethyl ether. The combined organics were dried with brine and sodium sulfate, filtered and concentrated. The residue was dissolved in minimal Dichloromethane and eluted on a 25 g Silicycle cartridge in a gradient of Ethyl acetate in Hexane 20-100% to afford the product (371 mg, 0.880 mmol) 83% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.12-7.22 (m, 1H) 7.02-7.08 (m, 1H) 3.77-3.95 (m, 1H) 3.59-3.77 (m, 2H) 3.34 (br. s., 3H) 2.53-2.71 (m, 1H) 2.10-2.24 (m, 1H) 1.75-1.89 (m, 1H) 1.62-1.75 (m, 1H) 1.39 (s, 6H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.58 (s, 1 C) 154.85 (s, 1 C) 153.07 (s, 1 C)
(s, 1 C) 139.95 (s, 1 C) 135.13 (s, 1 C) 135.10 (s, 1 C) 135.08 (s, 1 C) 134.99 (s, 1 C) 134.98 (s, 1 C) 134.96 (s, 1 C) 124.23 (s, 1 C) 124.20 (s, 1 C) 123.29 (s, 1 C) 121.60 (s, 1 C) 119.02 (s, 1 C) 117.03 (s, 1 C) 116.84 (s, 1 C) 116.45 (s, 1 C) 79.87 (s, 1 C) 79.73 (s, 1 C) 77.32 (s, 1 C) 76.69 (s, 1 C) 59.81 (s, 1 C) 56.99 (s, 1 C) 56.61 (s, 1 C) 48.57 (s, 1 C) 47.73 (s, 1 C) 45.95 (s, 1 C) 43.13 (s, 1 C) 41.84 (s, 1 C) 29.42 (s, 1 C) 28.15 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −58.97 (d, J=4.09 Hz, 1 F) −129.19-−128.97 (m, 1 F); LCMS (ESI+) m/z 423.11 (M+H+).
(2S)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine; trifluoromethanesulfonic acid salt: tert-butyl (3S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-hydroxyethyl)piperazine-1-carboxylate (443 mg, 1.05 mmol, 1.00 eq) was dissolved in dry dichloromethane (3 ml) and treated with 4M HCl in dry 1,4-dioxane (6 ml). The mixture was stirred for 2 hours under dry argon, then evaporated to afford a gummy solid which was immediately redissolved and stirred in dry dichloromethane (30 ml). To this was added Triethylamine (439 ul, 3.15 mmol, 3.00 eq) and the mixture was cooled in an icebath. Triisopropylsilyl trifluoromethanesulfonate (353 ul, 1.31 mmol, 1.25 equiv.) was added and the reaction mixture was allowed to warm to room temperature and checked for completion by TLC Upon completion (4 hours), the reaction was quenched by addition of saturated Sodium bicarbonate, partitioned between water and ethyl acetate with the water layer extracted twice with ethyl acetate, the combined organics were dried with brine, sodium sulfate, filtered and concentrated. The residue was redissolved in a small amount of Dichloromethane then eluted in a gradient of 0-10% Methanol in Dichloromethane to afford the product (435 mg, 0.909 mol) 87% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.16-7.26 (m, 1H) 7.09 (d, J=8.52 Hz, 1H) 6.24 (s, 1H) 3.96 (d, J=14.12 Hz, 1H) 3.71-3.83 (m, 1H) 3.30 (d, J=14.37 Hz, 1H) 3.19-3.27 (m, 1H) 3.06-3.16 (m, 1H) 2.94-3.06 (m, 1H) 2.85 (br. s., 1H) 2.74-2.81 (m, 1H) 2.38 (br. s., 1H) 1.85-1.97 (m, 1H) 1.72-1.85 (m, 1H) 0.94-1.13 (m, 23H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.77 (s, 1 C) 153.26 (s, 1 C) 139.80 (s, 1 C) 139.74 (s, 1 C) 135.32 (s, 1 C) 135.31 (s, 1 C) 135.20 (s, 1 C) 135.18 (s, 1 C) 124.77 (s, 1 C) 124.27 (s, 1 C) 124.08 (s, 1 C) 124.05 (s, 1 C) 123.48 (s, 1 C) 121.70 (s, 1 C) 121.59 (s, 1 C) 119.12 (s, 1 C) 118.42 (s, 1 C) 116.89 (s, 1 C) 116.70 (s, 1 C) 116.55 (s, 1 C) 115.25 (s, 1 C) 59.76 (s, 1 C) 56.39 (s, 1 C) 55.81 (s, 1 C) 48.22 (s, 1 C) 48.08 (s, 1 C) 44.11 (s, 1 C) 31.19 (s, 1 C) 17.85 (s, 1 C) 11.76 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −58.99 (d, J=4.09 Hz, 3 F) 78.53 (s, 1 F) −129.24-−128.60 (m, 1 F); LCMS (ESI+) m/z 479.26 (M+H+).
(2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine: (2S)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine; trifluoromethanesulfonic acid salt (217 mg, 0.345 mmol, 1.00 eq) was dissolved in DCM and cooled to 0° C. The reaction mixture was treated with trimethylamine (2.00 equiv). To it was added 98.0% 2-Chloroethanesulfonyl chloride (1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated to afford a crude product which was eluted on a 12 g Silicycle cartridge in a gradient of ethyl acetate in hexane to give the product (143 mg, 0.252 mmol) 73% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.18-7.25 (m, 1H) 7.09 (dd, J=8.52, 0.73 Hz, 1H) 6.43 (dd, J=9.98, 6.57 Hz, 1H) 6.23 (d, J=16.56 Hz, 1H) 6.05 (d, J=9.98 Hz, 1H) 3.77-3.85 (m, 1H) 3.75 (s, 1H) 3.46 (d, J=14.37 Hz, 1H) 3.20 (d, J=4.63 Hz, 1H) 3.03-3.11 (m, 1H) 2.90-2.95 (m, 1H) 2.72-2.80 (m, 1H) 2.36-2.44 (m, 1H) 1.80-1.89 (m, 1H) 0.96-1.12 (m, 10H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.77 (s, 1 C) 153.26 (s, 1 C) 140.25 (s, 1 C) 140.19 (s, 1 C) 135.15 (dq, J=12.47, 1.71 Hz, 1 C) 132.09 (s, 1 C) 128.80 (s, 1 C) 124.01 (d, J=3.67 Hz, 1 C) 123.41 (s, 1 C) 121.71 (s, 1 C) 120.41 (q, J=258.00 Hz, 1 C) 116.86 (s, 1 C) 60.14 (s, 1C) 56.63 (s, 1 C) 56.61 (s, 1 C) 55.57 (s, 1 C) 48.81 (s, 1 C) 47.88 (s, 1 C) 45.30 (s, 1 C) 29.04 (s, 1 C) 17.94 (s, 1 C) 11.81 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −58.90 (d, J=5.45 Hz, 3F) −129.07-−129.00 (m, 1F).
2-[(2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]ethan-1-ol (SMDC069): (2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine (143 mg, 0.252 mmol, 1.00 eq) was dissolved in dry Dichloromethane (4 ml) and stirred under dry argon. Tetrabutyl ammonium fluoride solution in THE (7 ml) was added and the progress of the reaction was monitored frequently by TLC to prevent formation of the cyclic product. As soon as the starting material disappeared, the reaction was quenched by the addition of 50% saturated Sodium bicarbonate in water. The mixture was diluted with Ethyl acetate and water and the water layer was extracted twice. The combined organic layer was dried with brine then Sodium sulfate, filtered and concentrated to afford a residue which was re-dissolved in Dichloromethane and purified on a 4 g Silicycle cartridge. Further purification was achieved by HPLC on C18 in a gradient of 30-80% Methanol in Water 12 min 18 total each 0.05% Formic acid. Since the UV absorbance of the compound was low in the 200-300 nm UV range, a sensitive collection method was used to obtain the product (41 mg, 0.098 mmol) 39% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.18-7.27 (m, 2H) 7.10 (d, J=8.28 Hz, 1H) 6.44 (dd, J=16.68, 9.86 Hz, 1H) 6.25 (d, J=16.56 Hz, 1H) 6.08 (d, J=9.98 Hz, 1H) 3.92 (d, J=13.88 Hz, 1H) 3.77-3.88 (m, 1H) 3.73 (ddd, J=10.84, 7.18, 5.60 Hz, 1H) 3.47 (d, J=13.88 Hz, 1H) 3.23-3.29 (m, 1H) 3.04-3.23 (m, 3H) 2.88-2.95 (m, 1H) 2.79-2.88 (m, 1H) 2.64 (s, 1H) 2.42 (ddd, J=12.30, 5.97, 3.65 Hz, 1H) 1.82-2.03 (m, 2H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.74 (s, 1 C) 153.23 (s, 1 C) 139.58 (d, J=5.87 Hz, 1 C) 135.31 (d, J=10.27 Hz, 1 C) 131.95 (s, 1C) 129.31 (s, 1 C) 129.12 (s, 1 C) 124.26 (d, J=3.67 Hz, 1 C) 123.51 (s, 1 C) 121.67 (s, 1 C) 120.39 (q, J=258.00 Hz, 1 C) 117.08 (s, 1 C) 116.89 (s, 1 C) 116.52 (s, 1 C) 60.02 (s, 1 C) 56.55 (d, J=1.47 Hz, 1 C) 56.42 (s, 1 C) 48.32 (s, 1 C) 47.70 (s, 1 C) 44.67 (s, 1 C) 28.72 (s, 1 C); LCMS (ESI+) m/z 413.04 (M+H+).
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-(hydroxymethyl)piperazine-1-carboxylate (c): To a solution of 3-fluoro-4-(trifluoromethoxy)benzaldehyde 1 (2.19 g, 10.2 mmol, 1.0 equiv.) in DCE (60 mL) was added tert-butyl (R)-3-(hydroxymethyl)piperazine-1-carboxylate 2 (2.19 g, 9.65 mmol, 1.0 equiv.). Half an hour later, sodium triacetoxyborohydride (3.02 g, 14.3 mmol, 1.4 equiv.) was added to the above reaction mixture. The reaction mixture was monitored by LCMS and TLC. Next day, 12 h later, 500 mg more sodium triacetoxyborohydride was added to push the reaction mixture to the completion. 12 h later, the reaction mixture was treated with sat. 10% saturated solution of sodium bicarbonate solution (100 mL). Then the organic layer was extracted with dichloromethane (2×80 mL), the combined layers was washed with water (2×100 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude liquid was loaded on to a 120 g silica column. The crude was purified by a gradient 100% hexane to 100% ethyl acetate. The yield was 68.4%. 1H NMR (400 MHz; METHANOL-d4) S: 7.32-7.40 (m, 2H), 7.26 (d, J=8.0 Hz, 1H), 4.86 (s, 1H), 4.06-4.14 (m, 1H), 3.73-3.81 (m, 2H), 3.53-3.68 (m, 2H), 3.46 (d, J=14.2 Hz, 1H), 3.14-3.29 (m, 2H), 2.64-2.72 (m, 1H), 2.45-2.52 (m, 1H), 2.16-2.25 (m, 1H), 1.46 (s, 9H); 13C NMR (100 MHz; METHANOL-d4) δ: 157.3, 156.9, 154.8, 142.9, 136.7, 136.5, 126.5, 125.0, 123.6, 121.0, 118.8, 81.6, 62.8, 61.9, 58.5, 51.3, 50.0, 29.0, 21.2, 14.8; 19F NMR (376 MHz; METHANOL-d4) S: 60.59 (s, 1F), −131.71 (s, 1F); MS m/z=431 as a Na+ salt.
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-((prop-2-yn-1-yloxy)methyl) piperazine-1-carboxylate (d): 60.0% Sodium hydride (482 mg, 12.0 mmol, 4.20 equiv.) was added to a solution of tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate c (1.16 g, 2.80 mmol, 1.00 equiv.) in tetrahydrofuran (6.00 mL) at 0° C. under N2. The reaction mixture was stirred under nitrogen for 60 min. Then 80.0% propargyl bromide in toluene (9.40 ml, 6.0 mmol, 2.1 equiv.) was added to the reaction mixture at 0° C. The reaction mixture was stirred for 12 h at 70° C. The reaction mixture was cooled to room temperature and treated with ice water. The reaction mixture was poured in a separator funnel, extracted with ethyl acetate (3×50 mL), dried over MgSO4 and concentrated under reduced pressure. Then the crude mixture was loaded on to a 40 g silica column and purified with a gradient 100% hexane to 100% ethyl acetate. The yield was 80%. 1H NMR (400 MHz; CHLOROFORM-d) S: 7.28-7.51 (m, 1H), 7.20-7.26 (m, 2H), 7.12 (br d, J=8.4 Hz, 1H), 4.71 (s, 1H), 3.95-4.19 (m, 3H), 3.89-3.91 (m, 1H), 3.52-3.78 (m, 3H), 3.41-3.52 (m, 2H), 3.21-3.37 (m, 1H), 2.77 (s, 1H), 2.57-2.73 (m, 2H), 2.43 (t, J=2.1 Hz, 1H), 2.13-2.34 (m, 1H), 2.05 (s, 1H), 1.64 (br d, J=15.9 Hz, 1H), 1.43-1.50 (m, 9H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 155.7, 154.8, 153.2, 140.4, 124.4, 123.4, 121.8, 117.3, 117.1, 79.8, 79.3, 77.3, 77.2, 77.0, 76.7, 74.8, 68.4, 60.7, 60.4, 58.5, 57.6, 28.4, 14.2; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.86 (s, 1F), −129.16 (s, 1F); MS m/z=447.4
tert-butyl (R)-3-(((1H-1,2,3-triazol-4-yl)methoxy)methyl)-4-(3-fluoro-4-(trifluoro methoxy)benzyl)piperazine-1-carboxylate (e): tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate d (0.239 g, 0.60 mmol, 1.0 equiv.) and copper(I) Iodide (0.005 g, 0.05 equiv.) was added in a mixture of N,N-dimethylformamide (5.69 ml, 73.8 mmol) and methanol (0.46 ml,) at 0° C. Then was added TMS azide (0.1 ml, 0.6 mmol, 1.5 equiv.) dropwise and heat the mixture at 90° C. for 18 hours. There was no starting material left in the reaction mixture and then the reaction mixture was passed via a celite plug. The reaction mass was concentrated under reduced pressure and loaded on to a column. The crude mixture was loaded on to a 12 g silica column and eluted with 50% hexane to 50% ethyl acetate to afford e (0.20 g, 76% yield). 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.48-7.78 (m, 1H), 7.21 (br d, J=9.5 Hz, 2H), 6.99-7.12 (m, 1H), 4.52-4.82 (m, 2H), 3.84-4.02 (m, 1H), 3.47 (br s, 8H), 2.52-2.86 (m, 2H), 2.07-2.36 (m, 1H), 1.46 (s, 10H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 156.0, 155.3, 153.5, 140.2, 140.2, 135.6, 124.7, 124.7, 123.7, 122.0, 119.5, 117.6, 117.4, 80.5, 77.6, 58.9, 58.9, 57.9, 53.7, 49.4, 30.0, 28.7; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.84 (s, 1F), −58.86 (s, 1F), −129.07 (s, 1F); MS m/z=490.17.
(R)-2-(((1H-1,2,3-triazol-4-yl)methoxy)methyl)-1-(3-fluoro-4-(trifluoromethoxy) benzyl)-4-(vinyl sulfonyl)piperazine (f) (SMDC556): tert-butyl (R)-3-(((1H-1, 2, 3-triazol-5-yl) methoxy) methyl)-4-(3-fluoro-4-(trifluoromethoxy) benzyl)piperazine-1-carboxylate e (0.1 g, 0.2 mmol, 1.0 equiv.) was treated with 4 M hydrochloric acid (1.502 ml, 6.0 mmol, 30.0 equiv.) in 1,4-dioxane in cold. The reaction mixture was stirred for 1 h and then LCMS was checked. The crude reaction mixture was evaporated under reduced pressure. To it was added N, N-diisopropylethylamine (0.073 ml, 0.4 mmol, 2.0 equiv.) and then was added 2-chloroethanesulfonyl chloride (0.021 ml, 0.2 mmol, 1.0 equiv.) at 0° C. The reaction was stirred for 2 h at cold. Then at cold was added N, N-diisopropylethylamine (0.070 ml, 0.4 mmol, 2.0 equiv.). The reaction mixture was stirred for 2 hr at room temperature. The crude was purified by silica column and then by reverse phase HPLC using 100% water to 100% methanol to afford f (0.01 g, 10% yield). 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.72 (s, 1H), 7.16-7.25 (m, 2H), 6.99-7.11 (m, 1H), 6.36-6.53 (m, 1H), 6.20-6.33 (m, 1H), 5.93-6.15 (m, 1H), 4.57-4.79 (m, 2H), 3.84-3.95 (m, 1H), 3.64-3.80 (m, 2H), 3.45-3.61 (m, 1H), 3.06-3.31 (m, 4H), 2.86-2.98 (m, 1H), 2.70-2.82 (m, 1H), 2.30-2.51 (m, 1H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 155.8, 153.3, 139.8, 131.9, 131.4, 129.2, 124.2, 123.5, 117.1, 116.9, 77.8, 67.3, 64.1, 58.2, 57.3, 48.4, 47.6, 45.4; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.84 (s, 1F), −58.85 (s, 1F), −58.86 (s, 1F), −128.75 (s, 1F), −128.76 (s, 1F), MS m/z=480.4.
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-(hydroxymethyl)piperazine-1-carboxylate (3): To a solution of 3-fluoro-4-(trifluoromethoxy)benzaldehyde 1 (2.19 g, 10.2 mmol, 1.0 equiv.) in DCE (60 mL) was added tert-butyl (R)-3-(hydroxymethyl)piperazine-1-carboxylate 2 (2.19 g, 9.65 mmol, and 1.00 equiv). Half an hour later, sodium triacetoxyborohydride (3.02 g, 14.3 mmol, 1.4 equiv.) was added to the above reaction mixture. The reaction mixture was monitored by LCMS and TLC. Next day, 12 h later, 500 mg more sodium triacetoxy borrohydride was added to push the reaction mixture to the completion. 12 h later, the reaction mixture was treated with sat. 10% saturated solution of sodium bicarbonate solution (100 mL). Then the organic layer was extracted with dichloromethane (2×80 mL), the combined layers was washed with water (2×100 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude liquid was loaded on to a 120 g silica column. The crude was purified by a gradient 100% hexane to 100% ethyl acetate. The yield was 68.4%. 1H NMR (400 MHz; METHANOL-d4) S: 7.32-7.40 (m, 2H), 7.26 (d, J=8.0 Hz, 1H), 4.86 (s, 1H), 4.06-4.14 (m, 1H), 3.73-3.81 (m, 2H), 3.53-3.68 (m, 2H), 3.46 (d, J=14.2 Hz, 1H), 3.14-3.29 (m, 2H), 2.64-2.72 (m, 1H), 2.45-2.52 (m, 1H), 2.16-2.25 (m, 1H), 1.46 (s, 9H); 13C NMR (100 MHz; METHANOL-d4) δ: 157.3, 156.9, 154.8, 142.9, 136.7, 136.5, 126.5, 125.0, 123.6, 121.0, 118.8, 81.6, 62.8, 61.9, 58.5, 51.3, 50.0, 29.0, 21.2, 14.8; 19F NMR (376 MHz; METHANOL-d4) δ: 60.59 (s, 1F), −131.71 (s, 1F); MS m/z=431 as a Na+ salt.
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-((prop-2-yn-1-yloxy)methyl)-piperazine-1-carboxylate (4): 60.0% Sodium hydride (482 mg, 12.0 mmol, 4.20 equiv.) was added to a solution of tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate 3 (1.16 g, 2.80 mmol, 1.00 equiv.) in tetrahydrofuran (6.00 mL) at 0° C. under N2. The reaction mixture was stirred under nitrogen for 60 min. Then 80.0% propargyl bromide in toluene (9.40 ml, 6.0 mmol, 2.1 equiv.) was added to the reaction mixture at 0° C. The reaction mixture was stirred for 12 h at 70° C. The reaction mixture was cooled to room temperature and treated with ice water. The reaction mixture was poured in a separator funnel, extracted with ethyl acetate (3×50 mL), dried over MgSO4 and concentrated under reduced pressure. Then the crude mixture was loaded on to a 40 g silica column and purified with a gradient 100% hexane to 100% ethyl acetate. The yield was 80%. 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.28-7.51 (m, 1H), 7.20-7.26 (m, 2H), 7.12 (br d, J=8.4 Hz, 1H), 4.71 (s, 1H), 3.95-4.19 (m, 3H), 3.89-3.91 (m, 1H), 3.52-3.78 (m, 3H), 3.41-3.52 (m, 2H), 3.21-3.37 (m, 1H), 2.77 (s, 1H), 2.57-2.73 (m, 2H), 2.43 (t, J=2.1 Hz, 1H), 2.13-2.34 (m, 1H), 2.05 (s, 1H), 1.64 (br d, J=15.9 Hz, 1H), 1.43-1.50 (m, 9H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 155.7, 154.8, 153.2, 140.4, 124.4, 123.4, 121.8, 117.3, 117.1, 79.8, 79.3, 77.3, 77.2, 77.0, 76.7, 74.8, 68.4, 60.7, 60.4, 58.5, 57.6, 28.4, 14.2; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.86 (s, 1F), −129.16 (s, 1F); MS m/z=447.4.
tert-butyl (R)-3-(((1H-pyrazol-4-yl)methoxy)methyl)-4-(3-fluoro-4-(trifluoro methoxy) benzyl)piperazine-1-carboxylate (5): To a sealed tube was added tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate 4 (0.61 g, 1.40 mmol, 1.00 equiv.) and (Trimethylsilyl)diazomethane (2.00 ml, 4.00 mmol, 2.90 equiv.) in hexane. The reaction mixture was heated at 135° C. for 1 h in a sealed tube. [Use a face shield while doing the reaction. Extremely careful while doing this reaction]. LCMS indicated the completion, total consumption of the starting material. The crude reaction mixture was dried under reduced pressure and then was loaded on to a 40 g silica column. The column was purified by 10% methanol in 90% dichloromethane. The yield was 84%. 1H NMR (400 MHz; METHANOL-d4) δ: 7.61 (br s, 1H), 7.28-7.37 (m, 2H), 7.19 (d, J=8.6 Hz, 1H), 6.31 (br s, 1H), 5.48 (s, 1H), 4.85 (s, 2H), 4.52 (br s, 2H), 4.44 (s, 1H), 4.02-4.19 (m, 1H), 3.96 (br d, J=14.1 Hz, 1H), 3.59-3.73 (m, 2H), 3.33-3.57 (m, 3H), 3.07-3.29 (m, 2H), 2.52-2.74 (m, 2H), 2.22 (br s, 1H), 1.44 (s, 9H); 13C NMR (100 MHz; METHANOL-d4) δ: 157.7, 155.2, 143.3, 137.1, 126.9, 125.4, 124.0, 121.4, 119.0, 106.4, 82.1, 61.1, 59.1, 55.6, 50.0, 29.4; 19F NMR (376 MHz; METHANOL-d4) δ:-60.61 (s, 1F), −131.79 (s, 1F); MS m/z=511 as a Na+ salt.
(R)-2-(((1H-pyrazol-4-yl)methoxy)methyl)-1-(3-fluoro-4-(trifluoromethoxy)benzyl)-4-(vinyl sulfonyl)piperazine (6) (SMDC203): tert-butyl (R)-3-(((1H-pyrazol-4-yl)methoxy) methyl)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)piperazine-1-carboxylate 5 (0.36 g, 0.80 mmol, 1.0 equiv.) was dissolved in dichloromethane (3 mL) and cooled to 0° C. The reaction mixture was treated with hydrochloric acid (0.939 ml, 3.8 mmol, 10 equiv.). The reaction mixture was stirred for 1 h and then LCMS was checked. The reaction was complete, and the reaction mixture was concentrated under reduced pressure. The gummy liquid was triturated with diethyl ether (3×5 mL). Then the reaction mixture was cooled to 0° C. The reaction mixture was treated with trimethylamine (0.71 mL, 4.09 mmol, 2.00 equiv.). To it was added 98.0% 2-Chloroethanesulfonyl chloride (0.062 ml, 0.8 mmol, 1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (0.71 ml, 4.09 mmol, 2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated and loaded in a column. The crude was purified by 100% DCM to 100% methanol and finally was purified by reverse phase HPLC using 100% water to 100% methanol. 1H NMR (400 MHz; METHANOL-d4) δ: 7.58 (s, 1H), 7.24-7.40 (m, 2H), 7.19 (br d, J=8.4 Hz, 1H), 6.51-6.72 (m, 1H), 6.26-6.40 (m, 1H), 6.07-6.23 (m, 1H), 4.43-4.64 (m, 2H), 3.96 (d, J=14.2 Hz, 1H), 3.56-3.85 (m, 2H), 3.33-3.55 (m, 2H), 3.16 (br dd, J=6.3, 3.3 Hz, 1H), 2.90-3.11 (m, 2H), 2.69-2.87 (m, 2H), 2.66 (s, 1H), 2.38 (br dd, J=7.7, 4.2 Hz, 1H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 158.0, 155.5, 143.5, 134.6, 130.8, 127.2, 125.7, 119.4, 106.8, 70.0, 67.6, 61.0, 59.0, 58.3, 51.3, 49.1, 47.5, 43.6, 18.5, 13.8; 19F NMR (376 MHz; METHANOL-d4) δ: −60.62 (s, 1F), −131.74 (s, 1F); MS m/z=479.13 (dimer)
tert-Butyl-(3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl) piperazine-1-carboxylate (3): tert-Butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate (2.5 g, 11.56 mmol, 1.0 eq), dichloroethane (20 mL, 0.58 M), and 3-fluoro-4-(trifluoromethoxy)benzaldehyde (2.4 mL, 17.34 mmol, 1.5 eq) were added to a 100 mL round bottom flask and allowed to stir for 5 minutes at room temperature. NaBH(OAc)3 (7.4 g, 34.68 mmol. 3.0 eq) was added, and the reaction was allowed to stir for an additional 16 hours, then carefully quenched by the addition of 1 M aqueous NaOH and extracted with CH2Cl2 (×3). The combined organics were dried over MgSO4, filtered, and concentrated in vacuo. The resulting residue was purified on silica (Hexanes/EtOAc, 0-45% gradient) to afford 4.34 g (92% yield) of tert-butyl-(3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate. 1H NMR (400 MHz, CDCl3): δ 7.26 (m, 2H), 7.10 (d, 1H, J=8.3 Hz), 3.99 (d, 1H, J=13.8 Hz), 3.80 (dd, 1H, J=5.9, 11.5 Hz), 3.64 (dd, 2H, J=4.1, 11.5 Hz), 3.50 (bs, 1H), 3.46 (d, 2H, J=13.9 Hz), 3.27 (bs, 1H), 2.74 (bs, 1H), 2.62 (bs, 1H), 2.39 (bs, 1H), 2.30-2.24 (m, 1H), 1.45 (2, 9H); MS (ES): m/z 409.4 [M+H]+.
tert-Butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-formylpiperazine-1-carboxylate (4): A solution containing oxalyl chloride (0.24 mL, 2.7 mmol, 1.1 eq,) in CH2Cl2 (30 mL, anhydrous) was cooled to −20° C., after which a solution of DMSO (0.35 mL, 4.9 mmol, 2.0 eq,) in CH2Cl2 (6.0 mL, anhydrous) was added and the mixture was allowed to stir for 5 min. A solution of 3 (1.0 g, 2.4 mmol, 1.0 eq) in CH2Cl2 (6.0 mL, anhydrous) was then added at −20° C. and the reaction was allowed to stir for 15 min. Et3N (1.7 mL, 12 mmol, 5.0 eq) was slowly added, and the reaction was allowed to warm to 20° C. and stir for 1 hour. The reaction was diluted with CH2Cl2 and then washed sequentially with H2O, 2 M HCl, and saturated aqueous NaHCO3. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo to give ˜800 mg of crude material as a clear, reddish oil that was used without any further purification. 1H NMR (400 MHz, CDCl3): δ 9.69 (d, 1H, J=2.0 Hz), 7.29-7.23 (m, 2H), 7.11 (d, 1H, J=8.8 Hz), 3.92 (d, 1H, J=14.0 Hz), 3.71 (bs, 1H), 3.62-3.58 (m, 2H), 3.43 (bs, 2H), 3.12 (bs, 1H), 2.96-2.90 (m, 1H), 2.36-2.30 (m, 1H), 1.45 (s, 9H); MS (ES): m/z 407.3 [M+H]+.
4-{[(2R)-1-{[3-Fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]methyl}-1λ6-thiomorpholine-1,1-dione Hydrochloride (5): Thiomorpholine 1,1-dioxide (173 mg, 1.28 mmol, 1.3 eq) was added to a solution of 4 (400 mg, 984 μmol, 1.0 eq,) in CH2Cl2 (8 mL) at room temperature. The reaction mixture was allowed to stir for 5 min and NaBH(OAc)3 (834 mg, 3.94 mmol, 4.0 eq) was added. The reaction mixture was allowed to stir at room temperature for an additional 16 hour, then quenched with H2O and extracted with CH2Cl2 (×3). The combined organic layers were washed with saturated aqueous NaHCO3, followed by saturated aqueous NaCl. The organic layers were then dried over MgSO4, filtered, concentrated in vacuo, and purified on silica (ISCO, 24 g, Hexanes/EtOAc, 0-80% gradient) to give 365 mg of carbamate (71% yield) as a clear, colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.26-7.22 (m, 2H), 7.09 (d, 1H, J=7.6 Hz), 3.93 (d, 1H, J=13.2 Hz), 3.46-3.38 (m, 5H), 3.03-2.99 (m, 8H), 2.69-2.50 (m, 4H), 2.30 (bs, 1H), 1.45 (s, 9H); MS (ES): m/z 526.4 [M+H]+
4 M HCl in dioxane (6.1 mL, 24.3 mmol, 35 eq) was added to a solution of the above material (365 mg, 0.694 mmol, 1.0 eq) in THE (6 mL). The reaction mixture was allowed to stir at room temperature overnight, then concentrated in vacuo to give 404 mg (93% yield) of crude material that was used in the next step without further purification; MS (ES): m/z 426.4 [M+H]+.
4-{[(2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]methyl}-1λ6-thiomorpholine-1,1-dione (SMDC275): 5 (295 mg, 0.694 mmol, 1.0 eq) and Et3N (380 uL, 2.78 mmol, 4.0 eq) were dissolved in CH2Cl2 (5 mL, 0.14 M) and cooled to 0° C. 2-chloroethane-1-sulfonyl chloride (109 μL, 1.04 mmol, 1.5 eq) was added and the reaction was allowed to stir at 0° C. for 2 hours. LC/MS analysis showed remaining starting material, so additional 2-chloroethane-1-sulfonyl chloride (36 μL, 0.347 mmol, 0.5 eq) was added, and the reaction was allowed to stir overnight. The reaction mixture was quenched with H2O and extracted with CH2Cl2 (×3). The combined organic layers were washed with saturated aqueous NaHCO3, then dried over MgSO4, filtered, and concentrated in vacuo. The crude material was dissolved in MeOH and purified by HPLC (H2O (0.1% TFA):Acetonitrile, 20-95% gradient) to give 66.6 mg (18.6% yield) of 6. 1H NMR (400 MHz, MeOD): δ 7.53 (s, 1H) 7.52 (d, 1H, J=8.8), 7.40 (d, 1H, J=8.8 Hz), 6.71 (dd, 1H, J=10.0, 16.4 Hz) 6.26 (d, 1H, J=16.8 Hz), 6.21 (d, 1H, J=10.0 Hz), 4.48 (d, 1H, J=13.6 Hz), 4.20 (d, 1H, J=13.6 Hz), 3.5-3.39 (m, 4H), 3.12 (bs, 11H), 2.93 (dd, 1H, J=7.2, 14.0 Hz); 13C NMR (150 MHz, MeOD): δ 43.52, 45.91, 48.48-51.47, 52.46, 53.02, 56.50, 57.97, 120.13 (d, J=19.5 Hz), 121.84 (q, J=256, 512 Hz), 125.55, 127.95, 130.60, 133.57, 155.81 (d, J=252 Hz); DEPT-135 (150 MHz, MeOD): S 43.23 (CH2), 45.62 (CH2), 48.48 (CH2), 51.18 (CH2), 52.17 (CH2), 52.74 (CH2), 56.21 (CH2), 57.69 (CH), 119.84 (d, J=18 Hz, CH), 125.26 (CH), 127.65 (CH), 130.32 (CH2), 133.28 (CH); MS (ES): m/z 516.3 [M+H]+.
tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl) piperazine-1-carboxylate: To a stirred solution of tert-butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate (250 mg, 1.2 mol, 1.0 eq) in Dimethylformamide (5 ml) was added Potassium carbonate (200 mg, 1.44 mmol, 1.25 eq) followed by 3-Fluoro-4-(trifluoromethoxy)benzyl bromide (200 ul, 1.18 mmol, 1.02 eq). The reaction mixture was stirred for 72 hours, partitioned between water and Ethyl acetate. The water layer was extracted with Ethyl acetate once again and the organics were dried with brine and Sodium sulfate, decanted, concentrated to afford a residue which was eluted on a 12 g Silicycle cartridge in a gradient of Ethyl acetate in Hexane to afford the product (395 mg, 0.969 mmol) 84% yield. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.42 (s, 9H) 2.13-2.30 (m, 1H) 2.45-2.62 (m, 1H) 2.62-2.74 (m, 1H) 2.74-3.09 (m, 1H) 3.16-3.56 (m, 4H) 3.63 (dd, J=11.40, 4.05 Hz, 2H) 3.72 (d, J=5.84 Hz, 1H) 3.97 (d, J=13.94 Hz, 1H) 7.02-7.13 (m, 1H) 7.14-7.26 (m, 2H); 19 F NMR (282 MHz, METHANOL-d4) δ ppm −128.93 (s, 1 F)-58.92-58.94 (d, 3 F); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 13.99 (s, 1 C) 20.84 (s, 1 C) 28.20 (s, 1 C) 44.22 (s, 1 C) 48.79 (s, 1 C) 57.00 (s, 1 C) 59.24 (s, 1C) 59.89 (s, 1 C) 60.28 (s, 1 C) 79.93 (s, 1 C) 115.20 (s, 1 C) 116.85 (s, 1 C) 117.10 (s, 1 C) 118.63 (s, 1 C) 122.05 (s, 1 C) 123.40 (s, 1 C) 124.21 (s, 1 C) 124.26 (s, 1 C) 125.48 (s, 1 C) 135.06 (s, 1 C) 135.09 (s, 1 C) 135.23 (s, 1 C) 135.26 (s, 1 C) 139.81 (s, 1 C) 139.89 (s, 1 C) 152.73 (s, 1 C) 154.99 (s, 1 C) 156.07 (s, 1 C) 171.12 (s, 1 C) 210.98 (s, 1 C); LCMS (ESI+) m/z 409.0 (M+H+).
tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate: Sodium Hydride, 60% (19 mg, 0.5 mmol, 1.5 equiv.) was dissolved in dry tetrahydrofuran (5 ml) and cooled in an icebath under dry argon with stirring. A solution of tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate (132 mg, 0.3 mmol, 1.0 equiv.) dissolved in 3 ml THE was added dropwise, and stirring was continued in the icebath for 30 min. Propargyl bromide 80% (0.167 ml, 1.9 mmol, 6.0 equiv.) was added, the reaction mixture was warmed to room temperature and stirred overnight. In the morning, the reaction was quenched by addition of saturated ammonium chloride, then basified with aqueous Sodium hydroxide. Water was added and the mixture was extracted twice with ethyl acetate. The combined organics were dried with brine then Sodium sulfate, filtered then concentrated. The residue was dissolved in Dichloromethane and eluted on a 12 g Silicycle cartridge, in a gradient of Ethyl acetate in hexane to afford the product (78.7 mg, 0.176 mmol) 55% yield 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.37-1.55 (m, 9H) 2.22 (br. s., 1H) 2.43 (br. s., 1H) 2.67 (br. s., 2H) 3.07-3.38 (m, 2H) 3.38-3.54 (m, 2H) 3.58 (dd, J=9.61, 5.27 Hz, 2H) 3.65-3.78 (m, 1H) 3.87-4.06 (m, 1H) 4.14 (br. s., 2H) 7.12 (d, J=8.48 Hz, 1H) 7.15-7.31 (m, 2H); 19F NMR (282 MHz, CHLOROFORM-d) δ ppm −129.20 (s, 1 F)-58.88 (d, J=4.12 Hz, 3 F); LCMS (ESI+) m/z 447.1 (M+H+).
(2R)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-[(prop-2-yn-1-yloxy)methyl]piperazine (SMDC883): tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate (47.4 mg, 0.107 mmol) was dissolved in DCM (10 mL) and cooled to 0° C. The reaction mixture was treated with trimethylamine (2.00 equiv). To it was added 98.0% 2-Chloroethanesulfonyl chloride (1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated to afford a crude product which was eluted on a 12 g Silicycle cartridge in a gradient of ethyl acetate in hexane with further purification by HPLC on C18 40-90% Methanol in-Water (all 0.05% formic acid) over 12 min 18 total to afford the product (20.0 mg, 0.046 mmol) 43% yield. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.19-7.27 (m, 2H) 7.10 (d, J=8.10 Hz, 1H) 6.44 (dd, J=16.58, 9.80 Hz, 1H) 6.26 (d, J=16.58 Hz, 1H) 6.08 (d, J=9.80 Hz, 1H) 4.07-4.24 (m, 2H) 4.00 (d, J=14.32 Hz, 1H) 3.79 (dd, J=9.89, 4.43 Hz, 1H) 3.68 (dd, J=9.89, 5.18 Hz, 1H) 3.49 (d, J=14.13 Hz, 1H) 3.35 (dd, J=11.21, 2.35 Hz, 1H) 3.15-3.27 (m, 1H) 2.98-3.14 (m, 2H) 2.72-2.91 (m, 2H) 2.45 (t, J=2.35 Hz, 1H) 2.35-2.44 (m, 1H) 19F NMR (282 MHz, CHLOROFORM-d) δ ppm −58.84-−58.85 (d, J=4.12 Hz, 3 F) (s, 1 F) −128.84-−128.90 (m, 1 F) LCMS (ESI+) m/z 437.1 (M+H+).
4-(Trifluoromethoxy) phenylacetic acid (46.6 mg, 0.212 mmol) was subjected to the general procedure of Burlingame, et al. to afford N-(3-{[2-(Dimethylamino)ethyl]disulfanyl}propyl)-2-[4-(trifluoromethoxy)phenyl]acetamide; trifluoroacetic acid salt (SMDC673) (7.0 mg, 0.014 mmol) 6.6% yield. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.90 (quin, J=6.88 Hz, 2H) 2.75 (t, J=6.97 Hz, 2H) 2.88 (s, 5H) 2.96-3.05 (m, 2H) 3.28-3.50 (m, 6H) 3.58 (s, 2H) 6.58 (br. s., 1H) 7.19 (d, J=7.72 Hz, 2H) 7.29-7.37 (m, 2H); 19F NMR (282 MHz, CHLOROFORM-d) δ ppm −60.70 (s, 3 F), −78.71 (s, 7 F); LCMS (ESI+) m/z 397.1 (M+H+).
4-(Trifluoromethoxy) phenylacetic acid (46.6 mg, 0.212 mmol) was subjected to the general procedure of Burlingame, et al. to afford N-(3-{[2-(Dimethylamino)ethyl]disulfanyl}propyl)-2-[4-(trifluoromethoxy)phenyl]acetamide; trifluoroacetic acid salt (SMDC673) (7.0 mg, 0.014 mmol) 6.6% yield. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.90 (quin, J=6.88 Hz, 2H) 2.75 (t, J=6.97 Hz, 2H) 2.88 (s, 5H) 2.96-3.05 (m, 2H) 3.28-3.50 (m, 6H) 3.58 (s, 2H) 6.58 (br. s., 1H) 7.19 (d, J=7.72 Hz, 2H) 7.29-7.37 (m, 2H); 19F NMR (282 MHz, CHLOROFORM-d) δ ppm −60.70 (s, 3 F), −78.71 (s, 7 F); LCMS (ESI+) m/z 397.1 (M+H+).
4-{[2-(dimethyl amino)ethyl]disulfanyl}-N-{[4-(trifluoromethoxy)phenyl]methyl}butanamide; trifluoroacetic acid salt (SMDC208):
4-Trifluoromethoxy benzylamine (100 ul, 0.655 mmol, 1.00 eq) was stirred in dry dichloromethane (4 ml) in an icebath. 4-[(4-chloro-4-oxobutyl)disulfanyl]butanoyl chloride (68.4 ul, 0.328 mmol) was added followed by N,N-diisopropylethylamine (171 ul, 0.983 mmol). The reaction was warmed to room temperature stirred until completion was seen by LC-MS [m/z 584.1 (M+H+)]. Solvent was removed under vacuum to afford a crude product which was used directly in the next reaction. A portion of the crude product (25 mg, 0.0 mmol, 1.0 equiv.) was dissolved in 300 ul DMSO. Meanwhile a solution of TCEP.HCl (2 mg, 0.0 mmol, 0.2 equiv.) in 100 ul of water was added to a suspension of bis[2-(N,N-dimethylamino)ethyl]disulfide dihydrochloride (60 mg, 0.2 mmol, 5.0 equiv.) in 100 ul DMSO. This was incubated for 10 min then was added to the DMSO solution of starting material, followed by N,N-diisopropylethylamine (0.094 ml, 0.5 mmol, 12.6 equiv.) and a precipitate formed. An additional 200 ul DMSO was added and the reaction mixture clarified and was stirred overnight. In the morning, the reaction mixture was loaded onto a 12 g C18 reverse-phase column that had been pre-equilibrated with water 0.05% TFA. It was then eluted in a gradient as follows: water: 3 CV, 0-80% MeOH water over 24 CV all 0.05% TFA. The fractions bearing product by LC-MS were lyophilized to afford the product (16 mg, 0.031 mmol, 73% yield). 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.06 (quin, J=6.88 Hz, 2H) 2.35-2.44 (m, 2H) 2.76-2.86 (m, 7H) 2.90-2.99 (m, 2H) 3.27-3.37 (m, 2H) 4.43 (d, J=5.84 Hz, 2H) 6.83 (br. s., 1H) 7.17 (d, J=7.91 Hz, 2H) 7.32 (d, J=8.48 Hz, 2H); LCMS (ESI) m/z (m+1) 397.1
[4-(trifluoromethoxy)phenyl]prop-2-enenitrile: Sodium hydride 60% dispersion in mineral oil (0.558 g, 14.0 mmol 1.00 eq) was dissolved in dry tetrahydrofuran (17 ml) and stirred in an icebath under dry Argon. Diethyl cyanomethyl phosphonate (2.25 ml, 14.0 mmol, 1.00 eq), followed by 4-(trifluoromethoxy)benzaldehyde (1.99 ml, 14.0 mmol, 1.00 eq) in 5 mL THF, was added to the cold NaH/THF solution. The reaction was stirred and allowed to warm to room temperature overnight. The reaction was quenched with water and the reaction mixture was partitioned between water and ethyl acetate with the water layer extracted twice. The combined organic layer was organics were dried with brine and Sodium sulfate, decanted, concentrated to afford a residue which was dissolved in 10:1 hexane ether and hexane was added until 20:1 when crystallization afforded pure intermediate (1.18 g, 5.55 mmol, 39% yield) which was used directly in the next reaction. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 5.88 (d, J=16.58 Hz, 1H) 7.26 (d, J=8.67 Hz, 2H) 7.40 (d, J=16.58 Hz, 1H) 7.45-7.55 (m, 2H).
3-[4-(trifluoromethoxy)phenyl]propan-1-amine: Lithium aluminum hydride (304 mg, 8.02 mmol, 3.20 eq) was suspended in dry diethyl ether (15 ml) with stirring under dry argon. This was heated to 50° C. and a solution of [4-(trifluoromethoxy)phenyl]prop-2-enenitrile (534 mg, 2.51 mmol, 1 eq) in diethyl ether (5 ml) was added dropwise with a syringe. Heating was continued for 1.5 hours, the reaction was cooled to room temperature and stirred overnight. The reaction was quenched by slow addition of water (5 ml) in an icebath followed by 1M NaOH (10 ml). The mixture was vigorously stirred with Ethyl acetate for 0.5 hours, partitioned and the water layer was extracted twice more with Ethyl acetate. The combined organics were dried with brine then sodium sulfate, filtered and concentrated to afford crude 3-[4-(trifluoromethoxy)phenyl]propan-1-amine (481 mg, 2.19 mmol) 87% yield, crude which was used crude in the next step. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.64-1.76 (m, 2H) 2.55-2.63 (m, 2H) 2.66 (t, J=7.06 Hz, 2H) 7.03-7.11 (m, 2H) 7.11-7.17 (m, 2H)
[4-(trifluoromethoxy)phenyl]propyl}ethene-1-Sulfonamide (SMDC714): 3-[4-(trifluoromethoxy)phenyl]propan-1-amine (74.1 mg, 0.385 mmol, 1.00 eq) was dissolved in DCM (10 mL) and cooled to 0° C. The reaction mixture was treated with trimethylamine (2.00 equiv). To it was added 98.0% 2-Chloroethanesulfonyl chloride (1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated to afford a crude product which was eluted on a 12 g Silicycle cartridge in a gradient of ethyl acetate 0-30% in Hexane to afford the product (34.8 mg, 0.113 mmol) 29% yield. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.79-1.94 (m, 2H) 2.63-2.73 (m, 2H) 3.04 (q, J=6.84 Hz, 2H) 4.68 (t, J=5.93 Hz, 1H) 5.94 (d, J=9.80 Hz, 1H) 6.23 (d, J=16.58 Hz, 1H) 6.51 (dd, J=16.48, 9.89 Hz, 1H) 7.08-7.16 (m, 2H) 7.16-7.24 (m, 2H); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 31.45, 31.99, 42.33, 121.10, 122.20, 126.89, 129.66, 135.76, 139.63, 147.62; 19 F NMR (282 MHz, METHANOL-d4) δ ppm −57.93 (s, 1 F); LCMS (ESI+) m/z 310.30 (M+H+).
1-(Ethenesulfonyl)piperazine hydrochloride: N-Boc piperazine (10.0 g, 53.7 mmol, 1.0 eq), was dissolved in CH2Cl2 (400 mL, 0.13 M), and Et3N (20 mL, 214 mmol, 4.0 eq) was added. The mixture was cooled to 0° C. in an ice bath and 2-chloroethane sulfonyl chloride (7.86 mL, 75.2 mmol, 1.4 eq) was added. After addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 16 hours. The reaction was diluted with H2O and extracted with CH2Cl2 (×3). The combined organic layers were washed with saturated aqueous NaCl, dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified on silica (0-70% gradient of EtOAc in Hexanes). 1H NMR (400 MHz, MeOD): δ 6.64 (dd, 1H, J=10.0, 16.5 Hz), 6.19 (d, 1H, J=16.5 Hz), 6.13 (d, 1H, J=10.0 Hz), 3.52 (4H, t, J=4.78 Hz), 3.10 (4H, t, J=5.2 Hz), 1.46 (s, 9H).
This material was dissolved in THF (˜200 mL) and 4 M HCl in dioxane was added (134 mL, 537 mmol, 10 eq) and the reaction was allowed to stir overnight at room temperature. The reaction mixture was then concentrated in vacuo and dried under low pressure to give 9.11 g (80% yield over 2 steps) of 1-(ethenesulfonyl)piperazine hydrochloride (1) as an off-white powder, which was used without further purification. 1H NMR (400 MHz, MeOD): δ 6.72 (dd, 1H, J=10.0, 16.5 Hz), 6.27 (d, 1H, J=16.5 Hz), 6.21 (d, 1H, J=10.0 Hz), 3.44-3.40 (m, 4H), 3.36-3.30 (m, 4H); MS (ES): m/z 177.1 [M+H]+
1-(ethenesulfonyl)-4-{[4-(trifluoromethoxy)phenyl]methyl}piperazine (SMDC967): 1-(ethenesulfonyl)piperazine hydrochloride (122 mg, 0.6 mmol, 1.0 equiv.) was suspended in a septum-capped 20 dram vial in ordinary non-dried reagent grade acetonitrile (3 ml), potassium carbonate (159 mg, 1.1 mmol, 2.0 equiv.) was added, followed by 4-(Trifluoromethoxy)benzyl bromide (97 ul, 0.6 mmol, 1.0 equiv.). The reaction mixture was stirred at room temperature for 2 hours, filtered through celite, concentrated, dissolved in a small amount dichloromethane and eluted on a 12 g Silicycle cartridge in a gradient of Ethyl Acetate 0-100% in Hexane. The product was further purified by HPLC 30-80% Methanol (0.05% Formic acid both) in water over 12 min 18 min total, to afford the product (49 mg, 0.1 mmol, 24% yield) as a clear oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.39-2.72 (m, 4H) 3.10-3.27 (m, 4H) 3.55 (s, 2H) 6.06 (d, J=9.98 Hz, 1H) 6.25 (d, J=16.58 Hz, 1H) 6.44 (dd, J=16.58, 9.80 Hz, 1H) 7.17 (m, J=8.29 Hz, 2H) 7.34 (m, J=8.29 Hz, 2H), 19F NMR (282 MHz, CHLOROFORM-d) δ ppm 57.87 (s, 1 F)13C NMR (75 MHz, CHLOROFORM-d) δ ppm 45.62 (s, 1 C) 52.21 (s, 1 C) 61.68 (s, 1 C) 76.58 (s, 1 C) 77.43 (s, 1 C) 120.89 (s, 1 C) 128.92 (s, 1C) 130.18 (s, 1 C) 132.13 (s, 1 C) 136.38 (s, 1 C); LCMS (ESI+) m/z 351.1 (M+H+).
1-(Ethenesulfonyl)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazine (SMDC689) (2): 3-Fluoro-4-(trifluoromethoxy)benzaldehyde (78 mg, 0.392 mmol, 1.0 eq.) and 1-(ethenesulfonyl)piperazine hydrochloride (100 mg, 0.47 mmol, 1.2 eq) were dissolved in dichloroethane (2.5 mL, 0.16 M). NaBH(OAc)3 was added, and the reaction was allowed to stir overnight at room temperature. After confirmation of product formation by LC/MS, the reaction was quenched with 2 M NaOH, then extracted with CH2Cl2 (×3). The combined organic layers were then washed with saturated aqueous NaCl, dried over MgSO4, and concentrated in vacuo. The crude residue was dissolved in MeOH and purified by HPLC to give 66.1 mg (45.6% yield) of the desired product. 1H NMR (400 MHz, CDCl3): δ 7.40-7.37 (m, 2H), 7.32 (d, 1H, J=8.0 Hz), 6.44 (dd, 1H, J=9.8, 16.5 Hz), 6.29 (d, 1H, J=16.5 Hz), 6.15 (d, 1H, J=9.8 Hz), 4.15 (s, 1H), 3.57 (bs, 4H), 3.22 (bs, 4H); 13C NMR (100 MHz, CDCl3): δ 42.84, 51.23, 59.64, 120.37 (q, J=249, 518), 120.25 (d, J=20 Hz), 124.56, 127.57 (d, J=2 Hz), 128.69 (d, 7 Hz), 130.98, 131.55, 138.16 (d, 12 Hz), 154.56 (d, J=255 Hz); DEPT-135 (100 MHz, CDCl3): δ 42.74 (CH2), 51.14 (CH2), 59.56 (CH2), 120.15 (d, J=19 Hz, CH), 124.47 (CH), 127.46 (d, J=4 Hz, CH), 130.88 (CH2), 131.46 (CH); MS (ES) m/z 369.3 [M+H]+.
1-(3-(Trifluoromethoxy)benzyl)-4-(vinyl sulfonyl)piperazine (SMDC723): To 1-(ethenesulfonyl)piperazine hydrochloride (100 mg, 0.47 mmol) in dichloroethane (4.0 mL) was added 3-(trifluoromethoxy)benzaldehyde (70 μL, 0.56 mmol) followed by NaBH(OAc)3 (350 mg, 1.61 mmol). The reaction vessel capped, purged with Argon, and stirred for 1.5 h at rt. The reaction solution was then diluted with CH2Cl2 (20 mL) and washed with 1 M aqueous NaOH (15 mL). The aqueous layer was then extracted 3× with CH2Cl2 (20 mL). The combined organics were then washed with brine and dried with MgSO4. The crude product was absorbed onto celite and purified on a C18 column with 0-50% water (0.1 TFA): acetonitrile to afford 1-(3-(trifluoromethoxy)benzyl)-4-(vinylsulfonyl)piperazine (33.5 mg, 20%). 1H NMR (400 MHz; MeOD): δ 7.64-7.60 (m, 1H), 7.54-7.51 (m, 2H), 7.45 (d, J=8.2 Hz, 1H), 6.71 (dd, J=16.6, 10.0 Hz, 1H), 6.28 (d, J=16.6 Hz, 1H), 6.22 (d, J=10.0 Hz, 1H), 4.38 (s, 2H), 3.44 (bs, 4H), 3.33 (bs, 4H); 13C NMR (100 MHz, CDCl3): δ 42.76, 51.22, 60.24, 120.38 (q, J=171, 343 Hz), 123.00, 123.51, 129.43, 129.76, 131.03, 131.25, 131.48, 149.84; DEPT-135 (100 MHz, CDCl3): δ 42.67 (CH2), 51.13 (CH2), 60.14 (CH2), 122.89 (CH), 123.41 (CH), 129.32 (CH), 130.90 (CH2), 131.15 (CH), 131.41 (CH); MS (ES) m/z 351.0 [M+H]+.
tert-butyl (3S)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate: 1-benzyl 4-tert-butyl (25)-2-(2-methoxy-2-oxoethyl)piperazine-1,4-dicarboxylate (1.23 g, 3.13 mmol, 1 eq) was dissolved in Ethanol (116 ml) and palladium 10% on carbon (465 mg) was added. The flask was fitted with a balloon adaptor, evacuated, and purged with hydrogen 3 times. The reaction mixture was then stirred under hydrogen for 2 hours, then filtered through celite and concentrated to afford a sooty-colored oil which was used in the next step. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.93-10.19 (brs, 1H) 4.05-4.28 (m, 1H) 3.93-4.06 (m, 1H) 3.72 (s, 2H) 3.69-3.78 (m, 1H) 3.53-3.63 (m, 1H) 3.19-3.54 (m, 1H) 3.07-3.18 (m, 1H) 2.95-3.06 (m, 1H) 2.69-2.85 (m, 1H) 1.43 (s, 5H).
tert-butyl (3 S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate: tert-butyl (3S)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate (509 mg, 1.97 mmol, 1 eq) was reacted with 3-fluoro-(trifluoromethoxy)benzaldehyde (0.341 ml, 1.97 mmol, 1 eq) in DCE (15 mL). Half an hour later, sodium triacetoxyborohydride (1.4 equiv.) was added to the above reaction mixture. The reaction mixture was monitored by LCMS and TLC. Next day, 12 h later, 100 mg more sodium triacetoxyborohydride was added to push the reaction mixture to the completion. 12 h later, the reaction mixture was treated with sat. 10% saturated solution of sodium bicarbonate solution (100 mL). Then the organic layer was extracted with dichloromethane (2×80 mL), the combined layers was washed with water (2×100 mL), dried over Na2SO4, and concentrated under reduced pressure to afford a residue which was purified on a 25 g Silicycle cartridge in a gradient of 0-100% Ethyl acetate in hexane to afford a product (546 mg, 1.21 mmol) 61% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.08-7.22 (m, 1H), 6.94-7.07 (m, 1H), 3.61 (br. s, 2H), 3.49-3.79 (m, 4H), 2.92-3.48 (m, 3H), 2.34-2.58 (m, 2H), 2.13-2.34 (m, 1H), 1.37 (s, 6H), 1.25-1.47 (m, 6H), 1.25-1.47 (m, 6H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 172.06 (s, 1 C), 155.56 (s, 1 C), 154.59 (s, 1 C), 153.05 (s, 1 C), 139.86 (s, 1 C), 134.97 (s, 1 C), 124.04 (s, 1 C), 123.21 (s, 1 C), 121.57 (s, 1 C), 118.99 (s, 1 C), 116.66 (s, 1 C), 79.54 (s, 1 C), 57.11 (s, 1 C), 55.31 (s, 1 C), 51.45 (s, 1 C), 47.50 (s, 1C), 46.83 (s, 1 C), 42.39 (s, 1 C), 29.93 (s, 1 C), 28.03 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −59.04 (d, J=4.09 Hz, 3 F), −129.27-−129.16 (m, 1 F); LCMS (ESI+) m/z 451.16 (M+H+)
tert-butyl (3 S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-hydroxyethyl) piperazine-1-carboxylate: Lithium aluminum hydride (54 mg, 1.42 mmol, 1.33 eq) was stirred in dry Tetrahydrofuran (15 ml) under dry argon with stirring. To this was added a solution of tert-butyl (3 S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate (480 mg, 1.07 mmol, 1.00 eq) in 10 ml tetrahydrofuran via syringe over a 3 minute period at room temperature. The reaction was monitored to be complete by TLC. If not complete a small amount of LiAlH4 may be added. The reaction was then cooled in an icebath with rapid stirring quenched by careful addition of 1.5 ml water, then 5 ml 2M NaOH, then 3 ml more water. The resulting mixture was filtered through celite then extracted twice with diethyl ether. The combined organics were dried with brine and sodium sulfate, filtered and concentrated. The residue was dissolved in minimal Dichloromethane and eluted on a 25 g Silicycle cartridge in a gradient of Ethyl acetate in Hexane 20-100% to afford the product (371 mg, 0.880 mmol, 83% yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.12-7.22 (m, 1H) 7.02-7.08 (m, 1H) 3.77-3.95 (m, 1H) 3.59-3.77 (m, 2H) 3.34 (br. s., 3H) 2.53-2.71 (m, 1H) 2.10-2.24 (m, 1H) 1.75-1.89 (m, 1H) 1.62-1.75 (m, 1H) 1.39 (s, 6H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.58 (s, 1 C) 154.85 (s, 1 C) 153.07 (s, 1 C)
(s, 1 C) 139.95 (s, 1 C) 135.13 (s, 1 C) 135.10 (s, 1 C) 135.08 (s, 1 C) 134.99 (s, 1 C) 134.98 (s, 1 C) 134.96 (s, 1 C) 124.23 (s, 1 C) 124.20 (s, 1 C) 123.29 (s, 1 C) 121.60 (s, 1 C) 119.02 (s, 1 C) 117.03 (s, 1 C) 116.84 (s, 1 C) 116.45 (s, 1 C) 79.87 (s, 1 C) 79.73 (s, 1 C) 77.32 (s, 1 C) 76.69 (s, 1 C) 59.81 (s, 1 C) 56.99 (s, 1 C) 56.61 (s, 1 C) 48.57 (s, 1 C) 47.73 (s, 1 C) 45.95 (s, 1 C) 43.13 (s, 1 C) 41.84 (s, 1 C) 29.42 (s, 1 C) 28.15 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −58.97 (d, J=4.09 Hz, 1 F)-129.19-−128.97 (m, 1 F); LCMS (ESI+) m/z 423.11 (M+H+).
(2S)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine; trifluoromethanesulfonic acid salt: tert-butyl (3S)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(2-hydroxyethyl)piperazine-1-carboxylate (443 mg, 1.05 mmol, 1.00 eq) was dissolved in dry dichloromethane (3 ml) and treated with 4M HCl in dry 1,4-dioxane (6 ml). The mixture was stirred for 2 hours under dry argon, then evaporated to afford a gummy solid which was immediately redissolved and stirred in dry dichloromethane (30 ml). To this was added Triethylamine (439 ul, 3.15 mmol, 3.00 eq) and the mixture was cooled in an icebath. Triisopropylsilyl trifluoromethanesulfonate (353 ul, 1.31 mmol, 1.25 equiv.) was added and the reaction mixture was allowed to warm to room temperature and checked for completion by TLC. Upon completion (4 hours), the reaction was quenched by addition of saturated sodium bicarbonate, partitioned between water and ethyl acetate with the water layer extracted twice with ethyl acetate, the combined organics were dried with brine, sodium sulfate, filtered and concentrated. The residue was redissolved in a small amount of dichloromethane then eluted in a gradient of 0-10% Methanol in dichloromethane to afford the product (435 mg, 0.909 mol, 87% yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.16-7.26 (m, 1H) 7.09 (d, J=8.52 Hz, 1H) 6.24 (s, 1H) 3.96 (d, J=14.12 Hz, 1H) 3.71-3.83 (m, 1H) 3.30 (d, J=14.37 Hz, 1H) 3.19-3.27 (m, 1H) 3.06-3.16 (m, 1H) 2.94-3.06 (m, 1H) 2.85 (br. s., 1H) 2.74-2.81 (m, 1H) 2.38 (br. s., 1H) 1.85-1.97 (m, 1H) 1.72-1.85 (m, 1H) 0.94-1.13 (m, 23H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.77 (s, 1 C) 153.26 (s, 1 C) 139.80 (s, 1 C) 139.74 (s, 1 C) 135.32 (s, 1 C) 135.31 (s, 1 C) 135.20 (s, 1 C) 135.18 (s, 1 C) 124.77 (s, 1 C) 124.27 (s, 1 C) 124.08 (s, 1 C) 124.05 (s, 1 C) 123.48 (s, 1 C) 121.70 (s, 1 C) 121.59 (s, 1 C) 119.12 (s, 1 C) 118.42 (s, 1 C) 116.89 (s, 1 C) 116.70 (s, 1 C) 116.55 (s, 1 C) 115.25 (s, 1 C) 59.76 (s, 1 C) 56.39 (s, 1 C) 55.81 (s, 1 C) 48.22 (s, 1 C) 48.08 (s, 1 C) 44.11 (s, 1 C) 31.19 (s, 1 C) 17.85 (s, 1 C) 11.76 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −58.99 (d, J=4.09 Hz, 3 F) 78.53 (s, 1 F)-129.24-−128.60 (m, 1 F); LCMS (ESI+) m/z 479.26 (M+H+).
(2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine: (2S)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine; trifluoromethanesulfonic acid salt (217 mg, 0.345 mmol, 1.00 eq) was dissolved in DCM and cooled to 0° C. The reaction mixture was treated with trimethylamine (2.00 equiv). To it was added 98.0% 2-Chloroethanesulfonyl chloride (1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated to afford a crude product which was eluted on a 12 g Silicycle cartridge in a gradient of ethyl acetate in hexane to give the product (143 mg, 0.252 mmol, 73% yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.18-7.25 (m, 1H) 7.09 (dd, J=8.52, 0.73 Hz, 1H) 6.43 (dd, J=9.98, 6.57 Hz, 1H) 6.23 (d, J=16.56 Hz, 1H) 6.05 (d, J=9.98 Hz, 1H) 3.77-3.85 (m, 1H) 3.75 (s, 1H) 3.46 (d, J=14.37 Hz, 1H) 3.20 (d, J=4.63 Hz, 1H) 3.03-3.11 (m, 1H) 2.90-2.95 (m, 1H) 2.72-2.80 (m, 1H) 2.36-2.44 (m, 1H) 1.80-1.89 (m, 1H) 0.96-1.12 (m, 10H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.77 (s, 1 C) 153.26 (s, 1 C) 140.25 (s, 1 C) 140.19 (s, 1 C) 135.15 (dq, J=12.47, 1.71 Hz, 1 C)132.09 (s, 1 C) 128.80 (s, 1 C) 124.01 (d, J=3.67 Hz, 1 C) 123.41 (s, 1 C) 121.71 (s, 1 C) 120.41 (q, J=258.00 Hz, 1 C) 116.86 (s, 1 C) 60.14 (s, 1C) 56.63 (s, 1 C) 56.61 (s, 1 C) 55.57 (s, 1 C) 48.81 (s, 1 C) 47.88 (s, 1 C) 45.30 (s, 1 C) 29.04 (s, 1 C) 17.94 (s, 1 C) 11.81 (s, 1 C); 19F NMR (376 MHz, CHLOROFORM-d) δ ppm −58.90 (d, J=5.45 Hz, 3F)-129.07-−129.00 (m, 1F).
2-[(2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]ethan-1-ol (SMDC069): (2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(2-{[tris(propan-2-yl)silyl]oxy}ethyl)piperazine (143 mg, 0.252 mmol, 1.00 eq) was dissolved in dry Dichloromethane (4 ml) and stirred under dry argon. Tetrabutyl ammonium fluoride solution in THE (7 ml) was added and the progress of the reaction was monitored frequently by TLC to prevent formation of the cyclic product. As soon as the starting material disappeared, the reaction was quenched by the addition of 50% saturated Sodium bicarbonate in water. The mixture was diluted with Ethyl acetate and water and the water layer was extracted twice. The combined organic layer was dried with brine then Sodium sulfate, filtered and concentrated to afford a residue which was re-dissolved in Dichloromethane and purified on a 4 g Silicycle cartridge. Further purification was achieved by HPLC on C18 in a gradient of 30-80% Methanol in Water 12 min 18 total each 0.05% Formic acid. Since the UV absorbance of the compound was low in the 200-300 nm UV range, a sensitive collection method was used to obtain the product (41 mg, 0.098 mmol) 39% yield. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.18-7.27 (m, 2H) 7.10 (d, J=8.28 Hz, 1H) 6.44 (dd, J=16.68, 9.86 Hz, 1H) 6.25 (d, J=16.56 Hz, 1H) 6.08 (d, J=9.98 Hz, 1H) 3.92 (d, J=13.88 Hz, 1H) 3.77-3.88 (m, 1H) 3.73 (ddd, J=10.84, 7.18, 5.60 Hz, 1H) 3.47 (d, J=13.88 Hz, 1H) 3.23-3.29 (m, 1H) 3.04-3.23 (m, 3H) 2.88-2.95 (m, 1H) 2.79-2.88 (m, 1H) 2.64 (s, 1H) 2.42 (ddd, J=12.30, 5.97, 3.65 Hz, 1H) 1.82-2.03 (m, 2H); 13C NMR (100 MHz, CHLOROFORM-d) δ ppm 155.74 (s, 1 C) 153.23 (s, 1 C) 139.58 (d, J=5.87 Hz, 1 C) 135.31 (d, J=10.27 Hz, 1 C) 131.95 (s, 1C) (s, 1 C) 129.12 (s, 1 C) 124.26 (d, J=3.67 Hz, 1 C) 123.51 (s, 1 C) 121.67 (s, 1 C) 120.39 (q, J=258.00 Hz, 1 C) 117.08 (s, 1 C) 116.89 (s, 1 C) 116.52 (s, 1 C) 60.02 (s, 1 C) 56.55 (d, J=1.47 Hz, 1 C) 56.42 (s, 1 C) 48.32 (s, 1 C) 47.70 (s, 1 C) 44.67 (s, 1 C) 28.72 (s, 1 C); LCMS (ESI+) m/z 413.04 (M+H+).
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-(hydroxymethyl)piperazine-1-carboxylate: To a solution of 3-fluoro-4-(trifluoromethoxy)benzaldehyde (2.19 g, 10.2 mmol, 1.0 eq.) in DCE (60 mL) was added tert-butyl (R)-3-(hydroxymethyl)piperazine-1-carboxylate 2 (2.19 g, 9.65 mmol, 1.0 eq.). Half an hour later, sodium triacetoxyborohydride (3.02 g, 14.3 mmol, 1.4 eq.) was added to the above reaction mixture. The reaction mixture was monitored by LCMS and TLC. Next day, 12 h later, 500 mg more sodium triacetoxyborohydride was added to push the reaction mixture to the completion. 12 h later, the reaction mixture was treated with a 10% saturated solution of sodium bicarbonate solution (100 mL). Then the organic layer was extracted with dichloromethane (2×80 mL), the combined layers were washed with water (2×100 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude liquid was loaded on to a 120 g silica column. The crude was purified by a gradient 100% hexane to 100% ethyl acetate. The yield was 68.4%. 1H NMR (400 MHz; METHANOL-d4) δ: 7.32-7.40 (m, 2H), 7.26 (d, J=8.0 Hz, 1H), 4.86 (s, 1H), 4.06-4.14 (m, 1H), 3.73-3.81 (m, 2H), 3.53-3.68 (m, 2H), 3.46 (d, J=14.2 Hz, 1H), 3.14-3.29 (m, 2H), 2.64-2.72 (m, 1H), 2.45-2.52 (m, 1H), 2.16-2.25 (m, 1H), 1.46 (s, 9H); 13C NMR (100 MHz; METHANOL-d4) δ: 157.3, 156.9, 154.8, 142.9, 136.7, 136.5, 126.5, 125.0, 123.6, 121.0, 118.8, 81.6, 62.8, 61.9, 58.5, 51.3, 50.0, 29.0, 21.2, 14.8; 19F NMR (376 MHz; METHANOL-d4) δ: −60.59 (s, 1F), −131.71 (s, 1F); MS m/z=431 as a Na+ salt.
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-((prop-2-yn-1-yloxy)methyl) piperazine-1-carboxylate: 60.0% Sodium hydride (482 mg, 12.0 mmol, 4.20 equiv.) was added to a solution of tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate c (1.16 g, 2.80 mmol, 1.00 equiv.) in tetrahydrofuran (6.00 mL) at 0° C. under N2. The reaction mixture was stirred under nitrogen for 60 min. Then 80.0% propargyl bromide in toluene (9.40 ml, 6.0 mmol, 2.1 equiv.) was added to the reaction mixture at 0° C. The reaction mixture was stirred for an additional 12 h at 70° C. The reaction mixture was cooled to room temperature and treated with ice water. The reaction mixture was poured in a separator funnel, extracted with ethyl acetate (3×50 mL), dried over MgSO4 and concentrated under reduced pressure. Then the crude mixture was loaded on to a 40 g silica column and purified with a gradient 100% hexane to 100% ethyl acetate. The yield was 80%. 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.28-7.51 (m, 1H), 7.20-7.26 (m, 2H), 7.12 (br d, J=8.4 Hz, 1H), 4.71 (s, 1H), 3.95-4.19 (m, 3H), 3.89-3.91 (m, 1H), 3.52-3.78 (m, 3H), 3.41-3.52 (m, 2H), 3.21-3.37 (m, 1H), 2.77 (s, 1H), 2.57-2.73 (m, 2H), 2.43 (t, J=2.1 Hz, 1H), 2.13-2.34 (m, 1H), 2.05 (s, 1H), 1.64 (br d, J=15.9 Hz, 1H), 1.43-1.50 (m, 9H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 155.7, 154.8, 153.2, 140.4, 124.4, 123.4, 121.8, 117.3, 117.1, 79.8, 79.3, 77.3, 77.2, 77.0, 76.7, 74.8, 68.4, 60.7, 60.4, 58.5, 57.6, 28.4, 14.2; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.86 (s, 1F), −129.16 (s, 1F); MS m/z=447.4.
tert-butyl (R)-3-(((1H-1,2,3-triazol-4-yl)methoxy)methyl)-4-(3-fluoro-4-(trifluoro methoxy)benzyl)piperazine-1-carboxylate: tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate d (0.239 g, 0.60 mmol, 1.0 eq.) and copper(I) iodide (0.005 g, 0.05 eq.) was added in a mixture of N,N-dimethylformamide (5.69 ml, 73.8 mmol) and methanol (0.46 ml,) at 0° C. TMS azide (0.1 ml, 0.6 mmol, 1.5 equiv.) was then added dropwise and the mixture was heated at 90° C. for 18 hours. Once there was no starting material left, the reaction mixture was passed over a celite plug. The reaction mass was concentrated under reduced pressure and the crude mixture was loaded on to a 12 g silica column and eluted with 50% hexane to 50% ethyl acetate to afford the product (0.20 g, 76% yield). 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.48-7.78 (m, 1H), 7.21 (br d, J=9.5 Hz, 2H), 6.99-7.12 (m, 1H), 4.52-4.82 (m, 2H), 3.84-4.02 (m, 1H), 3.47 (br s, 8H), 2.52-2.86 (m, 2H), 2.07-2.36 (m, 1H), 1.46 (s, 10H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 156.0, 155.3, 153.5, 140.2, 140.2, 135.6, 124.7, 124.7, 123.7, 122.0, 119.5, 117.6, 117.4, 80.5, 77.6, 58.9, 58.9, 57.9, 53.7, 49.4, 30.0, 28.7; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.84 (s, 1F), −58.86 (s, 1F), −129.07 (s, 1F); MS m/z=490.17.
(R)-2-(((1H-1,2,3-triazol-4-yl)methoxy)methyl)-1-(3-fluoro-4-(trifluoromethoxy) benzyl)-4-(vinylsulfonyl)piperazine (SMDC556): tert-butyl (R)-3-(((1H-1, 2, 3-triazol-5-yl) methoxy) methyl)-4-(3-fluoro-4-(trifluoromethoxy) benzyl)piperazine-1-carboxylate e (0.1 g, 0.2 mmol, 1.0 equiv.) was treated with 4 M hydrochloric acid (1.502 ml, 6.0 mmol, 30.0 equiv.) in 1,4-dioxane in cold. The reaction mixture was stirred for 1 h and then checked by LC-MS. The crude reaction mixture was evaporated under reduced pressure. To it was added N, N-diisopropylethylamine (0.073 ml, 0.4 mmol, 2.0 equiv.) then 2-chloroethanesulfonyl chloride (0.021 ml, 0.2 mmol, 1.0 equiv.) at 0° C. The reaction was stirred for 2 hours (cold). N, N-diisopropylethylamine (0.070 ml, 0.4 mmol, 2.0 equiv.) was then added (cold). The reaction mixture was stirred for 2 hours at room temperature. The crude was purified by silica column and then by reverse phase HPLC using 100% water to 100% methanol to afford the product (0.01 g, 10% yield). 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.72 (s, 1H), 7.16-7.25 (m, 2H), 6.99-7.11 (m, 1H), 6.36-6.53 (m, 1H), 6.20-6.33 (m, 1H), 5.93-6.15 (m, 1H), 4.57-4.79 (m, 2H), 3.84-3.95 (m, 1H), 3.64-3.80 (m, 2H), 3.45-3.61 (m, 1H), 3.06-3.31 (m, 4H), 2.86-2.98 (m, 1H), 2.70-2.82 (m, 1H), 2.30-2.51 (m, 1H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 155.8, 153.3, 139.8, 131.9, 131.4, 129.2, 124.2, 123.5, 117.1, 116.9, 77.8, 67.3, 64.1, 58.2, 57.3, 48.4, 47.6, 45.4; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.84 (s, 1F), −58.85 (s, 1F), −58.86 (s, 1F), −128.75 (s, 1F), −128.76 (s, 1F), MS m/z=480.4.
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-(hydroxymethyl)piperazine-1-carboxylate: To a solution of 3-fluoro-4-(trifluoromethoxy)benzaldehyde (2.19 g, 10.2 mmol, 1.0 equiv.) in DCE (60 mL) was added tert-butyl (R)-3-(hydroxymethyl)piperazine-1-carboxylate 2 (2.19 g, 9.65 mmol, and 1.00 equiv). Half an hour later, sodium triacetoxyborohydride (3.02 g, 14.3 mmol, 1.4 equiv.) was added to the above reaction mixture. The reaction mixture was monitored by LCMS and TLC. The next day (12 h later), 500 mg more sodium triacetoxy borrohydride was added to push the reaction mixture to the completion. 12 h later, the reaction mixture was treated with sat. 10% saturated solution of sodium bicarbonate solution (100 mL). Then the organic layer was extracted with dichloromethane (2×80 mL), the combined layers was washed with water (2×100 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude liquid was loaded on to a 120 g silica column. The crude was purified by a gradient 100% hexane to 100% ethyl acetate. The yield was 68.4%. 1H NMR (400 MHz; METHANOL-d4) δ: 7.32-7.40 (m, 2H), 7.26 (d, J=8.0 Hz, 1H), 4.86 (s, 1H), 4.06-4.14 (m, 1H), 3.73-3.81 (m, 2H), 3.53-3.68 (m, 2H), 3.46 (d, J=14.2 Hz, 1H), 3.14-3.29 (m, 2H), 2.64-2.72 (m, 1H), 2.45-2.52 (m, 1H), 2.16-2.25 (m, 1H), 1.46 (s, 9H); 13C NMR (100 MHz; METHANOL-d4) δ: 157.3, 156.9, 154.8, 142.9, 136.7, 136.5, 126.5, 125.0, 123.6, 121.0, 118.8, 81.6, 62.8, 61.9, 58.5, 51.3, 50.0, 29.0, 21.2, 14.8; 19F NMR (376 MHz; METHANOL-d4) δ: −60.59 (s, 1F), −131.71 (s, 1F); MS m/z=431 as a Na+ salt.
tert-butyl (R)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)-3-((prop-2-yn-1-yloxy)methyl)-piperazine-1-carboxylate: 60.0% Sodium hydride (482 mg, 12.0 mmol, 4.20 equiv.) was added to a solution of tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate 3 (1.16 g, 2.80 mmol, 1.00 equiv.) in tetrahydrofuran (6.00 mL) at 0° C. under N2. The reaction mixture was stirred under nitrogen for 60 min. Then 80.0% propargyl bromide in toluene (9.40 ml, 6.0 mmol, 2.1 equiv.) was added to the reaction mixture at 0° C. The reaction mixture was stirred for 12 h at 70° C. The reaction mixture was cooled to room temperature and treated with ice water. The reaction mixture was poured in a separator funnel, extracted with ethyl acetate (3×50 mL), dried over MgSO4 and concentrated under reduced pressure. Then the crude mixture was loaded on to a 40 g silica column and purified with a gradient 100% hexane to 100% ethyl acetate. The yield was 80%. 1H NMR (400 MHz; CHLOROFORM-d) δ: 7.28-7.51 (m, 1H), 7.20-7.26 (m, 2H), 7.12 (br d, J=8.4 Hz, 1H), 4.71 (s, 1H), 3.95-4.19 (m, 3H), 3.89-3.91 (m, 1H), 3.52-3.78 (m, 3H), 3.41-3.52 (m, 2H), 3.21-3.37 (m, 1H), 2.77 (s, 1H), 2.57-2.73 (m, 2H), 2.43 (t, J=2.1 Hz, 1H), 2.13-2.34 (m, 1H), 2.05 (s, 1H), 1.64 (br d, J=15.9 Hz, 1H), 1.43-1.50 (m, 9H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 155.7, 154.8, 153.2, 140.4, 124.4, 123.4, 121.8, 117.3, 117.1, 79.8, 79.3, 77.3, 77.2, 77.0, 76.7, 74.8, 68.4, 60.7, 60.4, 58.5, 57.6, 28.4, 14.2; 19F NMR (376 MHz; CHLOROFORM-d) δ: −58.86 (s, 1F), −129.16 (s, 1F); MS m/z=447.4.
tert-butyl (R)-3-(((1H-pyrazol-4-yl)methoxy)methyl)-4-(3-fluoro-4-(trifluoro methoxy) benzyl)piperazine-1-carboxylate: To a sealed tube was added tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate (0.61 g, 1.40 mmol, 1.00 equiv.) and (Trimethylsilyl)diazomethane (2.00 ml, 4.00 mmol, 2.90 equiv.) in hexane. The reaction mixture was heated at 135° C. for 1 h in a sealed tube. LCMS indicated completion, of the reaction. The crude reaction mixture was dried under reduced pressure and then was loaded on to a 40 g silica column. The column was purified by 10% methanol in 90% dichloromethane. The yield was 84%. 1H NMR (400 MHz; METHANOL-d4) δ: 7.61 (br s, 1H), 7.28-7.37 (m, 2H), 7.19 (d, J=8.6 Hz, 1H), 6.31 (br s, 1H), 5.48 (s, 1H), 4.85 (s, 2H), 4.52 (br s, 2H), 4.44 (s, 1H), 4.02-4.19 (m, 1H), 3.96 (br d, J=14.1 Hz, 1H), 3.59-3.73 (m, 2H), 3.33-3.57 (m, 3H), 3.07-3.29 (m, 2H), 2.52-2.74 (m, 2H), 2.22 (br s, 1H), 1.44 (s, 9H); 13C NMR (100 MHz; METHANOL-d4) δ: 157.7, 155.2, 143.3, 137.1, 126.9, 125.4, 124.0, 121.4, 119.0, 106.4, 82.1, 61.1, 59.1, 55.6, 50.0, 29.4; 19F NMR (376 MHz; METHANOL-d4) δ: −60.61 (s, 1F), −131.79 (s, 1F); MS m/z=511 as a Na+ salt.
(R)-2-(((1H-pyrazol-4-yl)methoxy)methyl)-1-(3-fluoro-4-(trifluoromethoxy)benzyl)-4-(vinyl sulfonyl)piperazine (SMDC203): tert-butyl (R)-3-(((1H-pyrazol-4-yl)methoxy) methyl)-4-(3-fluoro-4-(trifluoromethoxy)benzyl)piperazine-1-carboxylate (0.36 g, 0.80 mmol, 1.0 equiv.) was dissolved in dichloromethane (3 mL) and cooled to 0° C. The reaction mixture was treated with hydrochloric acid (0.939 ml, 3.8 mmol, 10 equiv.). The reaction mixture was stirred for 1 h and then LCMS was checked. The reaction was complete, and the reaction mixture was concentrated under reduced pressure. The gummy liquid was triturated with diethyl ether (3×5 mL). Then the reaction mixture was cooled to 0° C. The reaction mixture was treated with trimethylamine (0.71 mL, 4.09 mmol, 2.00 equiv.). To the mixture was added 98.0% 2-chloroethanesulfonyl chloride (0.062 ml, 0.8 mmol, 1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added trimethylamine (0.71 ml, 4.09 mmol, 2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated and loaded in a column. The crude was purified by 100% DCM to 100% methanol. And finally was purified by reverse phase HPLC using 100% water to 100% methanol. 1H NMR (400 MHz; METHANOL-d4) δ: 7.58 (s, 1H), 7.24-7.40 (m, 2H), 7.19 (br d, J=8.4 Hz, 1H), 6.51-6.72 (m, 1H), 6.26-6.40 (m, 1H), 6.07-6.23 (m, 1H), 4.43-4.64 (m, 2H), 3.96 (d, J=14.2 Hz, 1H), 3.56-3.85 (m, 2H), 3.33-3.55 (m, 2H), 3.16 (br dd, J=6.3, 3.3 Hz, 1H), 2.90-3.11 (m, 2H), 2.69-2.87 (m, 2H), 2.66 (s, 1H), 2.38 (br dd, J=7.7, 4.2 Hz, 1H); 13C NMR (100 MHz; CHLOROFORM-d) δ: 158.0, 155.5, 143.5, 134.6, 130.8, 127.2, 125.7, 119.4, 106.8, 70.0, 67.6, 61.0, 59.0, 58.3, 51.3, 49.1, 47.5, 43.6, 18.5, 13.8; 19F NMR (376 MHz; METHANOL-d4) δ: −60.62 (s, 1F), −131.74 (s, 1F); MS m/z=479.13 (dimer).
tert-Butyl-(3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl) piperazine-1-carboxylate: tert-Butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate (2.5 g, 11.56 mmol, 1.0 eq), dichloroethane (20 mL, 0.58 M), and 3-fluoro-4-(trifluoromethoxy)benzaldehyde (2.4 mL, 17.34 mmol, 1.5 eq) were added to a 100 mL round bottom flask and allowed to stir for 5 minutes at room temperature. NaBH(OAc)3 (7.4 g, 34.68 mmol. 3.0 eq) was added, and the reaction was allowed to stir for an additional 16 hours, then carefully quenched by the addition of 1 M aqueous NaOH and extracted with CH2Cl2 (×3). The combined organics were dried over MgSO4, filtered, and concentrated in vacuo. The resulting residue was purified on silica (Hexanes/EtOAc, 0-45% gradient) to afford 4.34 g (92% yield) of tert-butyl-(3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate. 1H NMR (400 MHz, CDCl3): δ 7.26 (m, 2H), 7.10 (d, 1H, J=8.3 Hz), 3.99 (d, 1H, J=13.8 Hz), 3.80 (dd, 1H, J=5.9, 11.5 Hz), 3.64 (dd, 2H, J=4.1, 11.5 Hz), 3.50 (bs, 1H), 3.46 (d, 2H, J=13.9 Hz), 3.27 (bs, 1H), 2.74 (bs, 1H), 2.62 (bs, 1H), 2.39 (bs, 1H), 2.30-2.24 (m, 1H), 1.45 (2, 9H); MS (ES): m/z 409.4 [M+H]+.
tert-Butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-formylpiperazine-1-carboxylate: A solution containing oxalyl chloride (0.24 mL, 2.7 mmol, 1.1 eq,) in CH2Cl2 (30 mL, anhydrous) was cooled to −20° C., after which a solution of DMSO (0.35 mL, 4.9 mmol, 2.0 eq,) in CH2Cl2 (6.0 mL, anhydrous) was added and the mixture was allowed to stir for 5 min. A solution of 3 (1.0 g, 2.4 mmol, 1.0 eq) in CH2Cl2 (6.0 mL, anhydrous) was then added at −20° C. and the reaction was allowed to stir for 15 min. Et3N (1.7 mL, 12 mmol, 5.0 eq) was slowly added, and the reaction was allowed to warm to 20° C. and stir for 1 hour. The reaction was diluted with CH2Cl2 and then washed sequentially with H2O, 2 M HCl, and saturated aqueous NaHCO3. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo to give ˜800 mg of crude material as a clear, reddish oil that was used without any further purification. 1H NMR (400 MHz, CDCl3): δ 9.69 (d, 1H, J=2.0 Hz), 7.29-7.23 (m, 2H), 7.11 (d, 1H, J=8.8 Hz), 3.92 (d, 1H, J=14.0 Hz), 3.71 (bs, 1H), 3.62-3.58 (m, 2H), 3.43 (bs, 2H), 3.12 (bs, 1H), 2.96-2.90 (m, 1H), 2.36-2.30 (m, 1H), 1.45 (s, 9H); MS (ES): m/z 407.3 [M+H]+.
4-{[(2R)-1-{[3-Fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]methyl}-1λ6-thiomorpholine-1,1-dione Hydrochloride: Thiomorpholine 1,1-dioxide (173 mg, 1.28 mmol, 1.3 eq) was added to a solution of tert-Butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-formylpiperazine-1-carboxylate (400 mg, 984 μmol, 1.0 eq,) in CH2Cl2 (8 mL) at room temperature. The reaction mixture was allowed to stir for 5 min and NaBH(OAc)3 (834 mg, 3.94 mmol, 4.0 eq) was added. The reaction mixture was allowed to stir at room temperature for an additional 16 hours, then quenched with H2O and extracted with CH2Cl2 (×3). The combined organic layers were washed with saturated aqueous NaHCO3, followed by saturated aqueous NaCl. The organic layers were then dried over MgSO4, filtered, concentrated in vacuo, and purified on silica (ISCO, 24 g, Hexanes/EtOAc, 0-80% gradient) to give 365 mg of carbamate (71% yield) as a clear, colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.26-7.22 (m, 2H), 7.09 (d, 1H, J=7.6 Hz), 3.93 (d, 1H, J=13.2 Hz), 3.46-3.38 (m, 5H), 3.03-2.99 (m, 8H), 2.69-2.50 (m, 4H), 2.30 (bs, 1H), 1.45 (s, 9H); MS (ES): m/z 526.4 [M+H]+
4 M HCl in dioxane (6.1 mL, 24.3 mmol, 35 eq) was added to a solution of the above material (365 mg, 0.694 mmol, 1.0 eq) in THE (6 mL). The reaction mixture was allowed to stir at room temperature overnight, then concentrated in vacuo to give 404 mg (93% yield) of crude material that was used in the next step without further purification; MS (ES): m/z 426.4 [M+H]+.
4-{[(2S)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]methyl}-1λ6-thiomorpholine-1,1-dione (SMDC275): 4-{[(2R)-1-{[3-Fluoro-4-(trifluoromethoxy)phenyl]methyl}piperazin-2-yl]methyl}-1λ6-thiomorpholine-1,1-dione hydrochloride (295 mg, 0.694 mmol, 1.0 eq) and Et3N (380 uL, 2.78 mmol, 4.0 eq) were dissolved in CH2Cl2 (5 mL, 0.14 M) and cooled to 0° C. 2-chloroethane-1-sulfonyl chloride (109 μL, 1.04 mmol, 1.5 eq) was added and the reaction was allowed to stir at 0° C. for 2 hours. LC/MS analysis showed remaining starting material, so additional 2-chloroethane-1-sulfonyl chloride (36 μL, 0.347 mmol, 0.5 eq) was added, and the reaction was allowed to stir overnight. The reaction mixture was quenched with H2O and extracted with CH2Cl2 (×3). The combined organic layers were washed with saturated aqueous NaHCO3, then dried over MgSO4, filtered, and concentrated in vacuo. The crude material was dissolved in MeOH and purified by HPLC (H2O (0.1% TFA):Acetonitrile, 20-95% gradient) to give 66.6 mg (18.6% yield) of final product. 1H NMR (400 MHz, MeOD): δ 7.53 (s, 1H) 7.52 (d, 1H, J=8.8), 7.40 (d, 1H, J=8.8 Hz), 6.71 (dd, 1H, J=10.0, 16.4 Hz) 6.26 (d, 1H, J=16.8 Hz), 6.21 (d, 1H, J=10.0 Hz), 4.48 (d, 1H, J=13.6 Hz), 4.20 (d, 1H, J=13.6 Hz), 3.5-3.39 (m, 4H), 3.12 (b s, 11H), 2.93 (dd, 1H, J=7.2, 14.0 Hz); 13C NMR (150 MHz, MeOD): δ 43.52, 45.91, 48.48, 51.47, 52.46, 53.02, 56.50, 57.97, 120.13 (d, J=19.5 Hz), 121.84 (q, J=256, 512 Hz), 125.55, 127.95, 130.60, 133.57, 155.81 (d, J=252 Hz); DEPT-135 (150 MHz, MeOD): δ 43.23 (CH2), 45.62 (CH2), 48.48 (CH2), 51.18 (CH2), 52.17 (CH2), 52.74 (CH2), 56.21 (CH2), 57.69 (CH), 119.84 (d, J=18 Hz, CH), 125.26 (CH), 127.65 (CH), 130.32 (CH2), 133.28 (CH); MS (ES): m/z 516.3 [M+H]+.
tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl) piperazine-1-carboxylate: To a stirred solution of tert-butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate (250 mg, 1.2 mol, 1.0 eq) in dimethylformamide (5 ml) was added potassium carbonate (200 mg, 1.44 mmol, 1.25 eq) followed by 3-fluoro-4-(trifluoromethoxy)benzyl bromide (200 ul, 1.18 mmol, 1.02 eq). The reaction mixture was stirred for 72 hours, partitioned between water and Ethyl acetate. The water layer was extracted with ethyl acetate once again and the organics were dried with brine and Sodium sulfate, decanted, concentrated to afford a residue which was eluted on a 12 g Silicycle cartridge in a gradient of ethyl acetate in Hexane to afford the product (395 mg, 0.969 mmol, 84% yield). 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.42 (s, 9H) 2.13-2.30 (m, 1H) 2.45-2.62 (m, 1H) 2.62-2.74 (m, 1H) 2.74-3.09 (m, 1H) 3.16-3.56 (m, 4H) 3.63 (dd, J=11.40, 4.05 Hz, 2H) 3.72 (d, J=5.84 Hz, 1H) 3.97 (d, J=13.94 Hz, 1H) 7.02-7.13 (m, 1H) 7.14-7.26 (m, 2H); 19 F NMR (282 MHz, METHANOL-d4) δ ppm −128.93 (s, 1 F)-58.92-58.94 (d, 3 F); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 13.99 (s, 1 C) 20.84 (s, 1 C) 28.20 (s, 1 C) 44.22 (s, 1 C) 48.79 (s, 1 C) 57.00 (s, 1 C) 59.24 (s, 1C) 59.89 (s, 1 C) 60.28 (s, 1 C) 79.93 (s, 1 C) 115.20 (s, 1 C) 116.85 (s, 1 C) 117.10 (s, 1 C) 118.63 (s, 1 C) 122.05 (s, 1 C) 123.40 (s, 1 C) 124.21 (s, 1 C) 124.26 (s, 1 C) 125.48 (s, 1 C) 135.06 (s, 1 C) 135.09 (s, 1 C) 135.23 (s, 1 C) 135.26 (s, 1 C) 139.81 (s, 1 C)139.89 (s, 1 C) 152.73 (s, 1 C) 154.99 (s, 1 C) 156.07 (s, 1 C) 171.12 (s, 1 C) 210.98 (s, 1 C); LCMS (ESI+) m/z 409.0 (M+H+).
tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate: sodium hydride, 60% (19 mg, 0.5 mmol, 1.5 equiv.) was dissolved in dry tetrahydrofuran (5 ml) and cooled in an icebath under dry argon with stirring. A solution of tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-(hydroxymethyl)piperazine-1-carboxylate (132 mg, 0.3 mmol, 1.0 equiv.) dissolved in 3 ml THE was added dropwise, and stirring was continued in the icebath for 30 min. Propargyl bromide 80% (0.167 ml, 1.9 mmol, 6.0 equiv.) was added, the reaction mixture was warmed to room temperature and stirred overnight. In the morning, the reaction was quenched by addition of saturated ammonium chloride, then basified with aqueous Sodium hydroxide. Water was added and the mixture was extracted twice with ethyl acetate. The combined organics were dried with brine then Sodium sulfate, filtered then concentrated. The residue was dissolved in Dichloromethane and eluted on a 12 g Silicycle cartridge, in a gradient of Ethyl acetate in hexane to afford the product (78.7 mg, 0.176 mmol, 55% yield). 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.37-1.55 (m, 9H) 2.22 (br. s., 1H) 2.43 (br. s., 1H) 2.67 (br. s., 2H) 3.07-3.38 (m, 2H) 3.38-3.54 (m, 2H) 3.58 (dd, J=9.61, 5.27 Hz, 2H) 3.65-3.78 (m, 1H) 3.87-4.06 (m, 1H) 4.14 (br. s., 2H) 7.12 (d, J=8.48 Hz, 1H) 7.15-7.31 (m, 2H); 19F NMR (282 MHz, CHLOROFORM-d) δ ppm −129.20 (s, 1 F)-58.88 (d, J=4.12 Hz, 3 F); LCMS (ESI+) m/z 447.1 (M+H+).
(2R)-4-(ethenesulfonyl)-1-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-[(prop-2-yn-1-yloxy)methyl]piperazine (SMDC883): tert-butyl (3R)-4-{[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-3-[(prop-2-yn-1-yloxy)methyl]piperazine-1-carboxylate (47.4 mg, 0.107 mmol) was dissolved in DCM (10 mL) and cooled to 0° C. The reaction mixture was treated with trimethylamine (2.00 equiv). To it was added 98.0% 2-Chloroethanesulfonyl chloride (1.0 equiv.). The reaction mixture was stirred for 2 h at cold. Then was added Trimethylamine (2 equiv.) at 0° C. The reaction was stirred for 2 h. The reaction mixture was evaporated to afford a crude product which was eluted on a 12 g Silicycle cartridge in a gradient of ethyl acetate in hexane with further purification by HPLC on C18 40-90% methanol in water (all 0.05% formic acid) over 12 min (18 total) to afford the product (20.0 mg, 0.046 mmol, 43% yield). 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.19-7.27 (m, 2H) 7.10 (d, J=8.10 Hz, 1H) 6.44 (dd, J=16.58, 9.80 Hz, 1H) 6.26 (d, J=16.58 Hz, 1H) 6.08 (d, J=9.80 Hz, 1H) 4.07-4.24 (m, 2H) 4.00 (d, J=14.32 Hz, 1H) 3.79 (dd, J=9.89, 4.43 Hz, 1H) 3.68 (dd, J=9.89, 5.18 Hz, 1H) 3.49 (d, J=14.13 Hz, 1H) 3.35 (dd, J=11.21, 2.35 Hz, 1H) 3.15-3.27 (m, 1H) 2.98-3.14 (m, 2H) 2.72-2.91 (m, 2H) 2.45 (t, J=2.35 Hz, 1H) 2.35-2.44 (m, 1H) 19F NMR (282 MHz, CHLOROFORM-d) δ ppm −58.84-−58.85 (d, J=4.12 Hz, 3 F) (s, 1 F)-128.84 128.90 (m, 1 F) LCMS (ESI+) m/z 437.1 (M+H+).
The following analogs were synthesized by reductive amination, in a manner similar to that described in Scheme 4, for compounds SMDC689 and SMDC723.
1-(4-(methylthio)benzyl)-4-(vinylsulfonyl)piperizine (SMDC739): 1H NMR (400 MHz, CDCl3): δ 7.30 (d, J=2.1 Hz, 4H), 6.45 (dd, J=9.6, 16.4 Hz, 1H), 6.30 (d, J=16.6 Hz, 1H), 6.16 (d, J=9.7 Hz, 1H), 4.17 (s, 2H), 3.51 (br mult, 8H), 2.51 (s, 3H); MS (ES) m/z 313.0 [M+H]+.
1-(4-((trifluoromethyl)thio)benzyl)-4-(vinyl sulfonyl)piperazine (SMDC807): 1H NMR (400 MHz, CDCl3): δ 7.76 (d, J=8.4 Hz, 2H), 7.51 (d, J=8.1 Hz, 2H), 6.45 (dd, J=9.8, 16.4 Hz, 1H), 6.31 (d, J=16.5 Hz, 1H), 6.17 (d, J=9.8 Hz, 1H), 4.23 (s, 2H), 3.55 (br mult, 4H), 3.25 (br mult, 4H); MS (ES): m/z 367.0 [M+H]+.
1-(4-(methylsulfonyl)benzyl)-4-(vinyl sulfonyl)piperazine (SMDC863): 1H NMR (400 MHz, D20): δ 8.11 (d, 2H, J=6.2 Hz), 7.83 (d, 2H, J=5.8 Hz), 6.78-6.68 (m. 1H), 6.42-6.29 (m, 2H), 4.55 (s, 2H), 3.49 (s, 8H), 3.32 (s, 3H); MS (ES): m/z 345.0 [M+H]+.
1-(4-(pentafluoro-16-sulfanyl)benzyl)-4-(vinylsulfonyl)piperazine (SMDC808). 1H NMR (400 MHz, CDCl3): δ 7.88 (d, 2H, J=8.6 Hz), 7.59 (d, 2H, J=8.3 Hz), 6.46 (dd, 1H, J=9.7, 16.5), 6.32 (d, 2H, J=16.5 Hz), 6.18 (d, 1H, J=9.8 Hz), 4.27 (s, 2H), 3.57 (br mult, 4H), 3.28 (br mult, 4H); MS (ES): m/z 393.0 [M+H]+.
1-(4-(1H-pyrazol-1-yl)benzyl)-4-(vinylsulfonyl)piperazine (SMDC866). 1H NMR (400 MHz, MeOD): δ 8.33 (d, 1H, J=2.5 Hz), 7.93 (d, 2H, J=8.6 Hz), 7.78 (d, 1H, J=1.6 Hz), 7.66 (d, 2H, J=8.6 Hz), 6.73 (dd, 1H, J=10.0, 16.4 Hz), 6.58 (dd, 1H, J=1.9, 2.4 Hz), 6.29 (d, 1H, J=16.5 Hz), 6.23 (d, 1H, J=10.0), 4.46 (s, 2H), 3.45 (br mult, 8H); MS (ES): m/z 333.1 [M+H]+.
Taspase1 (Tasp1) is a unique threonine aspartyl protease, which is expressed as an inactive 420-residue proenzyme and is structurally homologous to Asparaginase-2. The proenzyme self-activates, undergoing autoproteolysis and forming two subunits (a/13) that associate as a heterodimer (Hsieh, 2003). Tasp1 is classified as a Ntn protease; after cis-activation, as the N-terminal residue of the beta subunit is the catalytic threonine (Thr234). The major substrates of Tasp1 include MLL family of epigenetic regulatory proteins, and the TFIIA family of cell cycle regulatory nuclear proteins (Zhou, 2006; Niizuma, 2015).
As a regulator of both MLL and TFIIA, Tasp1 has been implicated in multiple oncogenic and developmental diseases, (Wunch, 2016; Stauber, 2016). In particular, processing of MLL-1 by Tasp1 splits the protein into two fragments: (1) a 320 kDa N-terminal domain, and (2) a 180 kDa C-terminal domain, which are associated with chromatin binding and histone lysine methylation, respectively. Importantly, the N-terminal MLL fragment is susceptible to forming fusion proteins which influence the aberrant expression of oncogenic proteins including the HOX and cyclin families (Dorrance, 2006; Takeda, 2006). Similarly, Tasp1 cleaves TFIIAa-β, forming a heterotrimer with TFIIAγ, and is critical in the development of the head and neck, liver hematopoetic stem cells, and mammalian germ cell lines (Oyama, 2013; Stauber, 2016) A recent report also demonstrated that Tasp1 processes REV3L, the catalytic subunit of DNA polymerase C, which is involved with DNA lesion repair (Wang, 2020). In this case, Tasp1 stabilizes REV3L against ubiquitination and degradation, potentially allowing for unregulated DNA lesion repair by a polymerase which lacks proofreading functions.
Tasp1 is overexpressed in numerous liquid and solid malignancies and has been termed a ‘non-oncogene addiction’ protease (Hsieh, 2003; Chen, 2010). Loss of Tasp1 sensitizes glioblastoma and melanoma cells to chemotherapy-induced apoptosis, disrupts proliferation of human cancer cell lines in vitro, and reduces growth of tumor xenograft modes of several aggressive tumor types (Takeda, 2006; Scrideli, 2008; Chen, 2010). In addition, loss of Tasp1 strongly inhibits development of HER2-driven breast tumors and EGFR-driven lung cancer, including drug-resistant, EGFR-T790M mutant tumors (Dong, 2014). Other evidence points to a key role of Tasp1 in invasion and metastasis via proteolysis of MLL in HepG2 hepatocellular carcinoma metastasis models in vitro and in vivo (Niehof, 2008). High expression levels of Tasp1 correlated with poor prognosis in patients with gall bladder carcinoma, with an upregulation of FAM49B via the MLL-PI3K/AKT signaling pathway (Zhang, 2020). Another recent study suggested that Tasp1 plays an important role in head and neck squamous cell carcinomas by regulating nuclear localization and transcriptional activity of TFIIA, leading to a reduction of CDK inhibitor expression levels (Gribko, 2017). Therefore, growth factor-driven, drug-resistant cancers represent promising clinical indications for Tasp1 inhibitors. Previous attempts of developing Tasp1 inhibitors have met with limited success. Early peptidic inhibitors designed to target the substrate binding pocket included either electrophilic warheads (Lee, 2009) or hypothesized succinimide intermediates (van den Boom 2014). However, these peptide-based inhibitors demonstrated modest in vitro potency with fluorescently labeled substrates: assays with recombinant Tasp1 yielded IC50 values in the micromolar range. In addition, no further biochemical evaluation in the form of cellular activity assays were performed on these peptides. Small molecule Tasp1 inhibitors have also been reported. One study (Knauer, 2011), used an in silico approach to dock low molecular weight compounds into the crystal structure of activated Tasp1 (Khan, 2005). Two resulting groups, clustered into “deep hole” and “chloride hole” compounds were evaluated using a cell-based fluorescent Tasp1 cleavage assay, but only identified two fragments that demonstrated Tasp1 inhibition at 50 μM when added to cell culture media. A second study (Chen, 2012) likewise used a cell-based proteolysis assay to evaluate the NCI Diversity Set Library. Confirmatory and specificity in vitro screens later identified one arsenate compound that acted as a non-competitive allosteric inhibitor, with an IC50 of 7.5 μM. This compound also demonstrated efficacy in breast cancer and brain tumor xenograft models. Critically, none of these aforementioned examples further evaluated modes of action of their respective lead compounds in order to improve their efficacy, or to determine exact binding poses within hypothetical binding pockets.
In light of this, we have focused on a structure-based approach to develop and validate novel Tasp1 inhibitors. While no tractable hits emerged from an initial high-throughput screen (HTS) performed in our group, strong interest was retained in the potential of Tasp1 as a novel oncology drug discovery target. Thus, we employed an alternative hit-finding approach using a disulfide-trapping tethering screen (Erlanson, 2004; Kathman, 2016) to target and covalently modify surface exposed cysteines. Recently, tethering screens have also been used to successfully discover lead compounds targeting K-Ras G12C (Ostrem 2013; Gentile 2017; Nnadi 2018), Caspases (Hardy, 2004; Gao 2012), PTP1B (Keedy 2018), BRD4 (Olp, 2020), NADH dehydrogenase (Heikal, 2018), and 14-3-3 (Sijbesma, 2019).
Disulfide-trapping was an especially suited screening method for targeting Tasp1 due to a non-catalytic cysteine residue (Cys293) located in the substrate binding pocket, and in close proximity to the catalytic Thr234 (
Results
Tethering Screen Hits and Evolution to Warheaded Compounds
A primary LC-MS-based disulfide-trapping tethering screen using a library containing 1280 thiol-containing compounds (Burlingame, 2011; Turner, 2014;
The 1,4-disubstituted phenyl acetamide series was subsequentially chosen for further structure-activity relationship (SAR) studies due to its high potency against split Tasp1 WT (IC50=11.3 μM for SMDC673 after re-synthesis), lack of inhibition against the split Tasp1 C293A construct, and relative tolerance for multiple linker lengths (
Significant improvement of the inhibitory activity was observed upon rigidifying the scaffold by replacing the flexible linker with a piperazine (SMDC967, WT IC50=0.114 μM, Table 1a and
In order to more accurately define these interactions, we embarked on a crystallography campaign. Previous studies had suggested that both the N- and C-terminal residues of the alpha domain in the activated form of Tasp1 were too dynamic to form a lattice sufficient for crystallography (Khan, 2005). Examination of the full-length inactive single-chain crystal structure (2A8Lpdb) shows a lack of electron density between residues 1-40 and 206-229. The Tong group was subsequently able to crystallize a truncated split Tasp1 construct which deleted residues 206-233 (split Tasp1 delta206, 2A8J.pdb). However, residues 184-205 were still unobserved in the delta206 structure (Khan, 2005). In this study, we designed two truncations to remove both of the conformationally dynamic alpha domain N-terminal and C-terminal tails (
Concurrent with the binding and enzymatic inhibition studies, we crystallized the Tasp1 cp1 construct in the presence of SMDC967 (6VKU.pdb;
Evolution of Warheaded Compounds: Addition of Shoulders
Based on the binding, enzymatic and crystallography results, we performed further SAR studies to improve the biophysical and biochemical characteristics of the SMDC967 scaffold (
With the phenyl ring optimized, our structure-guided design strategy shifted to the piperazine ring. Efforts yielded a series of compounds (SMDC069, SMDC 883, SMDC 203, and SMDC 275) with an additional 2 to 3-fold increased inhibitory activity (all IC50 values˜0.020 μM) over SMDC689 (
Cell Efficacy (and +Xenografts?)
With improvements in the scaffold reaching an IC50 lower limit approaching 20 nM, we forwarded the compounds for further ex vivo cell efficacy and cytotoxicity studies. Using a previously established dual-fluorescent proteolytic reporter (DFPR) assay (Chen/Hsieh, 2012), we examined the efficacy of selected potent inhibitors against Taspase-1 in transfected HEK-293T cells (
Viability of selected compounds (SMDC689, SMDC 069, SMDC 203, and SMDC 275) were evaluated against four lung cancer (PC9, H1975, H522, and HSAEC 1-KT), one triple-negative breast cancer (MDA-MB-231), and one prostate (PC3) cell lines (Table 2a,
Taspase-1 Expression and Purification
Biochemical and Biophysical Constructs (Full-Length Split Tasp1)
Split Taspase-1 wild-type construct (1-233/234-420): DNA sequences were ligated into a pETDuet-1 vector (Novagen/EMD Millipore), with residues 1-233 (alpha domain) in Multiple Cloning Site-1 (MCS-1) and residues 234-420 (beta domain) in MCS-2. The alpha domain also contained a TEV-cleavable N-terminal His6-tag. Vectors were heat-shocked transformed into E. coli Rosetta2(DE3) competent cells (Novagen/EMD Millipore) and grown on LB/Agar plates supplemented with carbenicillin.
Site-directed mutagenesis: All site-directed mutagenesis reactions were performed on the above template DNA with QuikChange Lightning kits (Agilent). Optimized forward primers (C293A, TGT→GCG; T234A, ACG→GCG; T234S, ACG→TCG; T234V, ACG→GTG), and their respective reversed complements were designed using Agilent's QuikChange Primer Design website and purchased from IDT.
Expression and Purification: All full-length split Tasp1 constructs used for biochemical and biophysical assays were expressed in 2×YT media containing carbenicillin. Bacterial pellets were harvested and frozen at −80° C. prior to lysis via sonication. Lysis buffer consisted of 50 mM Tris (pH 8), 500 mM NaCl, 5% glycerol, 5 mM BME, and 30 mM imidazole. Solutions were clarified prior to loading onto HisTrap FF columns (daisy-chained 2×5 mL, GE Healthcare Lifesciences) attached to an AKTA Pure FPLC (GE Healthcare Lifesciences). Proteins were eluted using a step function from 30 mM to 200 mM imidazole. Major fractions were collected and dialyzed overnight using a 6-8 kD MWCO dialysis tubing (Spectra/Por-1, Spectrum Labs) in the presence of 1 mg/mL TEV protease. Dialysis buffer consisted of 20 mM Tris (pH 8), 500 mM NaCl, 5% (v/v) glycerol, 0.5 mM TCEP. Samples were applied through the HisTrap FF columns again to remove the His6-tag and TEV protease. The flow-through from the loading step was concentrated with 30 kD MWCO Amicon Centrifiugal Filter Units (Millipore) to 2 mL prior to injection on a Superdex 200 16/60 or Superdex 200 10/300 Increase column (GE Healthcare Lifesciences). Proteins were eluted using 1.5 CV of fresh dialysis buffer. Major fractions were pooled and concentrated to ˜0.5-1 mL final volume prior to aliquoting and flash freezing. All protein samples were stored at −80° C. until ready for analysis. Protein concentrations for all full length Tasp1 constructs (wild-type, C293 Å, and T234X) were evaluated using a NanoDrop 2000c (Thermo Scientific) using ε280=26930 M−1 cm−1.
Crystallography constructs (split truncated Tasp1 and circularly permuted Tasp1)
Split Taspase1 delta183 construct (41-183/234-420): DNA encoding residues 41-183 with a non-cleavable N-terminal His6-Tag (MCS-1) and residues 234-420 (MCS-2) were ligated into pCDFDuet vectors (Novagen/EMD Millipore). Vectors were then transformed into E. coli BL21 (DE3) Star competent cells. Split Tasp1 delta183 was expressed and purified as previously reported (Khan, 2005). Expression was induced with 0.3 mM IPTG at 20° C. for 18 hours and purified with Ni-NTA Superflow (Qiagen) and gel filtration (Sephacryl S-300) chromatography (in a buffer containing 450 mM NaCl, 20 mM Tris-HCl (pH 7.5) and 5 mM DTT). Split Tasp1 delta183 protein stock was supplemented with 5% (v/v) glycerol and concentrated to 5 mg/ml before being flash-frozen in liquid nitrogen.
Circularly permuted Taspase1 (CP-1: CID 11900): The truncated Tasp1 cp-1_2-339 (a.a. 234-416-GSGS-41-183) human Taspase1 constructs with a hexa-histidine tag at the C-terminus was expressed and purified as previously reported (Nagaratnam, 2020).
Dynamic Light Scattering (DLS)
All small molecule inhibitors were subjected to DLS analysis on a DynaPro Plate Reader II (Wyatt) using either one of two buffers: (1, crystallography conditions) 100 mM MES pH 7.5, 250 mM KF, 0.005% (v/v) Tween20, 5% (v/v) DMSO; (2, biophysics and biochemical conditions) 100 mM NH4OAc pH 8.3, 0.005% (v/v) Tween20, 5% (v/v) DMSO. DLS data were collected in a dose-dependent manner. Small molecule samples in assay buffer alone were serially diluted in 2-fold steps, starting with a 1 mM high concentration (40 μL total volume; 11 steps, with a replicate), and were loaded onto a 384-well clear bottom plate (Corning #3540), with the 2 outside columns containing blank buffer solution. Samples were incubated in the plate reader at 25° C. during the data collection, which consisted of 10 reads per well and a 2 second acquisition time per read. Data was acquired and analyzed using Dynamics 7.1.7.16, with the output reporting estimated particle radius size. Experimental errors were estimated by a sum-of-squares parameter resulting from the 10 reads/well. Samples with estimated particle sizes >1 nm were considered to contain aggregates. All compounds included in this study, with the exception of SMDC556, exhibited estimated particle sizes >1 nm at concentrations up to 125 μM in both buffer conditions (data not shown).
LC-MS Tethering and Dose-Response Assays
The general methodology for the high-content primary screen using a 1280-member disulfide-containing compound library (Burlingame, 2011; Turner, 2014) was as previously described (Hallenbeck, 2018). All LC-MS tethering and dose response assays were collected on a Waters Acquity UPLC with either a (1) Micromass LCT Premier or (2) Xevo G2-XS Q-Tof mass spectrometer. A Waters UPLC Protein BEH-C4 Column (300 Å, 1.7 μm, 2.1 mm×50 mm) was used to desalt the samples prior to application on the mass spectrometer. For the primary tethering assays, 500 nM protein samples in 100 mM NH4OAc (pH 8.3) and 625 μM BME were loaded onto a 384-well plate. For the follow-up dose-response tethering assays, 200-300 nM protein samples in 100 mM NH4OAc (pH 8.3) buffer containing either 1 mM BME or glutathione were loaded onto a 384-well plate. A Biomek FX Automation Workstation (Beckman Coulter) equipped with a 384-pin tool was used to simultaneously apply the 50 mM compound stocks in 50 nL increments to individual wells containing protein solution. Final concentration of the compounds was 10011M for the single-dose high content screen. In the case of the 8-point dose response assays, the 50 mM compound stocks were serially diluted in 3-fold increments, with a final high concentration of 125 μM after pinning. Mixed samples were incubated at room temperature for at least 1 hr prior to loading the plates into the LC-MS, and at 10° C. during the data acquisition. All data acquisition, processing, and analysis were performed using MassLynx 4.1 (Waters). Raw m/z spectra were processed with the MaxEnt-1 deconvolution algorithm (Ferrige, 1991) within the MassLynx program suite.
Crystallization, Data Collection and Structure Determination
Split Taspase1 delta183. Split Tasp1 delta183 crystals were obtained using the hanging-drop vapor-diffusion method at 20° C. with a reservoir solution containing 20-26% (v/v) MPD and 0.1 M IVIES (pH 6.5). Seeding resulted in faster growth and more consistent good quality crystals. To obtain inhibitor-bound split Tasp1 delta183 structures, crystals were soaked with 5 to 25 mM inhibitor for 5 to 20 hours. Split Tasp1 delta183 crystals were cryoprotected with 40% (w/v) MPD before being flash-frozen in liquid nitrogen for diffraction analysis and data collection at 100 K. X-ray diffraction data were collected at the Advanced Photon Source (APS) beamline 24-ID-C and the diffraction images were processed and scaled using the XDS program (Kabsch, 2010). The structure was solved by molecular replacement with Phaser (McCoy et al., 2007) using Taspase1 (PDB 2A8J) as the initial model. Further structure refinement was performed using PHENIX (Adams et al., 2002) or Refmac (Murshudov, 1997) and the atomic model was rebuilt with the Coot program (Emsley, 2004). The crystallographic information is summarized in
Circularly permuted Taspase1 (CP-1: CID 11900): The crystallization conditions of CP-1 (Tasp1 cp-1_2-339) human Taspase1 at ˜9-10 mg/ml were identified from PACT screen condition (B11: 0.2 M calcium chloride, 0.1 M MES pH 6, 20% (w/v) PEG 6000) at 16° C. using hanging-drop vapor-diffusion method. Ligand bound co-crystals were obtained with a 1 hour incubation at 4° C. with 2.5 mM compound prior to crystal tray set-up. Cryo-protection of 20% ethylene glycol was used for all CP-1 crystals. X-ray diffraction data were collected at the APS beamline 21-ID-F and the diffraction images were processed and scaled as described above. The crystallographic data collection and structure refinement statistics are summarized in
This application claims the benefit of U.S. Provisional Application No. 62/939,258, filed Nov. 22, 2019, which is incorporated herein by reference in its entirety and for all purposes.
This invention was made with government support under contract no. HHSN261200800001E awarded by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US20/61657 | 11/20/2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62939258 | Nov 2019 | US |
